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For over a decade, the use of double-stranded short interfering RNAs (siRNAs) to silence
the expression of genes associated with disease at the translational level has gained much
attention. Using a highly conserved endogenous pathway within cells, siRNA technology
displays a high degree of target specificity and potency. However, traits required for the
successful design of siRNA-based therapeutics such as resistance to nuclease-mediated
degradation, improved cell membrane permeability and reduced off-target toxicity, are
compromised by the native structure of duplex RNA′s charged backbone. This study
therefore focused on synthesizing novel and neutrally-charged triazole-linked nucleoside
dimer analogs which were incorporated throughout siRNA duplexes using DMT-
phosphoramidite chemistry, in order to attenuate the negative contributions of RNA′s
native backbone. In order to further elucidate the mechanism of the RNA interference
(RNAi) pathway, additional siRNAs were synthesized containing commercially available
abasic alkyl spacers. Through the robust copper(I)-catalyzed Huisgen [3+2]
cycloaddition, azide and alkyne nucleic acid monomers were joined through the
heterocyclic linkage in nearly quantitative yields, producing the novel triazole-linked
uracil-uracil (UtU) and cytosine-uracil (CtU) dimers. Results from cell-based assays
indicate that triazole-modified siRNAs are capable of silencing the transiently-expressed
reporter gene firefly luciferase and the endogenous gene glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) in a dose-dependent manner. In addition, modifying the 3′-
overhangs of siRNAs with the triazole backbone linkage, gave rise to increased nuclease
resistance well beyond that of wild-type siRNA. Duplex RNAs containing abasic spacer
linkages in the sense strand also maintained activity while targeting the luciferase
reporter gene, indicating the capability to tune the efficacy of siRNA constructs by
altering their thermodynamic profiles, in addition to providing evidence for an alternative
RNAi mechanism. The studies describe herein, emphasize the compatibility of these
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Chapter I – Literature Review
1.0 Nucleic Acid Therapeutics
There are a myriad of diseases with roots linked to uncontrollable gene expression, gene
mutations, and viral infections.1 Diseases which are related to deviant expression of
endogenous genes such as cancer and Alzheimer′s disease,2, 3 or the mis-expression of
genes introduced by viruses are difficult to diagnose and treat with modern day
therapeutics because of their lower tissue, oligonucleotide, or protein-target specificity.
With a focus on existing therapies for the treatment of cancer, patients can undergo
invasive surgery to remove the affected tissues. Although less invasive, radiation and
chemotherapies are non-specific alternatives to surgery, which affect healthy cells along
with the diseased cells.4 It is well known that these existing therapies can produce harsh
side effects and are often plagued with instances of disease recurrence.4 In order to
overcome these issues associated with current therapeutic strategies, the growing trend in
molecular biology has been to effectively control the expression of problematic proteins
involved with undesirable pathologies, either at the transcriptional,5, 6 or translational
level.7 In addition, the ability to control the expression of genes is crucial towards
increasing our understanding of gene function and to ultimately advance the development
of gene-modulating therapeutics. Most therapeutics today are used to destabilize or
deactivate over-expressed proteins or multi-protein complexes by binding to these
proteins of interest, or to bind to those further upstream or downstream within the
signalling pathway thus preventing proper signal transduction.3 An alternative to these
small-molecule drugs is the use of nucleic acid-based anti-gene agents, which have
shown great capability and promise as prospective gene-silencing therapeutics, along
with their continued use as indispensible tools used for functional genomics.8 In addition
to their potential anti-gene properties, nucleic acid polymers can be manipulated to form
useful aptamers designed to disrupt protein function through binding-induced
conformational changes3, 9 and to perform as molecular probes.10, 11
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1.1 Antisense Oligonucleotides
In 1978, it was demonstrated by Stephensen and Zamecnik that chemically synthesized
oligonucleotides can effectively target and interrupt the translation of complementary
RNA molecules once introduced in cells.12 The study involved the introduction of
antisense oligonucleotides (ASOs), which are exogenous single-stranded DNA or RNA-
based oligonucleotides with sequences complimentary to their DNA or RNA targets.6
These ASOs demonstrated effective targeting and repressed expression of viral RNA
molecules belonging to Rous sarcoma.12 Since then, chemically or enzymatically
synthesized antisense oligonucleotides (ASOs) have been employed as very powerful
tools used to control gene expression through post-transcriptional targeting of
complimentary mRNA molecules, thus preventing their translation.13 As a result of this
discovery, it follows that a commercially available therapeutic known as Vitravene14, 15
has incorporated ASO technology into their pharmacophore, with many others still
undergoing clinical trials.3, 14, 16 The discovery of effective small-molecule therapeutics is
a difficult task due to their lack of specificity for their intended targets in the cell.15
Alternatively, disrupting the expression of oncogenes with ASOs is showing great
promise due to the potential of increased specificity from Watson-Crick hybridization.17
Significant research has been performed on ASOs in order to increase their target
specificity, binding affinity and resiliency within physiological environments.
Although the framework of ASO constructs generally employs the use of the deoxyribose
moiety, RNA-based ASOs have also previously been employed and have displayed
favourable transcript targeting.18 The gene-silencing mode of action for typical DNA-
based ASOs once inside the cell, begins with the single-stranded oligonucleotide
construct annealing to its mRNA target producing a DNA/RNA hybrid.3, 19 This hybrid
duplex is either rendered as non-translatable due to blocking of the ribosome,20 or it
recruits a member of the RNAse III family referred to as RNAse H, which recognizes and
binds to the hybrid duplex and cleaves the target mRNA transcript.19, 21
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1.2 Short-Interfering RNA
Natural mechanisms exist within cells which guard organisms from disease arising from
exogenous virulents, or from the unregulated expression of endogenous genes. Unlike the
route through which ASOs downregulate gene expression, an endogenous and highly
conserved mechanism known as RNA interference (RNAi) was discovered in 1998 by
Fire and Mello while studying the model organism C. elegans.22 In this study, researchers
were comparing the RNA interference capabilities of antisense RNAs to dsRNAs, by
targeting the abundant unc-22 gene which expresses a non-essential muscle protein and
noting the resultant phenotypes.22 This was a continuation from earlier research showing
evidence that reduced expression of the same unc-22 transcript was obtained through the
introduction of sense RNA, which in turn produced antisense RNA in the cell.23 The
RNAi pathway is a natural defense against invasive genetic information,24 and is essential
for eukaryotic cells to self-regulate the expression of endogenous genes. This regulation
is performed using double-stranded RNA molecules known as short-interfering RNAs
(siRNAs) which range from 19 to 21 base pairs in length, and contain distinct 2-
nucleotide long 3′-overhangs at each end of the duplex. These siRNAs are then
incorporated into a multi-eznyme complex known as the RNA-Induced Silencing
Complex (RISC). The RISC complex selects one strand of the RNA duplex as the active
antisense or “guide” strand while discarding the inactive sense or “passenger” strand and
together, they target messenger RNAs based on Watson-Crick complementarity for
subsequent degradation.25
Significant contributions towards the advancement of siRNA technology can be largely
attributed to the research history and expansion of our knowledge of ASOs.3 As a result,
siRNAs have become the most commonly used tool for discovering protein function and
elucidating transduction pathways due to their ability to promote the accurate targeting
and facile cleavage of mRNAs.8 Disruption of mRNA translation has been crucial in
distinguishing between different protein subtypes, which was difficult to perform using
traditional small-molecule drugs26 and gene knockouts.27
4
1.2.1 The Known RNAi Mechanism in Human Cells
Under natural circumstances, siRNAs are produced through the act of cleaving longer
double-stranded RNA (dsRNA) molecules which are exogenously introduced into cells.
These long dsRNAs are recognized and cleaved into shorter duplex RNAs with 2-
nucleotide 3′ sticky ends by an enzyme known as Dicer.25 Dicer is part of a heterotrimer
with the trans-activation response (TAR) RNA binding protein (TRBP) and an
endonuclease known as Argonaute 2 (Ago2).28 With a bound newly-formed siRNA, this
complex is referred to as the RISC loading complex (RLC).25, 29 The Dicer-TRBP portion
of the RLC helps select the active guide strand from the passenger strand of the siRNA
by assessing the duplex′s natural thermodynamic asymmetry. The guide strand selection
process starts with the TRBP protein determining the least thermodynamically stable end
of the duplex.30 Once the least thermodynamically stable end of the siRNA and
subsequently the guide strand is determined, Dicer-TRBP then transfers the duplex to
Ago2.29 Ago2 then proceeds to cleave the inactive passenger strand of the siRNA duplex.
The cleavage site on this strand opposes nucleotide residues 10 and 11 from the 5′-end of
the guide strand.29, 31, 32 The passenger strand is subsequently discarded from the
complex, leaving the active guide strand whose 5′-end formed the least
thermodynamically stable portion of the siRNA duplex as determined by Dicer-TRPB of
the RLC.29 The remaining RISC-guide complex which is also referred to as active RISC,
is responsible for targeting and binding to the mRNA transcripts containing sequences
complementary to that of the antisense strand.33 Once the guide-mRNA duplex is formed,
Ago2 proceeds to cleave the transcript at the site of the phosphodiester linkage, once
again opposite from antisense residues 10 and 11, counting from the 5′-end (Figure
1.1).31, 33
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1.2.2 RISC in Other Organisms
Depending on the organism, there are different sets of proteins which comprise the RLC
complex. In Drosophila for instance, the dsRNA binding protein in the RLC is R2D2;
whereas in C. elegans, it is the RDE-4 protein.25, 28 It is understood that regardless of the
organism being studied, all dsRNA binding proteins are responsible for helping prepare
siRNAs for Ago2 loading by sensing the RNA duplex′s thermodynamic asymmetry to
determine which of the strands will become the active guide strand. In humans, although
it is clear that TRBP is required for siRNAs to proceed with RNAi, it is not entirely clear
as to the exact role of this particular dsRNA binding protein. Studies have shown that
TRBP senses the asymmetry of siRNA duplexes by binding to the most
thermodynamically stable end of the duplex. However, more characterization is
required.28, 30
6
Figure 1.1 RISC-mediated RNA Interference pathway
following the production of siRNAs.
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1.2.3 Argonaute 2 Endonuclease
The Ago2 endonuclease is an essential component of the RNAi pathway, since it carries
out the majority of the pathway′s catalytic activity. Of the four isoforms of Argonaute
proteins found in humans, it was determined that RNAi activity could not be properly
guided without Ago2 playing the key role of removing the inactive passenger strand from
the siRNA duplex and degrading the target transcript after guide strand hybridization.25,
31-36 There are conflicting views as to whether Ago2 is complexed with Dicer and TRBP
whilst guiding the active guide strand towards its target, or that it dissociates from the
heterotrimeric complex and performs RNAi on its own.28 Prior to forming the pre-RISC
complex which occurs once the siRNA is loaded into Ago2, the 5′-ends of the RNA
duplex are phosphorylated by a kinase known as Clp1.34, 37 It has been shown that 5′-
phosphorylation of the guide strand is essential in order to properly associate with Ago2
and form the active RISC complex.37
The Ago2 endonuclease is made up of three main domains: The PIWI domain at the
amino terminus; the centrally localized Mid section; and the PAZ domain at the carboxyl
terminus.31, 32, 34, 38 The PIWI domain is known as the section responsible for the
enzyme′s catalytic activity and resembles the structure of the RNAse H endonuclease.
The Mid domain has been shown to bind to the 5′-phosphorylated end of the antisense
strand, while the PIWI domain binds to the strand′s 5′-region. While the PAZ domain is
known to interact with the 3′-overhang of the antisense strand, there isn′t any noticeable
interaction between the enzyme and the strand′s 3′-region.32, 33 Having been elucidated,
these Ago2-guide interactions can provide further assistance when chemically modifying
designer oligonucleotides.
1.3 Problems with ASOs and siRNAs
The evolution of  clinically approved antisense and siRNA-based therapeutics has been
slow due to problems inherent with the native nucleic acid sugar-phosphate backbone.8, 35,
39 These problems to be addressed include: 1) the susceptibility of the phosphodiester
linkage to enzymatic cleavage; 2) its polyanionic charge density; and 3) off-target
toxicity.3, 7, 8 In DNA as well as RNA, the phosphodiester linkage is easily hydrolyzed
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and susceptible to cleavage by endo- and exo-nucleases in the blood serum thus limiting
their half-life under physiological conditions.35, 40 The multiple anionic nature of the
phosphate backbone in both DNA and RNA reduces their cell membrane permeability,
affecting their delivery to target cells.7, 8, 41, 42 This excessive charge density on the native
backbone also makes it more difficult for ASOs or siRNAs to interact with serum
transport proteins such as albumin,8 in addition to making them more susceptible to
enzyme-assisted hydrolysis as a result of heavy hydration.8, 35 Particular to RNA, there is
also the problem of having the 2′-OH functionality on the ribose moiety which can attack
the adjacent phosphate group, thus truncating the construct by cyclizing into a stable five-
membered heterocycle.43, 44 Another problem which is commonly displayed when
targeting transcripts for degradation using ASOs or siRNAs is the issue of off-target
toxicity45-47 and activation of the host′s immune system.48, 49 Focusing primarily on
siRNAs, there is evidence that the RISC-guide complex can incorrectly target non-
homologous anti-parallel sequences thus knocking down the wrong transcript. This is
thought to occur when Watson-Crick base pairing occurs between the off-target transcript
and the guide strand′s ′seed′ region, referring to nucleotide residues 2 to 8 from the 5′-
end, forming the guide-target hybrid despite the presence of base-pair mismatches
elsewhere in the duplex.8, 35 In light of this behaviour, chemical modification of the
residues within the seed region on the guide strand of siRNAs, has proven to reduce off-
target toxicity in cells.8, 35 In order to address these drawbacks, chemical modification of
native oligonucleotide structures is essential for the development of clinically feasible
anti-gene agents which are: 1) less susceptible to enzymatic cleavage by
endo/exonucleases thus increasing their bioavailability; 2) display increased cell
membrane permeability through minimizing the poly-anionic nature of the backbone; and
3) have increased specificity for target mRNA. While mitigating these known issues
through chemical modification, a fine balance must be maintained between the chemical
enhancements and the pharmacological utility of the modified compounds.
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1.4 Chemical Modification of Nucleic Acids
1.4.1 Chemical Synthesis of Oligonucleotides
Other than being responsible for the propagation of genetic information, it was later
determined that oligonucleotides could serve other unique purposes. The production of
synthetic genes could lead to novel proteins used for medical or industrial application,50
or nucleotide derivatives can serve as antitumor and antiviral agents.51-53 Another
component of oligonucleotide-based technology was the additional functionality which
could be extracted from these derivatives through the chemical modification of their
native structures. In order to implement these modifications more effectively in a site-
specific manner, the development of an alternative strategy to chemically synthesize
DNA and RNA molecules became a desirable goal. The original and familiar technology
involving the use of enzymatic means to grow polynucleotide chains had its drawbacks
such as poor nucleobase insertion accuracy, and the inability to control the specificity of
introducing unnatural bases or nucleosides within the growing construct.54 After several
attempts to optimize synthetic strategies for both DNA and RNA,50, 55 it was determined
that synthesis performed on a solid-support was the simplest and most efficient
technology,50, 54 and has remained the primary strategy through which oligonucleotides
are synthesized today.
Synthesis of both DNA and RNA molecules on a controlled-pore glass (CPG) solid
support is typically performed using DMT-phophoramidite chemistry,54, 56 where
nucleotide building blocks containing specific 5′ and 3′ protecting groups are joined
together through a step-wise process. This optimized and fully-automated form of
synthetic chemistry can be utilized to effectively yield any oligonucleotide sequence with
high efficiency. In addition, this method allows the incorporation of virtually any
designer molecule into the growing sequence, provided it contains all of the necessary
protecting groups in order to form the native phosphodiester internucleotide linkage.
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Unlike the natural 5′ to 3′ direction of DNA and RNA synthesis within biological
systems, solid-support synthesis of oligonucleotides typically occurs in the opposite
direction (3′ to 5′) with very few alternative methodologies.44 Unless the goal is to insert
a modified nucleoside analog at the 3′-end of the designer sequence, the solid support
itself will contain the first of the known four DNA or five RNA bases. The initial step in
solid-support DMT-phosphoramidite chemistry involves the removal of the acid-labile
dimethoxytrityl group which protects the 5′-alcohol of the nucleoside on the support
using trichloroacetic acid. Having exposed the 5′-OH of the nucleoside on the support, it
is now prepared to couple with the 3′-phosphoramidite group of the incoming nucleobase
(Figure 1.2).
________________________________________________________________________
The second synthetic step involves activating the incoming 3′-phosphoramidite group
with 1H-tetrazole. This occurs through 1H-tetrazole′s extremely rapid protonation of the
Figure 1.2 Step-Wise Automated Solid-Support Synthesis of Oligonucleotides Using
DMT-phosphoramidite Chemistry.
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tertiary amine, followed by an attack of the phosphorus center by tetrazole′s anion and
subsequent displacement of diisopropylamine. Being a much better leaving group, the use
of tetrazole to activate the phosphoramidite and form the more reactive tetrazolide
intermediate,57 greatly facilitates the attack on the phosphorus center by the exposed 5′-
OH on the solid support (Figure 1.2).
The next step involves coupling the new base to the solid support. As previously
mentioned, this occurs when the exposed 5′-OH on the support attacks the incoming
phosphorus center, thus displacing the tetrazole anion which deprotonates the 5′-oxygen.
This has been referred to as the cyanoethyl-protected phosphite intermediate (Figure
1.2).50, 55 Alternatives to using 1H-tetrazole as activators such as 5-ethylthio- or 5-
benzylthio-1H-tetrazole58 are widely being used in order to reduce coupling times and to
enhance coupling efficiency due to their increased acidity and nucleophilicity.
The following is a precautionary measure which involves utilizing an acetic anhydride
solution to effectively cap any remaining 5′-OH groups which did not successfully react
with the incoming residue. The protected alcohol is then prevented from reacting with
any successive bases which would introduce anomalies in the desired oligonucleotide
sequence (Figure 1.2).
The synthesis continues with oxidation of the phosphite in order to form the cyanoethyl-
protected phosphotriester intermediate; the precursor to the desired phosphodiester
linkage. By adding I2 as a solution in pyridine and water, iodine acts a Lewis acid
creating an electrophilic center after forming an unstable P-I bond. Water then attacks the
P+ center displacing iodide (I-) and is fully deprotonated by pyridine giving us the
aforementioned phosphotriester intermediate (Figure 1.2).
This particular juncture in the step-wise synthetic procedure immediately following the
final oxidation step presents the opportunity to either continue elongating the
oligonucleotide sequence through repetition of the six-step cycle, or to remove the
support from the automated synthesizer once the desired sequence is complete. The solid
support is then treated with NH4OH in order to deprotect all nucleobase exocyclic amines
and to eliminate the β-cyanoethyl protecting group giving us the native phosphodiester
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linkage, all while simultaneously cleaving the oligonucleotide from the solid support
(Figure 1.2). After synthesizing RNA oligonucleotides, there is the necessity for an
additional deprotection step of RNA′s 2′-hydroxyl group which is performed following
base deprotection and cleavage from the solid support.59
The entire automated process for chemically synthesizing DNA molecules using the
DMT-phosphoramidite method just described, is also compatible with the synthesis of
RNA molecules. The most commonly used building blocks for they synthesis of RNA
oligonucleotides are 5′-O-DMT-2′-O-tert-butyldimethylsilyl (2′-O-TBS) protected
phosphoramidites. However, through constant exposure to basic conditions during each
step of oligonucleotide synthesis, the 2′-O-TBS protecting group on RNA amidites has
been known to migrate to the 3′ position on the ribose sugar. This 2′ to 3′-O-TBS
migration would ultimately lead to the unfavourable production of 2′ – 5′ phosphodiester
linkages for each subsequent base addition.44 It is for this reason that alternative RNA
phosphoramidites containing 2′ protecting groups that are resilient to 2′ – 3′ migration are
often used such as 2′-O-triisopropylsilyloxymethyl (2′-O-TOM) protected
phosphoramidites.60 Both the 2′-O-TBS and TOM silyl ethers are fluoride ion-labile and
are removed following the concerted base deprotection and solid-support cleavage step.
Advancements in the automated synthesis of RNA oligonucleotides have yielded
methodologies that can produce RNA molecules with comparable efficiency, speed, and
purity to DNA molecules. An alternative to DMT-phosphoramidite chemistry for RNA
synthesis was devised in 1998 known as bis(acetoxyethoxy)orthoformate (ACE)
chemistry.61 The use of ACE chemistry for RNA synthesis can not only mitigate the issue
of 2′ – 3′ migration which 2′-O-TBS protected RNA oligonucleotides can undergo, but it
eliminates the growing oligonucleotide′s exposure to harsh acidic conditions due to the
repetitive 5′ detritylation step. Increased exposure to acidic conditions during DNA and
RNA synthesis can ultimately lead to depurination, which describes the hydrolytic
cleavage of the purine-ribose glycosidic linkage.62 ACE chemistry involves the use of 3′-
phosphoramidites which are 5′-silyl ether and 2′-orthoester protected. The unique 2′-O-
bis(2-acetoxyethoxy)methyl (ACE) protecting group is used with a fluoride ion-labile 5′-
O-silyl protecting group such as 5′-O-bis(trimethylsiloxy)cyclododecyloxysilyl ether
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(DOD). The synthetic scheme is similar to DMT-phosphoramidite chemistry in that RNA
oligonucleotides are synthesized in the 3′ to 5′ direction. However, instead of the acidic
conditions use to detritylate the 5′ end prior to activation and 3′ – 5′ coupling in DMT
chemistry, a source of fluoride ions is required to deprotect the 5′-silyl ether. The finished
RNA oligonucleotide is exposed to mild acidic conditions, only following the base
deprotection/support cleavage step in order to remove the acid-labile 2′-O-ACE group.61
1.4.2 Common Chemical Modifications of the Ribose Sugar
There are three main sites within an oligonucleotide where chemical modifications have
been studied: the ribose sugar, the nitrogenous base and the phosphodiester backbone
linkage. With respect to RNAs, modifications to the ribose moiety have been heavily
researched. A widely used sugar modification involves methylating the 2′-OH group (2′-
O-Me), which has shown to increase siRNA stability and potency depending on where
the modification is performed within the construct, by blocking the free 2′-OH′s
nucleophilicity and preventing sequence truncation as mentioned earlier (Figure 1.3). For
example, a report by Collingwood and colleagues (2008) demonstrated that the preferred
structure of siRNA molecules due their observed potency when compared to unmodified
siRNA included an alternating pattern of 2′-O-Me sugar modifications in either the
antisense or sense strand. This alternating pattern was shown to provide good siRNA
stability while retaining potency, when targeting two different types of human genes in
vitro.40 Another sugar modification which has the capability of recruiting RNAse H for
RNA degradation when incorporated into ASOs and can act as a suitable ligand for
polymerases, is the 2′-deoxy-2′-fluoroarabinonucleic acid (2′-FANA) nucleoside analog
(Figure 1.3).63, 64 Although typically used as a DNA mimic in ASO-based applications,
reports have demonstrated that siRNAs containing sense strands which are moderately or
entirely made up of 2′-FANA residues retain their potency, are more resilient to cleavage
by nucleases and are less prone to stimulating innate immune responses.65 Another sugar
modification which has produced RNA analogs with high binding affinity is the locked
nucleic acid (LNA) modification, which involves the linkage between the 2′-OH and the
4′ sugar carbon through a methylene group (Figure 1.3). This covalent linkage, as well as
the aforementioned 2′-O-Me modification, induces a locked C3′-endo pucker
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conformation of the ribose which enhances RNA′s natural A-form helical structure.13, 66-69
When added to the 5′ end of the sense strand in an siRNA molecule, the LNA
modification was shown to improve the guide strand′s incorporation into the RISC
complex through biasing the duplex′s thermostability, thus reducing any non-specific
targeting by the sense strand and increasing the overall silencing efficiency.70 Other 2′-
sugar modifications such as 2′-O-methoxyethyl (2′-O-MOE) and 2′-flouro RNA (2′-F-
RNA) positioned throughout the siRNA construct in either the sense or antisense strands
(Figure 1.3) have also shown to produce stable molecules less prone to enzyme digestion
and displaying a reduction in off-target toxicity.63, 64, 68 Most of the sugar modifications,
particularly the 2′ modifications allow the siRNA molecule to retain its native Watson-
Crick base-pairing characteristics while increasing its stability within biological
environments. Although sugar modifications such as 2′ alkylation have shown potential,
there is still the possibility that enzymatic cleavage of the polyanionic RNA backbone
can occur, which is likely a main factor in delaying the use of these modifications in
commercial therapeutics.
________________________________________________________________________
1.4.3 Common Chemical Modifications of the Nitrogenous Bases
Modification of the known nucleobases is typically achieved by conjugating new
functionalities to specific sites on both the purine and pyrimidine heterocycles, or by
substituting the nucleobases with unnatural groups. Nucleobases are the most frequently
modified portions of nucleic acids due to the presence of easily modifiable sites, shorter
Figure 1.3 Common modifications to the 2′-OH of the furanose sugar: (A) 2′-O-
methyl (2′-O-Me); (B) 2′-O-methoxyethyl (2′-O-MOE); (C) 2′-fluoro (2′-F);  (D) 2′-
deoxy-2′-fluoroarabinonucleic acid (2′-FANA) and ; (E) 2′,4′-locked nucleic acid
(LNA)
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synthetic routes for their modification, and the functional versatility of the derivatized
products.71, 72 In the form of nucleotide phosphoramidite building blocks typically used to
chemically synthesize DNA and RNA oligonucleotides through an automated process,55,
73 nucleobase analogues can be site-specifically incorporated throughout the oligomer.
Similarly, nucleotide sugar or backbone modifications can be incorporated into synthetic
oligonucleotides using  this process. However, unlike certain modified sugars or
phosphates, all modified nucleobases have the advantage of unrestricted positioning
throughout growing polynucleotides.74
1.4.3.1 Bioconjugation of Nitrogenous Bases
Synthetically conjugating select functionalities or large molecules to specific sites on
either purine, or pyrimidine nucleobase heterocycles, can significantly alter the
thermodynamic properties, conformational arrangements and delivery capabilities of the
resultant modified oligonucleotides. The most common accessible sites for chemical
alteration on the purine heterocycles include, but are not limited to the 7-aza or deaza and
the N9-positions of both adenine and guanine, the 6-N exocyclic amine of guanine and the
2-N exocyclic amine of adenine. Regarding the pyrimidine heterocycles, positions C5, the
4-N exocyclic amine of cytosine and the N1-positions are most notable for chemical
modification.75
1.4.3.2 Nucleobase Substitution
Finding suitable substitutions for nucleobases which are compatible within DNA and
RNA strands and duplexes is another prominent area of research. The discovery of 2,4-
difluorotoluene (dF) (Figure 1.4), an analog which can replace thymidine in DNA and
RNA oligomers,76, 77 eventually lead to trials involving its incorporation in siRNA
duplexes as a replacement for uracil. Work done by Xia and associates showed that
siRNA guide strands containing single dF substitutions in the 5′ region displayed
decreased non-specific targeting, increased RNA stacking abilities due its non-polar
nature and conjugated system, and increased the strand′s affinity for binding to the RISC
complex.78 Despite these promising results, it was also shown that dF substitutions in the
center of the guide strand were detrimental to the overall stability of the siRNA construct,
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and placement anywhere else along the duplex lowered the overall melting temperature
due to dF′s inability to hydrogen bond with its compliment.78
Following the discovery of nucleobase analogs such as dF, growing interest within the











focused on using highly conjugated substituents, capable of stacking with near and
opposing neighbours.80 Some examples of alternative base substitutions include pyrene
and benzene residues which can behave as universal bases with enhanced stacking
capabilities due to their complete aromaticity and have provided extensive probing
capabilities to modified oligonucleotides (Figure 1.4).77
1.4.4 Typical Modifications of the Sugar-Phosphate Backbone
While most studies concentrate on chemically modifying the sugar and nucleobase
moieties within nucleic acids, fewer studies have focused on altering the native backbone
due to the complexity and multi-step fashion of the proposed synthetic strategies and the
reactivity of certain alterations to the automated process of synthesizing designer
oligonucleotides.81 However, some modifications to the backbone have proven to be
quite effective and have led to the synthesis of novel DNA/RNA-based oligomers as well
as polypeptides. One of the more popular modifications involves the substitution of a
non-bridging oxygen atom with a sulphur atom producing a phosphorothioate (PS)
linkage,3, 8 which have been shown to stabilize siRNA molecules by inhibiting
endonuclease cleavage and increase their circulation half-life by enhancing their binding
Figure 1.4 Non-hydrogen bonding substitutions for existing
nucleobases with enhanced stacking and fluorescent
capabilities: (A) 2,4-difluorotoluene (dF); (B) C1′-benzene;
(C) C1′-pyrene. C2′-R refers to ribose or deoxyribose sugar.
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affinity for serum transport proteins (Figure 1.5).3 A 21 base-pair ASO entirely
comprised of PS linkages known as Vitravene, was the first ASO to be FDA approved as
an antiviral agent for the treatment of cytomegaloviral infection of the eye in
immunocompromised patients.14 Despite these promising results, it has been found that
siRNA duplexes containing PS modifications near the center of the sense strand or across
the Ago2 cleavage site are non-functional,8 and extensive PS modification can give rise
to cytotoxic effects.3, 8 One example that attempts to resolve this problem of cytotoxicity
as an alternative to PS involves the introduction of a borane (-BH3) moiety in the
phosphodiester linkage (Figure 1.5).35, 82 Shaw and coworkers have found that this
modification has been shown to increase siRNA potency when compared to the PS
modification.82 Furthermore, the boranophosphate (BP) modified siRNA molecule does
not induce significant cytotoxicity in mammalian cells and can be readily incorporated
into DNA and RNA oligomers by DNA or RNA polymerase with high binding
specificity.82
PS and BP backbone modifications were chosen so as to provide added stability to
oligonucleotide scaffolds, without compromising the ability to synthesize DNA or RNA
molecules through polymerase activity.82, 83 It is important to note that although both the
PS and BP backbone modifications maintain natural synthesis of DNA or RNA
oligomers,82, 83 the problem inherent in the BP backbone modification in particular, is that
all native unmodified nucleotides are replaced with those that are BP-modified.82 This
drawback concerning BP modification is important to address because there is much
evidence to support the optimization of ASOs or siRNAs through selective modification
in specified regions, thus improving resistance and functionality of the resultant
molecules.70, 82, 84 Another concern is that by introducing an additional functionality
attached to the phosphate group, adds another chiral center to the oligonucleotide. The
consideration of stereochemistry during the design and synthesis of modified oligomers is
an important factor when trying to determine duplex thermostability, as well as target
affinity.85-87 Despite the aforementioned backbone modifications, they are not fully
resistant to degradation and still retain the anionic nature of the siRNA complex, which
remains the main culprit leading to decreased cell membrane permeability and hydrolysis.
Expanding our repertoire of oligonucleotide backbone modifications, increases the
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chance of discovering a unique and favourable nucleic acid modification profile with
globalized applications. Unnatural modifications involved in replacing the
phosphodiester, or the entire sugar-phosphate linkage could advance our pursuit in the
discovery of this unique profile, which would propagate the development of ASOs and
siRNA duplexes with effective gene-silencing capabilities in vivo, while still maintaining
structural and functional integrity.
1.4.4.1 Unnatural Oligonucleotide Backbone Modifications
During the discovery of novel backbone modifications involving the replacement of
native nucleotide structures, there is one modification that has shown considerable
promise for some time and has been implicated in the formation of novel peptides and
DNA oligomers. This has been achieved through the replacement of the sugar-phosphate
backbone with repeating N-(2-aminoethyl) glycine units, where the nucleobases are
attached to the chain via a methylene amide, forming what are known as peptide nucleic
acids (PNAs) (Figure 1.5).5, 83, 85, 88-94 Synthesized in 1991 by Nielsen and colleagues,94
PNA is a DNA mimic which follows standard Watson-Crick base pairing and maintains a
six-atom distance between successive bases in a strand, similar to wild-type strands of
DNA and RNA. PNAs can form hybrid duplexes with DNA or RNA and also triplexes
with all three constituents with remarkable binding affinities, even found to be notably
higher than in natural DNA/RNA homo and heteroplexes.83, 92, 95 PNAs are uncharged
achiral molecules that are resistant to enzymatic cleavage and pass through cell
membranes much more readily than their polyanionic counterparts.83, 91, 92, 95 These
properties inherited by PNAs are attributed to the amide linkages between successive
nucleobases, which are neutral and therefore much more stable than the anionic
phosphate linkages in native DNA/RNA molecules.
Aside from blocking gene expression at the translational level, ASOs have also been
employed to invade double-stranded genomic DNA (dsDNA) and bind to their
compliments, which is of interest to researchers who wish to discover the means of
controlling gene expression at the transcriptional level. Development of synthetic
oligonucleotides which are capable of dsDNA invasion with rapidity and efficiency was
progressing slowly prior to the discovery of PNA.5 PNA may be the simple yet effective
19
solution to the problem of dsDNA invasion because of its remarkable ability to sense and
anneal to its complimentary sequence with very high affinity, and is a testament to the
possibilities inherited through the chemical manipulation of oligonucleotides.
In addition to PNA as a novel backbone replacement modification, a number of studies
have proven the rather non-discriminating nature of the RNAi pathway towards adopting
and utilizing backbone homologues of this nature. Several backbone replacements have
also shown compatibility within ASO constructs. Although few in number, some
successful examples of backbone-modified
siRNA constructs include: 1) a study by
Iwase and associates showing that siRNAs
containing a 3′- overhang amide-bond
linkage displayed promising results;96 and
2) a study by Zhang and associates
involving a heterocyclic morpholino
structure replacing the sugar.97 This
indicates that non-ionic backbone
modifications are compatible with siRNA
duplex formation and function. Examples
of other novel backbone modifications
incorporated into ASOs with comparable
attributes to their native counterparts
include: 1) double-constrained thymine
dimers with 2′-4′ ethylene ribose bridges,
joined by a cyclic phosphotriester
internucleotide linkage (1,3,2-
dioxaphosphorinane);66 2) benzene rings
in place of the ribose sugar;11 and 3) the
N3′-P5′ phosphoramidate linkage.98
The evidence supporting the compatibility of novel and diverse backbone modifications
such as the successful PNA scaffold with antisense or RNAi applications, suggests the
Figure 1.5 Structures of common
phosphate backbone modifications: (A)
phosphorothioate (PS), and (B)
boranophosphate (-BH3); and a
comparison of the native DNA/RNA
backbone with the unique peptide
nucleic acid (PNA) scaffold. R-group
denotes ribose or deoxyribose sugar.
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likely discovery of new and effective backbone modification strategies in order to
enhance the structural integrity, thermodynamic properties, cell membrane permeability
and enzymatic resistance of both DNA and RNA-based oligonucleotides.
1.5 Click Chemistry
Since its discovery by Meldal and Sharpless in 2001,99 the Cu(I)-catalyzed adaptation of
Huisgen′s 1,3-dipolar [3 + 2] azide-alkyne (CuAAC) cycloaddition has not only earned
the title of “click” reaction, but has nearly become synonomous with the term due its
speed, versatility, simplicity and its broad application.100-103 This particular click
cycloaddition has had a considerable impact on chemical transformations leading to the
production of new materials104, 105 and libraries of molecules with applications in
biological systems.101 The CuAAC reaction is an ideal bioorthogonal transformation
because it can be performed under various environmental conditions, is high-yielding and
expedient, the azide and alkyne moieties are physiologically inert,106 and the regio- and
stereospecificity of the triazole product is tightly controlled.99 The CuAAC reaction gives
rise to only the 1,4-disubstituted 1,2,3-triazole isomer, and in some cases eliminates the
need for further purification of the final product.99, 101, 103
1.5.1 Modifying Nucleic Acids with Click Chemistry
Although there are many examples of chemical transformations being used to modify
nucleic acid residues, click chemistry is becoming ubiquitous in its ability to modify the
three main areas of nucleic acids with relative ease. According to the literature, most
click-mediated modifications are performed on the nitrogenous bases by introducing
novel base analogues,107-110 attaching fluorophores or isotopic elements for molecular
imaging,71, 111-113 forming inter-strand linkages between oligonucleotides,114-116 and the
bioconjugation of molecules used for the assisted delivery of nucleic acid-based
therapies.117 Click chemistry has also given researchers the opportunity to target the
backbone using a fairly simple synthetic procedure, with the goal of negating the effects
imposed on nucleic acid derivatives through the problematic sugar-phosphate linkage.
Knowing that the polyanionic structure of the native phosphodiester linkage is one of the
main problems faced by oligonucleotides trying to emerge on the market as therapeutic
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agents,3, 35 click chemistry can introduce a neutrally-charged and physiologically stable
heterocycle at this site. Another desirable property associated with the 1,2,3-triazole is its
ability to form hydrogen bonds through N2 and N3 of the heterocycle,101 which could
allow triazole-linked polymers to interact with biological molecules such as blood-serum
proteins, thus increasing their circulatory half-lives and biodistribution in living systems.
The use of triazoles in biological systems has gained popularity, due to their chemically
inert nature within natural systems.101, 105, 118 Triazoles have been used for many years as
Figure 1.6 Examples of novel and unnatural non-phosphate triazole-linked nucleoside
dimer analogues and a triazole-modified phosphate linkage, all introduced through the
Cu(I) catalyzed “click” cycloaddition. Triazole-linked dimers A-D and H have found
use in oligodeoxyribonucleotides, whereas E-G have formed both RNA and
RNA:DNA chimeric oligonucleotides.
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the basis for several varieties of antiviral and antifungal pharmaceuticals.87 A widely
studied antiviral pharmaceutical known as Virazole, is a nucleoside analogue with a
substituent 1,2,4-triazole isoform tethered to the 1′ position of the furanose ring.52, 119-121
Although there are other examples of oligonucleotides which tether nucleobases or
nucleobase analogues to the sugar through a triazole linkage,122, 123 or that link iterative
bases through novel triazole-based internucleotide linkages (Figure 1.6),81, 124-130 there is
a need for expanding the use of triazole linkages within an siRNA context.
1.6 Modifying Nucleic Acids with Non-Phosphate Alkyl-Chain Linkages
Besides modifications to the existing backbone or the synthesis and implementation of
novel sugar-phosphate replacement scaffolds, another avenue of backbone modifications
which lacks sufficient investigation involves altering the physical distance between
adjoined nucleotides. Given that the typical distance separating iterative bases in native
oligonucleotides is in the form of a repetitive six atom linkage along the sugar-phosphate
backbone: O3′, P, O5′, C5′, C4′, and C3′ (Figure 1.5), studies have associated alterations
to this distance with potentially favourable changes to the physical and functional
characteristics of modified oligomers.131-133
1.6.1 Physical Characteristics of Alkyl Chain-Modified Duplex Oligonucleotides
Many studies have investigated the target affinity and conformation of oligonucleotides
which have been modified with nucleoside dimers, joined through non-phosphate alkyl
linkers which increase the native inter-nucleobase distance by one atom. Influenced by
PNA and its high affinity for both RNA and DNA target sequences, some studies adopted
the use of alternative amide-based linkages. One such study by Kochetkova et al.
synthesized a thymine-thymine dinucleoside linked through an amide and aminomethyl-
based linker.133 Through UV-monitored thermal denaturation experiments, the thermal
stabilities of DNA duplexes steadily decreased as the number of modified dimers
increased. A similar study observed the same phenomenon in dsDNA molecules when
modified with one or more thioacetamido nucleic acid (TANA) linkages. In addition,
TANA-modified DNA duplexes were noticeably transitioning from their natural B-form
helical conformation, to the more RNA-like A-form conformation.134 A contrasting study
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characterized the RNA-binding affinities of DNA strands modified with several different
amide-based linkages.131 A general trend was observed, favouring the RNA binding
capabilities of these amide-modified DNA strands, despite the presence of these seven
atom inter-nucleobase linkages.
1.6.2 Functional Characteristics of Alkyl Chain-Modified siRNAs
Although the aforementioned studies were helpful in outlining the compatibility of alkyl
chain linkages within DNA:DNA and DNA:RNA hybrid duplexes, few studies have
shown the functional characteristics of DNA or RNA molecules containing these
modifications. Using an amino-based linkage which shortens the native inter-nucleobase
distance by two atoms, Sobczak et al. discovered that siRNA duplexes, modified at their
3′-overhangs with amino-linked thymine-thymine dimers were still capable of silencing
their endogenous gene transcript with a potency comparable to wild-type, and greater
than the activity of an siRNA known to target the same transcript.135 Even more
intriguing was the discovery made in 2009 by Ueno et al, whereby siRNAs containing
variable-length alkyl-chain bulges which were centrally located between residues in the
sense strand, were as efficacious at silencing the target reporter gene as the wild-type
construct.11 Of greater interest, was the discovery that an siRNA containing an abasic site
on its sense strand upon inserting an alkyl-chain linkage, was still capable of silencing its
target with a potency comparable to the siRNA with all of its nitrogenous bases, modified
with an alkyl bulge of similar length.11 These observations not only demonstrate the
feasibility of introducing non-phosphate alkyl chain internucleotide linkages, but support
the production of functional abasic oligonucleotides containing spacers of variable length
to be used as ligands for the RNAi pathway.
1.7 Passenger Strand Cleavage and RNAi Activity
Given the world-wide utility of siRNAs for various biological purposes, the literature
shows that remarkably little is known about the exact stepwise mechanism through which
the process of RNAi is conducted. Some studies have attempted to elucidate this
mechanism, with a particular focus on the steps involved while forming the active RISC-
guide complex following the cleavage and removal of the passenger strand.31, 36, 136 As
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mentioned earlier, the endonuclease Ago2 is responsible for cleaving the passenger strand
at the phosphate linkage, opposite residues 10 and 11 counting from the 5′ end of the
guide strand, prior to its removal from the duplex. However, some studies have shown
retention of the silencing activity elicited by siRNAs with sense strands containing
chemical modifications surrounding, or directly within the Ago2 cleavage site.29, 137 This
phenomenon suggests the possibility of an alternative RNAi pathway, devoid of any
physical sense strand cleavage event. By modifying the passenger strand with non-
cleavable functionalities, the existence of this alternative pathway can be proven with
more validity.
1.8 Research Objectives
The ability to silence the expression of any gene at the translational level, has proven its
ubiquitous utility in the discovery of gene function and can eventually become a powerful
therapeutic tool used to control genetic disease. The endogenous RNAi process provides
us with an avenue through which synthetic siRNAs can enforce the down-regulation of
gene expression with high accuracy and efficacy at low concentrations. Studies have
proven that chemical modification of siRNAs is required to overcome their limitations
such as poor cell membrane permeability, susceptibility to nuclease-mediated degradation
and off-target toxicity. These drawbacks within both DNA and RNA molecules result
from the negatively charged phosphodiester linkage which can be enzymatically
hydrolyzed and can suffer an intramolecular attack from the 2′-OH group in ribonucleic
acids.
The primary focus of this study involved chemically modifying the sugar-phosphate
backbone of both DNA and RNA oligonucleotides. Novel PNA-based nucleoside dimer
analogs containing a neutrally charged triazole-based internucleotide linkage introduced
through “click” chemistry, were site-specifically introduced throughout synthetic
oligonucleotides. These triazole-linked nucleoside dimer analogs should be compatible
within duplex DNA and RNA molecules and ultimately within siRNAs. This hypothesis
was supported by the demonstrated use of the triazole heterocycle within the backbone of
DNA molecules in the literature and the relative ease of its synthesis, along with the
success of the popular DNA-mimic known as PNA which served as our scaffold. Based
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on this hypothesis, the following are the tests that were performed involving our triazole-
linked nucleoside dimer analogs: 1) to check the hybridization capabilities of these
dimers within duplex DNA molecules and whether or not they increase or decrease the
thermostability of these duplexes. Since they proved compatible and destabilizing within
duplex DNAs; 2) both physical and functional characteristics of duplex siRNAs which
contain these modifications throughout the sense strand, and within the 3′ overhangs of
either strand were monitored. The physical characteristics of interest were siRNA duplex
thermostability, helical conformation, and nuclease stability. The potency of our siRNAs
was tested by targeting the transiently-expressed reporter gene firefly luciferase and the
endogenous gene GAPDH using cell-based assays. Upon discovering that siRNAs
modified with our neutral triazole-based internucleotide linkages were very capable of
silencing gene expression, maintaining RNA′s helical conformation and proved to last
longer in blood serum than native siRNAs, the effects of using simpler, neutrally-charged
and destabilizing modifications positioned throughout siRNAs were explored. For the
final phase of this study: 3) the physical and functional characteristics of f. luciferase-
targeting siRNAs which were modified with abasic alkyl chain linkages of varying length
were assessed. As was performed in the previous phase of this study, the thermostability
and helical conformation of these spacer-modified siRNAs were monitored, and the
potency of these siRNAs was tested within cell-based assays by targeting the firefly
luciferase transcript.
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Synthesis and Properties of Oligonucleotides that Contain
a Triazole-Linked Nucleic Acid Dimer
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New chemically modified oligonucleotides at the site of the backbone are needed to
improve the properties of oligonucleotides. A practical synthesis for a triazole-linked
nucleoside dimer based on a PNA-like structure has been developed. This involves
synthesizing two uracil-based monomers that contain either an azide or an alkyne
functionality, followed by copper-catalyzed 1,3-dipolar cycloaddition. This dimer was
incorporated within an oligonucleotide via phosphoramidite chemistry and UV-monitored
thermal denaturation data illustrates slight destabilization relative to its target
complementary sequence. This chemically modified dimer will allow for a future
investigation of its properties within DNA and RNA-based applications.
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2.1 Introduction
Oligonucleotides have found tremendous use as biological tools and as agents with
therapeutic promise. One promising example involves RNA interference (RNAi), and
exploiting this pathway has become a major tool in elucidating gene function [1].
Furthermore, utilization of the RNAi pathway by administering short interfering RNAs
(siRNAs) to cells [2] has offered therapeutic hope in combating diseased cells with
aberrant gene expression profiles [3]. Despite awareness of this potential, improvements
in enzymatic stability, biodistribution, cell-membrane permeability, and reducing off-
target effects are still needed [4, 5]. One way to potentially overcome these limitations
involves altering the stability and specificity profile of the siRNA through chemical
modification.
Within the areas of siRNA, the most common type of chemical modification involves
alterations within the ribose moiety. Extensive studies involving 2′-O-Me, fluorinated
sugars and locked nucleic acids (LNA) have shown favorable siRNA knockdown results
depending on its position and sequence context [6–9]. Studies involving chemical
modification of the backbone within the field of siRNA are less prevalent than sugar
modifications. Some key examples include the negatively charged backbone modification
involving a phosphorothioate [10] and boranophosphates [11]. Backbone-altering
modifications such as a morpholino analogue [12] and neutral amide bonds at 3′
overhangs of siRNA duplexes, have shown favorable results when utilized for gene-
knockdown studies [13, 14]. Therefore, it is possible that the RNAi pathway will adopt
less conventional backbone modifications at specific positions of the oligonucleotide.
Given that siRNA duplexes exhibit thermodynamic asymmetry, being able to potentially
destabilize the 5′ end of the guide strand with novel backbone modifications may offer
favorable properties. Outside of the RNAi field, modified backbone constructs could
have many other potential applications such as in antisense technology, artificial aptamer
design or template driven enzymatic reactions. To explore this prospective, we are
interested in pursuing alternative backbone modifications such as nonionic hydrophobic
backbone mimics.
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Within the field of backbone modified oligonucleotides, one of the most successful
examples involves peptide nucleic acid (PNA) [15] and this has shown remarkable
stability and specificity to its complementary targets [16, 17]. PNA synthesis occurs by
the successful amide-bond formation between an acid and an amine with high-yields.
Therefore, we envisioned that a scaffold based on a triazole functional group would serve
as a potentially good candidate (Fig. 2.7). To date, a number of different triazole-based
backbone modifications have
been reported [18–20] from the
one presented herein.
The repetitive backbone unit in
most analogues, including PNA,
contains six atoms. Although the
six-atom spacer unit dominates
by choice for a large number of
chemically modified nucleic
acids, analogues with shorter
(five atom linker) [21–23] and longer backbones (seven atom linker) [24, 25] have shown
varying degrees of specificity to its target, depending on its sequence context and type of
backbone. This suggests that site-specific incorporation of unnatural nucleoside
backbones of different atom lengths can produce functioning oligonucleotides, capable of
binding to their complement strand with varying specificity and stability. As such,
chemically modifying oligonucleotides could offer an alternative way to fine-tune their
functional effects.
We hypothesized that a copper (I)-catalyzed Huisgen [3 + 2] cycloaddition [26] based on
a PNA-type structure would generate an alternative scaffold for bridging adjacent
nucleotides together. We report the synthesis of a modified 1,4-triazole-linked uracil
dimer through a distance of seven atoms and report its compatibility with hybridization to
a complement sequence when appended at the 5′ or 3′ end of a DNA oligonucleotide.
Figure 2.7 Chemical differences between peptide
nucleic acid (left) and triazole-linke nucleic acid
(right).
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2.2 Materials and Methods
2.2.1 General Synthetic Methods
Unless otherwise noted, all starting materials were obtained from commercial sources and
were used without any additional purification. Anhydrous CH2Cl2, THF, and DMF were
purchased from Sigma-Aldrich and degassed by stirring under a dry N2 atmosphere.
Purification by flash chromatography was carried out with Silicycle Siliaflash 60 (230–
400 mesh) according to the procedure of Still et al. [27] 1H NMR spectra were recorded
in DMSO-d6 or CDCl3 at 400 or 500 MHz and
13C NMR spectra were recorded at 100 or
125 MHz. High-Resolution MS (HRMS) was recorded on a Micromass AutoSpec Ultima
Magnetic sector mass spectrometer.
2.2.2 Synthesis and Characterization of Organic Compounds
2.2.2.1 Synthesis of 2-(tert-Butyldimethylsilyloxy)ethanamine – Compound (1)
To a solution of ethanolamine (9.6 mL, 159 mmol) in 100 mL of CH2Cl2 was dissolved
imidazole (10.8 g, 159 mmol) and this solution was cooled in an ice-water bath. To this
solution was added tert-butyldimethylsilyl chloride (24 g, 159 mmol) and the reaction
mixture was stirred overnight at rt. Sat. NaHCO3 was added and the resulting mixture
was partitioned.  The organic fractions were concentrated in vacuo to afford the title
compound as a clear light yellow oil (26.8 g, 96%). [28]
2.2.2.2 Synthesis of N-(2-(tert-Butyldimethylsilyloxy)ethyl)prop-2-yn-1-amine –
Compound (2)
To a solution of 1 (10 g, 57 mmol) in 100 mL of CH2Cl2 was added
diisopropylethylamine (3.7 g, 28.5 mmol), and this solution was cooled in an ice-water
bath. To this solution was added 3-bromoprop-1-yne (3.4 g, 28.5 mmol) dropwise over
30 min. This reaction mixture was stirred at rt. until TLC analysis indicated the complete
consumption of starting material (3 h). Sat. NaHCO3 was added and the reaction mixture
was partitioned.  The organic fraction was concentrated in vacuo, to afford an oil which
was purified by silica gel chromatography eluting with a gradient of hexanes/EtOAc (7:3
to 3:7) to afford the title compound as a clear yellow oil (2.9 g, 71%); 1H NMR (500
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MHz, CDCl3) δ 0.07 (s, 6H), 0.90 (s, 9H), 1.67 (br s, 1H), 2.21 (s, 1H), 2.80 (t, 2H, J =
5.5 Hz), 3.46 (s, 2H), 3.75 (t, 2H, J = 5.1 Hz); 13C NMR (100 MHz, CDCl3) δ -5.36,
25.89, 29.66, 38.18, 50.52, 62.32, 71.21, 82.15; ESI-HRMS (ES+) m/z calcd for
C11H23NOSi: 213.1549, found 214.1626 [M + H]
+. Anal. Calcd. For C11H23NOSi: C,
61.91; H, 10.86. Found: C, 61.56; H, 10.49.
2.2.2.3 Synthesis of N-(2-(tert-Butyldimethylsilyloxy)ethyl)-uracil-1-yl-N-(prop-2-yn-
1-yl)acetamide – Compound (3)
To a solution of uracil-1-yl acetic acid (2.4 g, 14 mmol) in 240 mL of DMF was added
diisopropylethylamine (1.8 g, 14 mmol) and this solution was cooled in an ice-water bath.
The acid was activated with the addition of O-Benzotriazole-N,N,N′,N′-tetramethyl-
uronium-hexafluorophosphate (5.3 g, 14 mmol) to the stirring solution over the course of
5 min, followed by the dropwise addition of 2 (2 g, 9.4 mmol) over 15 min. The reaction
mixture was stirred for 24 h at ambient temperature and then extracted with EtOAc and
the organic layer was washed with H2O and brine (x3). The organic layer was collected
and concentrated in vacuo to afford the crude product. This crude product was purified by
flash chromatography with a gradient of hexanes/EtOAc (7:3) to 100% EtOAc to elute
the title compound as a white solid (1.5 g, 44%). Compound 3 is a pair of rotamers; the
signals to the major (ma.) and minor (mi.) rotamers are designated; 1H NMR (500 MHz,
CDCl3) δ 0.04 (s, 2H, mi.), 0.08 (s, 4H, ma.), 0.88 (s, 3H, mi.), 0.89 (s, 6H, ma.), 2.25 (br
s, 0.66H, ma.), 2.41 (br s, 0.33H, mi.), 3.58 (t, 0.6H, J = 5.3 Hz, mi.), 3.65 (t, 1.4H, J =
5.2 Hz, ma.), 3.76 (t, 0.6H, J = 5.3 Hz, mi.), 3.85 (t, 1.4H, J = 5.0 Hz, ma.), 4.27 (2s, 2H),
4.68 (m, 2H), 5.71–5.74 (m, 1H), 7.13 (d, 0.66H, J = 7.9 Hz, ma.), 7.17 (d, 0.33H, J = 7.9
Hz, mi.), 9.43 (br s, 0.66H, ma.), 9.48 (br s, 0.33H, mi.); 13C NMR (125 MHz, CDCl3) δ -
5.61, -5.55, -5.41, -5.36, -3.72, -3.53, 17.94, 18.11, 18.28, 25.54, 25.69, 25.75, 25.81,
25.89, 25.96, 35.16, 38.67, 48.03, 48.06, 48.78, 49.55, 60.58, 61.67, 72.72, 73.59, 77.93,
78.13, 102.13, 102.24, 145.02, 145.09, 150.90, 150.93, 163.58, 166.30, 166.66; ESI-
HRMS (ES+) m/z calcd for C17H27N3O4Si: 365.1771, found 366.1845 [M + H]
+. Anal.
Calcd. for C17H27N3O4Si: C, 55.86; H, 7.45; N, 11.50. Found: C, 55.67; H, 7.80; N,
11.89.
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2.2.2.4 Synthesis of 2-Azidoethanamine – Compound (4)
To a solution of NaN3 (23.8 g, 366 mmol) in 200 mL of water was added 2-
bromoethylamine hydrobromide (25 g, 122 mmol) and this solution was heated to 75 ᵒC.
The reaction mixture was stirred for 24 h and was then cooled in an ice-water bath.  To
the cooled solution was added NaOH (28.5 g, 712.5 mmol) and the reaction mixture was
stirred until the NaOH was fully dissolved. To this aqueous solution was added Et2O
(x3).  The ether fractions were collected, dried over Na2SO4 and evaporated in vacuo to
afford the title compound as a clear oil (6.7 g, 64%). The 1H proton and 13C NMR shifts
were confirmed with the report by Mayer and Maier. [29]
2.2.2.5 Synthesis of Ethyl 2-(2-azidoethylamino)acetate – Compound (5)
To a solution of 4 (5 g, 58.1 mmol) in 100 mL of DMF was added triethylamine (5.9 g,
58.1 mmol).  Ethyl 2-bromoacetate (5.8 g, 34.9 mmol) was then added dropwise over 15
min to the stirring solution and the reaction was stirred for 4 h at room temperature. The
solution was then extracted with EtOAc, washed with H2O (three times) and the EtOAc
fractions were collected and dried over Na2SO4. This solution was evaporated under
reduced pressure to yield a crude orange oil. The oil was loaded directly onto a silica
column for purification by gradient eluting with hexanes/EtOAc (5:5) to 100% EtOAc to
afford the title compound as a clear light yellow oil (5.0 g, 83%); 1H NMR (400 MHz,
CDCl3) δ 1.25 (t, 3H, J = 7.1 Hz), 1.98 (br s, 1H), 2.80 (t, 2H, J = 5.7 Hz), 3.39 (t, 2H, J
= 5.9 Hz), 3.40 (s, 2H), 4.17 (q, 2H, J = 7.4 Hz); 13C NMR (100 MHz, CDCl3) δ 14.09,
48.01, 50.50, 51.33, 60.74, 172.07; ESI-HRMS (ES+) m/z calcd for C6H12N4O2:
172.0960, found 173.1034 [M + H]+. Anal. Calcd. for C6H12N4O2: C, 41.85; H, 7.02; N,
32.54. Found: C, 41.65; H, 6.82; N, 32.12.
2.2.2.6 Synthesis of Ethyl 2-(N-(2-azidoethyl)-uracil-1-yl-acetamido)acetate –
Compound (6)
To a solution of uracil-1-yl acetic acid (1.1 g, 6.4 mmol) in 100 mL of anhydrous DMF
under N2 was added dicyclohexylcarbodiimide (1.3 g, 6.4 mmol) and 1N-
hydroxybenzotriazole (1.0, 6.4 mmol). This solution was stirred for 15 min on an ice-
water bath, followed by 1 h of stirring at ambient temperature.  To this solution was
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added compound 5 (1 g, 5.8 mmol) dropwise over 10 min, and the reaction mixture was
stirred for 24 h after which the DCU precipitate was collected by filtration.  The filtrate
was dried down in vacuo, dissolved in EtOAc, and washed with water and brine (x3).
The EtOAc solutions were concentrated in vacuo. The resulting crude product was
dissolved in a minimal amount of CH2Cl2 and purified by flash chromatography with a
gradient of hexanes/EtOAc (5:5) to 100% EtOAc to elute the title compound as a white
solid (1.2 g, 62%). Compound 6 is comprised of a pair of rotamers, each displaying
signals of equal intensity; 1H NMR (500 MHz, CDCl3) δ 1.28 (t, 1.5H, J = 7.1 Hz), 1.33
(t, 1.5H, J = 7.1 Hz), 3.55 (s, 2H), 3.59 (t, 1H, J = 5.6 Hz), 3.66 (t, 1H, J = 5.4 Hz), 4.12
(s, 1H), 4.21 (q, 1H, J = 7.1 Hz), 4.26 (s, 1H), 4.28 (q, 1H, J = 7.1 Hz), 4.49 (s, 1H), 4.72
(s, 1H), 5.74 (d, 0.5H, J = 6.0 Hz), 5.75 (d, 0.5H, J = 5.6 Hz), 7.20 (d, 0.5H, J = 2.0 Hz),
7.21 (d, 0.5H, J = 2.0 Hz), 9.08 (br s, 1H); 13C NMR (125 MHz, CDCl3) δ 14.11, 47.75,
47.82, 48.05, 48.31, 48.86, 49.84, 49.92, 50.95, 61.67, 62.31, 102.30, 102.38, 145.02,
145.14, 150.90, 150.92, 163.44, 167.16, 167.46, 168.64, 169.03; ESI-HRMS (ES+) m/z
calcd for C12H16N6O5: 324.1182, found 325.1262 [M + H]
+. Anal. Calcd. For
C12H16N6O5: C, 44.44; H, 4.97; N, 25.91. Found: C, 44.40; H, 5.10; N, 25.41.
2.2.2.7 Synthesis of Ethyl 2-(N-(2-(4-((N-(2-(tert-butyldimethylsilyloxy)ethyl)-uracil-
1-yl-acetamido)methyl)-1H-1,2,3-triazol-1-yl)ethyl)-Uracil-1-yl-
acetamido)acetate – Compound (7)
To a solution of compounds 3 (677 mg, 1.9 mmol) and 6 (600 mg, 1.9 mmol) dissolved
in 18 mL of THF/t-BuOH/H2O (1:1:1) was added sodium ascorbate (733 mg, 3.7 mmol)
followed by Cu(II)SO4 (231 mg, 925 μmol). This reaction mixture was stirred for 24 h at
room temperature and then extracted with CH2Cl2. The organic layer was washed with
H2O (three times) to wash off the excess copper. The precipitate in the organic layer was
collected by filtration and washed with cold H2O to afford the crude product. This crude
product was redissolved in minimal CH2Cl2/MeOH for 1 h and purified by flash column
chromatography eluting with 5% (10% NH4OH in MeOH) in CH2Cl2 to afford the title
compound as a white solid (1.3 g, 98%). Compound 7 is a mixture of rotamers with
varying signal intensities. 1H NMR (400 MHz, DMSO-d6) δ 0.03 (s, 2H), 0.05 (m, 4H),
0.85, 0.86 (2s, 9H), 1.18 (t, 1.5H, J = 7.2 Hz), 1.23 (t, 1.5H, J = 7.0 Hz), 3.48–3.50 (m,
1H), 3.63–3.91 (m, 4H), 4.01–4.03 (m, 1H), 4.08 (q, 1.2H, J = 7.3 Hz), 4.16 (q, 0.8H, J =
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7.3 Hz), 4.24, 4.29 (2s, 1H), 4.44–4.77 (m, 9H), 5.56 (d, 2H, J = 7.8 Hz), 7.31–7.47 (m,
2H), 7.89, 8.05, 8.13, 8.24 (4s, 1H), 11.29 (br m, 2H); 13C NMR (100 MHz, DMSO-d6) δ
-5.45, -5.39, 13.99, 14.04, 17.89, 18.04, 25.82, 25.90, 41.05, 47.31, 47.58, 47.91, 48.00,
60.18, 60.65, 60.83, 61.25, 100.57, 100.79, 123.70, 124.04, 124.12, 124.61, 143.18,
143.34, 143.41, 143.56, 146.12, 146.19, 146.29, 146.50, 146.54, 150.92, 150.98, 151.04,
151.07, 151.11, 163.76, 163.80, 163.81, 163.85, 163.88, 166.74, 166.82, 166.88, 166.90,
167.43, 167.97, 168.03, 168.85, 169.15; ESI-HRMS (ES+) m/z calcd for C29H43N9O9Si:
689.2953, found 690.3030 [M + H]+. Anal. Calcd. for C29H43N9O9Si: C, 50.50; H, 6.28.
Found: C, 50.47; H, 6.24.
2.2.2.8 Synthesis of N-(2-(tert-Butyldimethylsilyloxy)ethyl)-uracil-1-yl-N-((1-(2-
(uracil-1-yl-N-(2-hydroxyethyl)acetamido)ethyl)-1H-1,2,3-triazol-4-
yl)methyl)acetamide – Compound (8)
To a solution of compound 7 (300 mg, 435 µmol) suspended in 12 mL of dry THF, drops
of MeOH were added until the compound was dissolved. To this solution was then added
LiBH4 (544 µL, 1.09 mmol) and the reaction mixture was refluxed until TLC analysis
indicated the complete consumption of starting material (1.5 h). This reaction mixture
was quenched with MeOH and dried down in vacuo to afford the crude product. The
crude product was then redissolved in minimal CH2Cl2/MeOH and purified by flash
column chromatography eluting with a gradient of 10% NH4OH in MeOH (5 to 15%) in
CH2Cl2 to afford the title compound as a white crystalline solid (213 mg, 76%).
Compound 8 is a mixture of rotamers with varying signal intensities; 1H NMR (500
MHz, DMSO-d6) δ 0.03 (s, 2H), 0.05 (s, 4H), 0.85, 0.87 (2s, 9H), 3.16–3.27 (m, 2H),
3.43–3.54 (m, 4H), 3.63–3.74 (m, 3H), 3.80–3.87 (m, 2H), 4.36–4.38 (m, 1H), 4.46 (t,
1.2H, J = 6.3 Hz), 4.51 (t, 0.8H, J = 6.3 Hz), 4.56–4.81 (m, 6H), 4.94–5.00 (m, 1H),
5.54–5.58 (m, 2H), 7.35–7.47 (m, 2H), 7.87, 8.04, 8.13, 8.23 (4s, 1H), 11.30 (br s, 2H);
13C NMR (DMSO-d6) δ -5.44, -5.37, 17.91, 18.05, 25.83, 25.92, 30.74, 41.04, 46.24,
46.55, 46.71, 46.92, 48.29, 48.32, 48.51, 49.07, 49.26, 58.49, 58.81, 58.85, 60.21, 60.85,
100.57, 100.63, 123.76, 124.11, 124.55, 143.23, 143.39, 143.43, 143.58, 146.48, 146.52,
146.58, 151.04, 151.08, 151.11, 163.84, 163.87, 166.69, 166.74, 166.81, 167.43, 167.54;
ESI-HRMS (ES+) m/z calcd for C27H41N9O8Si: 647.2847, found 648.2918 [M + H]
+.
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Anal. Calcd. for C27H41N9O8Si: C, 50.06; H, 6.38; N, 19.46. Found: C, 50.23; H, 6.84; N,
19.36.




To a solution of compound 8 (1.06 g, 1.64 mmol) dissolved in 10 mL of dry pyridine
under N2, was added an excess of 4,4′-dimethoxytrityl chloride (1.66 g, 4.91 mmol) until
TLC analysis revealed the consumption of starting material. This reaction mixture was
stirred overnight at room temperature while under N2, after which the entire mixture was
extracted with CH2Cl2 and washed with H2O (two times). The organic fractions were
collected, dried over Na2SO4 and subsequently condensed in vacuo to afford the crude
product. The crude was dissolved in minimal CH2Cl2/MeOH and purified by flash
column chromatography eluting with a gradient of MeOH (5 to 15%) in CH2Cl2 to afford
the title compound as a white solid (1.22 g, 79%). Compound 9 is a mixture of rotamers
with varying signal intensities; 1H NMR (400 MHz, CDCl3) δ 0.03 (s, 2H), 0.06 (s, 4H),
0.86, 0.88 (2s, 9H), 2.87–2.94 (m, 1.5H), 3.03–3.08 (m, 0.5H), 3.20 (t, 1.5H, J = 4.7 Hz),
3.26 (t, 0.5H, J = 4.5 Hz), 3.29–3.31 (m, 0.2H), 3.36–3.43 (m, 0.3H), 3.46–3.55 (m,
2.5H), 3.60–3.67 (m, 2H), 3.72–3.75 (m, 0.75H), 3.76, 3.77 (2s, 7H), 3.80 (t, 1.25H, J =
4.9 Hz), 4.51 (t, 1.5H, J = 5.3 Hz), 4.55 (t, 0.5H, J = 5.3 Hz), 4.59 (s, 1H), 4.63–4.64 (m,
1H), 4.67 (s, 3H), 4.73 (d, 1H, J = 7.4 Hz), 5.51–5.55 (m, 1H), 5.62 (d, 0.1H, J = 1.6 Hz),
5.64 (d, 0.1H, J = 1.6 Hz), 5.64–5.68 (m, 0.8H), 6.57 (d, 0.1H, J = 7.8 Hz), 6.66 (d, 0.7H,
J = 7.8 Hz), 6.80–6.84 (m, 4.3H), 7.06–7.09 (m, 0.8H), 7.17–7.36 (m, 7.2H), 7.71, 7.81,
7.88, 7.94 (4s, 1H), 10.11 (br s, 2H); 13C NMR (100 MHz, CDCl3) δ -5.44, -5.16, 18.13,
18.29, 25.61, 25.83, 25.90, 41.33, 44.08, 47.64, 47.74, 48.27, 48.50, 48.62, 48.87, 48.93,
49.09, 55.23, 60.41, 60.66, 60.79, 60.98, 87.24, 87.39, 102.02, 102.21, 102.25, 113.15,
113.25, 124.37, 125.24, 127.18, 127.24, 127.86, 127.98, 128.15, 129.91, 130.08, 135.03,
135.09, 135.70, 143.49, 143.76, 144.01, 144.05, 144.65, 145.00, 145.10, 145.15, 145.21,
145.54, 151.26, 151.32, 151.38, 151.46, 158.42, 158.67, 158.71, 163.91, 164.00, 164.08,
166.48, 167.25, 167.67. ESI-HRMS (ES+) m/z calcd for C48H59N9O10Si: 949.4154, found
972.4035 [M + Na]+. Anal. Calcd. for C48H59N9O10Si: C, 60.68; H, 6.26; N, 13.27.
Found: C, 60.50; H, 6.28; N, 12.90.
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2.2.2.10 Synthesis of N-(2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)-2-(Uracil-
1-yl)-N-((1-(2-(2-(Uracil-1-yl)-N-(2-hydroxyethyl)acetamido)ethyl)-1H-
1,2,3-triazol-4-yl)methyl)acetamide – Compound (10)
To a solution of compound 9 (1.12 g, 1.18 mmol) dissolved in 26 mL of dry THF was
added TBAF (926 mg, 3.54 mmol). This reaction mixture was stirred for 12 h at room
temperature and then extracted with CH2Cl2. The organic layer was washed with H2O and
brine (x2), at which point the combined organic fractions were dried over Na2SO4, and
evaporated under reduced pressure. The crude was dissolved in minimal CH2Cl2/MeOH
and purified by flash column chromatography, first eluting with 100% CH2Cl2 followed
by a gradient of MeOH (5 to 15%) in CH2Cl2 to afford the title compound as a yellow
solid (840 mg, 85%). Compound 10 is a mixture of rotamers with varying signal
intensities; 1H NMR (400 MHz, CDCl3) δ 2.49 (br s, 1H), 2.98 (br s, 1H), 3.16–3.20 (br
m, 2H), 3.27–3.31 (m, 3H), 3.45–3.57 (m, 4H), 3.68–3.81 (m, 8H), 4.45–4.80 (m, 8H),
5.50–5.53 (m, 0.8H), 5.56–5.60 (m, 1.2H), 6.63 (d, 0.15H, J = 8.2 Hz), 6.66 (d, 0.35H, J
= 7.8 Hz), 6.78–6.83 (m, 4H), 7.17–7.31 (m, 8.5H), 7.69, 7.88, 7.90, 8.09 (4s, 1H),
10.20–10.42 (br m, 2H); 13C NMR (100 MHz, CDCl3) δ 22.13, 27.75, 29.14, 29.64,
42.18, 47.37, 48.29, 49.13, 50.35, 55.24, 59.15, 60.78, 68.46, 87.23, 87.32, 101.65,
101.91, 107.85, 113.16, 113.26, 124.97, 127.16, 127.99, 128.17, 129.92, 130.09, 135.15,
135.73, 143.56, 144.11, 144.28, 145.47, 146.36, 151.41, 151.47, 158.40, 158.64, 164.30,
164.39, 164.56, 167.63, 167.68; ESI-HRMS (ES+) m/z calcd for C42H45N9O10: 835.3289,
found 858.3217 [M + Na]+. Anal. Calcd. for C42H45N9O10: C, 60.35; H, 5.43. Found: C,
60.72; H, 5.81.
2.2.2.11 Synthesis of 2-(N-(2-(4-((N-(2-(bis(4-
methoxyphenyl)(phenyl)methoxy)ethyl)-2-(Uracil-1-yl)acetamido)methyl)-
1H-1,2,3-triazol-1-yl)ethyl)-2-(Uracil-1-yl)acetamido)ethyl (2-cyanoethyl)
diisopropylphosphoramidite – Compound (11)
To a solution of compound 10 (230 mg, 275 µmol) dissolved in 6 mL of dry CH2Cl2
under N2, was added diisopropylethylamine (196 mg, 1.51 mmol) along with 4-
dimethylaminopyridine (16.8 mg, 138 µmol). To this solution was added 2-cyanoethyl
N,N-diisopropylchlorophosphoramidite (195 mg, 825 µmol), until TLC analysis revealed
the maximum consumption of starting material. This mixture was then stirred for 6 h at
room temperature under N2 and dried in vacuo to afford the crude product. The crude was
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dissolved in minimal 2% triethylamine in hexanes/acetone and purified by flash column
chromatography eluting with a gradient of 2% triethylamine in acetone/hexanes (1:1 to
4:1) to afford the title compound as a white solid (180 mg, 63%). Compound 11 is a
mixture of rotamers with varying signal intensities; 1H NMR (400 MHz, CDCl3) δ 1.14–
1.19 (m, 12H), 2.62–2.66 (m, 3.25H), 2.92 (t, 1H, J = 3.9 Hz), 3.07 (t, 0.75H, J = 4.3
Hz), 3.21 (t, 1.25H, J = 4.7 Hz), 3.26 (t, 0.5H, J = 4.3 Hz), 3.29–3.37 (m, 0.25H), 3.54–
3.61 (m, 5.5H), 3.70–3.77 (m, 2H), 3.78 (s, 6.25H), 3.81–3.90 (m, 2.25H), 4.52 (t, 1H, J
= 5.3 Hz), 4.55 (t, 0.5H, J = 5.5 Hz), 4.61–4.65 (m, 2H), 4.70 (s, 2.5H), 4.74–4.77 (m,
1H), 5.52–5.55 (m, 1H), 5.66–5.70 (m, 1H), 6.56 (d, 0.33H, J = 7.8 Hz), 6.63 (d, 0.66H, J
= 7.8 Hz), 6.81–6.84 (m, 4H), 7.17–7.31 (m, 12H), 7.70, 7.76, 7.89, 7.95 (4s, 1H); 13C
NMR (100 MHz, CDCl3) δ 14.10, 14.84, 20.45, 20.52, 22.66, 23.34, 24.58, 24.62, 24.65,
24.69, 24.77, 29.24, 29.34, 29.66, 31.72, 31.89, 33.80, 34.43, 41.51, 43.02, 43.14, 45.82,
47.67, 47.80, 48.29, 48.60, 48.71, 48.93, 53.76, 55.26, 58.08, 58.30, 60.53, 60.70, 60.80,
69.48, 87.29, 87.42, 102.08, 102.20, 102.25, 113.27, 117.90, 118.12, 125.13, 127.24,
128.01, 128.20, 130.12, 135.05, 135.09, 143.39, 143.82, 144.05, 145.07, 145.46, 151.24,
151.34, 151.45, 158.71, 158.75, 163.63, 163.87, 163.91, 166.67, 167.41, 167.74; ESI-
HRMS (ES+) m/z calcd for C51H62N11O11P: 1035.4368, found 1058.4298 [M + Na]
+.
2.2.3 Procedure for the Chemical Synthesis of Oligonucleotides
All standard β-cyanoethyl DNA phosphoramidites, solid supports and reagents were
purchased from Glen Research. All oligonucleotides were synthesized on an Applied
Biosystems 394 DNA/RNA synthesizer using a 0.2 µM cycle with a 25 s coupling time
for unmodified phosphoramidites. All phosphoramidites were dissolved in anhydrous
acetonitrile to a 0.1 M concentration immediately prior to synthesis. Synthesis on solid
phase was accomplished using 0.2 µM solid supports. Cleavage of the unmodified
oligonucleotides from their solid supports was performed through exposure to 1.5 mL of
30% NH4OH for 2 h at room temperature, followed by incubation in 30% NH4OH at 55ᵒC overnight. All oligonucleotides were purified on a 20% denaturing polyacrylamide gel
by utilizing the ′′crush and soak′′ method, followed by ethanol precipitation and desalting
through Millipore 3000 MW cellulose centrifugal filters. The oligonucleotides were
characterized by MALDI-TOF mass spectrometry (Waters Tofspec-2E) (Table 2.1).
50
2.2.3.1 Synthesis of 5′ and 3′ Triazole-Modified Oligonucleotides
Phosphoramidite 11 was attached to the 5′ end of the growing oligonucleotide being
synthesized on the ABI 394 DNA/RNA synthesizer, with an increased coupling time of
600 s. To perform the 3′ modification, compound 11 was attached to a Universal III solid
support (Glen Research) via the ABI 394 synthesizer with a 600 s coupling time.
Cleavage from the Universal III solid support was performed through exposure to 1.5 mL
of 2 M NH3 in MeOH for 30 min at room temperature, followed by incubation in 30%
NH4OH at 55 ᵒC for 8 h.
2.2.3.2 Oligonucleotide Sequences Used in the Study
Oligonucleotides synthesized using standard dT/dA supports: (i) 5′-AAG AGA GAG
AAA AA–3′; (ii) 5′–TTT TTC TCT CTC TT–3′; and (iii) 5′–UUT TTC TCT CTC TT–3′.
The UU–3′ modified sequence synthesized on the Universal III solid support: 5′–TTT
TTC TCT CTC UU–3′. The sequence 5′-AAG AGA GAG AAA AA-3′ was purchased
and purified from Integrated DNA Technologies.
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2.3 Results
2.3.1 Synthesis of Uracil-Based Alkyne Monomer
Our strategy involves the synthesis of a uracil-based monomer possessing an alkyne
functional group and a uracil-based monomer with an azide. For the synthesis of the
uracil-based alkyne monomer, the first step involved tert-butyldimethylsilyl (TBS)
protection of ethanolamine and this was conducted using TBSCl under standard basic
conditions to afford 1 in 96% yield. Alkylation of 1 with propargyl bromide generated the
alkyne 2 as a liquid in 71% yield. Utilizing peptide bond coupling conditions involving
HBTU, the alkyne 2 was amide-bond coupled to uracil-1-yl acetic acid [30] to afford
compound 3 as a white solid in 44% yield (Scheme 2.1).
Scheme 2.1 Reagents and conditions: (i) 1 equiv imidazole, 1 equiv TBS-Cl,
DCM, room temperature 96% yield of 1; (ii) 0.5 equiv DIPEA, 0.5 equiv propargyl
bromide, DCM, room temperature, 3 h, 71% yield of 2; (iii) 1.5 equiv uracil-1-yl
acetic acid, 1.5 equiv DIPEA, 1.5 equiv HBTU, DMF, 24 h, 44% yield of 3.
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2.3.2 Synthesis of Uracil-Based Azide Monomer
For the synthesis of the azide-based uracil monomer 6, 2-azidoethylamine 4 was prepared
by the addition of 2-bromoethylamine to an aqueous solution of sodium azide. Alkylation
of 4 with a limiting amount of ethyl 2-bromoacetate afforded compound 5 as an off-
colored liquid in 83% yield. This liquid 5 was amide-bond coupled with uracil-1-yl acetic
acid using DCC/HOBt to afford the azide-based uracil monomer, compound 6 in 62%
yield (Scheme 2.2).
________________________________________________________________________
2.3.3 Synthesis of Triazole-Linked Uracil Nucleoside Dimer Phosphoramidite
With respect to the synthesis of the phosphoramidite, the first task was to cyclize both
monomers together. Under copper (I) conditions, 1,4-triazole formation occurred with
copper sulfate and sodium ascorbate to afford a white solid 7 in 98% yield. This newly
formed dimer 7 was selectively reduced with 2.5 equivalents of LiBH4 in a
methanol/THF mixture to afford the alcohol 8 in 76% yield. Alcohol 8 was treated with
Scheme 2.2 Reagents and conditions: (i) 3 equiv NaN3, H2O, 75 ᵒC, 24 h; (ii) 5.8
equiv NaOH, 0 ᵒC, Et2O, 64% yield of 4; (iii) 1 equiv NEt3, 0.6 equiv ethyl 2-
bromoacetate, DMF, 4 h, 83% yield of 5; (iv) 1.1 equiv uracil-1-yl acetic acid, 1.1
equiv DCC, 1.1 equiv HOBt, DMF, 24 h, 62% yield of 6.
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4,4′-dimethoxytrityl-chloride (DMT-Cl) to afford the compound 9 in 79% yield. The
subsequent removal of the TBS group using TBAF provided the alcohol 10 in 85% yield.
This was then followed by synthesis of phosphoramidite 11 by reacting alcohol 10 with
2-cyanoethyl N,N-diisopropylchlorophosphoramidite to afford a clear oil in 63% yield
(Scheme 2.3). With this phosphoramidite 11, its incorporation within a DNA
oligonucleotide was accomplished by employing solid-phase oligonucleotide synthesis on
a 394 ABI synthesizer.
Scheme 2.3 Reagents and conditions: (i) 2 equiv sodium ascorbate, 0.5 equiv
Cu(II)SO4, THF/t-BuOH/H2O (1:1:1), 24 h, 98% yield of 7; (ii) 2.5 equiv LiBH4,
THF/MeOH (12:1), reflux 1.5 h, 76% yield of 8; (iii) 3 equiv DMT-Cl, pyridine, 24 h,
79% yield of 9; (iv) 3 eq TBAF, THF, 12 h, 85% yield of 10; (v) 2 equiv 2-cyanoethyl
N,N-diisopropylchlorophosphoramidite, 5.5 equiv DIPEA, 0.5 equiv DMAP, DCM, 8
h, 63% yield of 11.
54
2.3.4 Melting Temperatures (Tm) Through UV-Monitored Thermal Denaturation
UV-melting denaturation studies indicate that moderate destabilization occurs with the
UU-dimer on both the 5′ and 3′ position relative to the native strand (Table 2.1). A
reduction in Tm of 4.5 ᵒC and 2.8 ᵒC is observed when native TT is replaced with the UU-
dimer modification at the 5′ end and the 3′ end, respectively. However, this suggests a
certain degree of compatibility as the Tm values for both modified oligonucleotides are
higher when compared to corresponding 12-mer sequences lacking the heterocyclic
pyrimidine dimer (UU) (Table 2.1). In comparison to other studies [31] and that of
Kraicsovits and coworkers, a similar Tm drop was observed when compared to a PNA-
DNA chimera that contained a PNA element at the terminal end [32].
Table 2.1 UV-melting denaturation studies.
UV melting temperatures for duplexes to complement strand DNA (5′-AAG AGA
GAG AAA AA-3′). The total strand concentration ranged from 2.4 to 3.0 µM in 90
mM NaCl, 10 mM sodium phosphate, and 1 mM EDTA at pH 7.0.
aFor the ΔTm values, the Tm of Entry I is the reference (Tm = 40.9 ᵒC).
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2.4 Discussion & Conclusion
In conclusion, a facile and practical synthesis of a new uracil-uracil dimer linked together
through a triazole functionality has been developed and is readily synthesized from
inexpensive starting material precursors. Our alkyne-uracil monomer 3 was synthesized
in 44% yield and the azide-uracil monomer 6 was generated in 62% yield. Following
heterocyclic cyclization, the phosphoramidite 11 was generated in four steps in 32%
yield. Incorporation of the heterocyclic dimer at both the 5′ and 3′ ends of DNA
oligonucleotides suggests a certain degree of compatibility when analyzed by UV-
monitored thermal denaturation. The effects of this modification within different
positions of other various oligonucleotides will be investigated. Notwithstanding, these
oligonucleotides may have potential use when targeted at messenger RNA in diseased
cells, or for other downstream applications.
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Connecting Statement I
Having clearly established the compatibility of the unnatural triazole-based linkage with
Watson-Crick interactions in duplex DNA molecules, and having determined that it is a
destabilizing modification from the Chapter I study, our results paved the way towards
the use of this unnatural linkage within synthetic siRNA constructs. In the following
study, we chemically incorporated both triazole-linked uracil-uracil and cytosine-uracil
nucleoside dimer analogs throughout siRNAs using phosphoramidite chemistry. These
siRNAs were designed to either target the exogenous firefly luciferase reporter gene or
the endogenous glyceraldehyde-3-phosphoate dehydrogenase (GAPDH) gene. We
characterized the resultant triazole-modified siRNAs using Circular Dichroism
spectroscopy and UV-monitored thermal denaturation experiments, while ascertaining
their efficacy through a dual-reporter luciferase assay and qRT-PCR.
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An efficient synthesis of siRNAs modified at the backbone with a triazole functionality is
reported. Through the use of 4,4′-dimethoxytrityl (DMT) phosphoramidite chemistry,
triazole backbone dimers were site-specifically incorporated throughout various siRNAs
targeting both firefly luciferase and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene transcripts as representatives of an exogenous and endogenous gene,
respectively. Following the successful silencing of the firefly luciferase reporter gene,
triazole-modified siRNAs were also found to be capable of silencing GAPDH in a dose-
dependent manner. Backbone modifications approaching the 3′-end on the sense strand
were tolerated without compromising siRNA potency. This study highlights the
compatibility of triazole-modified siRNAs within the RNAi pathway, and the




In 1998, Fire and Mello reported that short interfering RNAs (siRNAs) could be
introduced into cells in Caenorhabditis elegans and block gene expression.1 This process
involves the incorporation of siRNAs into an RNA-induced silencing complex (RISC),
which serves to select and deliver the guide strand to its target messenger RNA (mRNA)
for selective gene silencing.2 Since this discovery, there has been considerable interest in
utilizing siRNAs as potential therapeutic agents in combating disease.3 However, natural
siRNAs are prone to degradation by nucleases and exhibit poor cell membrane
permeability due to their polyanionic charge. There is wide interest in chemically
modifying siRNAs in order to alleviate the aforementioned problems.
A vast number of studies have thoroughly explored the properties of chemically modified
oligonucleotides that contain the unnatural architecture at the sugars4 and bases.5
However, relatively very little has been done with respect to modifying the
internucleotide linkage of siRNAs with nonionic moieties. With respect to negatively
charged backbone mimics, phosphorothioates (PS) have been shown to be accommodated
within the RNAi pathway; however, ranges in potency are often observed and
cytotoxicity is a concern.6 Alternatively, functional data of siRNAs bearing
boranophosphate linkages show RNAi compatibility and offer enhanced potency
comparable to PS with reduced cytotoxicity.7
With respect to nonionic backbone modifications, two studies have shown that these can
be accommodated within the 3′-overhangs of siRNAs. Iwase and co-workers have shown
that an amide linkage enhances thermodynamic stability and resistance to nucleases.8
Potenza and co-workers have also illustrated that an amide-bond at the 3′-end of siRNAs
acts as a substrate for the RNAi pathway.9
The crystal structure of the RISC complex by Patel et al., complexed with a duplex
oligonucleotide reveals that a number of key phosphodiester contacts are necessary for its
interaction with the protein complex; however, many of these ionic contacts are not
present on the sense strand of the oligonucleotide.10 Therefore, we envisioned that by
modifying the sense strand, we could synthesize novel siRNAs with uncharged
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backbones within the duplex that could thus serve as appropriate substrates for the RNAi
pathway without compromising their potency.
Utilizing the well-known Cu(I)-assisted Huisgen 1,3-dipolar cycloaddition,11 the triazole
moiety can be introduced as an uncharged oligonucleotide backbone modification with
relative ease. Although a variety of triazole-modified oligonucleotide mimics have been
reported, most constructs are DNA-based.12 Reports of click-ligated RNAs include one
from El-Sagheer and Brown,13 who were successful in synthesizing functional hairpin
ribozymes containing both cross- and intra-strand triazole linkages. Other reports of
triazoles within RNAs include work from Das and co-workers,14a and most recently from
Rozners and co-workers14b who demonstrated site-specific incorporation of a triazole-
linked nucleoside dimer within RNAs.
In previous work, we have synthesized a triazole-
linked nucleoside dimer phosphoramidite based on a
PNA-like structure, and this modification displayed
compatibility when hybridized to its complement.15
Despite the numerous examples of distinct nucleoside
backbone derivatives linked together through a triazole
moiety, none of the derivatives have been reported as
substrates within the RNAi pathway. Herein, we report
the incorporation of triazole-linked nucleic acids based
on a PNA-type scaffold (Fig. 3.8) within duplex
siRNAs. The RNAs display effective gene silencing
and thus exhibit a high degree of compatibility as
RNAi substrates.
3.2 Materials and Methods
3.2.1 General Synthetic Methods
Unless otherwise noted, all starting materials were obtained from commercial sources and
were used without any additional purification. Anhydrous CH2Cl2, THF and DMF were




Purification by flash column chromatography was carried out with Silicycle Siliaflash 60
(230-400 mesh) according to the procedure of Still, Kahn, and Mitra.16 1H NMR, 13C
NMR, and 31P NMR spectra were recorded at 400 or 500 MHz, 100 or 125 MHz, and 167
MHz, respectively, in either DMSO-d6 or CDCl3. ESI-MS spectra were recorded on a
Waters Quattro Micro MS. Both HRMS and ESI Q-TOF spectra were recorded on an
Agilent Q-TOF. Circular Dichroism (CD) spectroscopy and UV-monitored thermal
denaturation were both performed on a Jasco J-815 CD equipped with temperature
control.
3.2.2 Procedure for the Chemical Synthesis of Oligonucleotides
All standard β-cyanoethyl RNA phosphoramidites, reagents and solid supports were
purchased from Chemgenes Corporation and Glen Research. Wild-type sequences were
purchased and purified from Integrated DNA Technologies (IDT). All modified
oligonucleotides were synthesized on an Applied Biosystems 394 DNA/RNA synthesizer
using 0.2 μM or 1.0 μM cycles with 16 min coupling times for all modified and
unmodified phosphoramidites. All commercial phosphoramidites were dissolved in
anhydrous acetonitrile to a concentration of 0.1 M, while chemically synthesized triazole-
modified phosphoramidites were dissolved to a concentration of 0.08 M. A lower
concentration (0.08 M) of the triazole-linked amidite dimers was used because the
compound was not fully soluble in acetonitrle at 0.1 M concentration. We observed an
average coupling efficiency of >98% with the use of the triazole amidites as monitored
by trityl cation absorbance. Sequences containing 3′ modifications were synthesized on
1.0 μM Universal III solid supports, while all other sequences were synthesized on 0.2
μM or 1.0 μM dT solid supports (Glen Research). Antisense sequences were chemically
phosphorylated on the 5′ end using 2-[2-(4,4′-Dimethoxytrityloxy)ethylsulfonyl]ethyl-(2-
cyanoethyl)-(N,N-diisopropyl)-phosphoramidite (Glen Research). Cleavage of
oligonucleotides from their solid supports was performed through on-column exposure to
1.5 mL of EMAM (methylamine 40% wt. in H2O and methylamine 33% wt. in ethanol,
1:1 (Sigma-Aldrich)) for 30 min at room temperature, followed by incubation in EMAM
overnight to deprotect the bases. Crude oligonucleotides were precipitated in EtOH and
desalted through Millipore Amicon Ultra 3000 MW cellulose centrifugal filters.
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Oligonucleotides were excised from the 20% denatured gel and were gel purified,
followed by desalting through centrifugal filters. Final oligonucleotide purity was
visualized on a denaturing 20% polyacrylamide gel electrophoresis (PAGE) stained with
ethidium bromide or by UV-shadowing. These RNAs were subjected to ESI Q-TOF to
confirm their expected mass. Equimolar amounts of complimentary RNAs were annealed
at 90 ᵒC for 2 min in a binding buffer (75 mM KCl, 50 mM Tris-HCl, 3 mM MgCl2, pH
8.3) and this solution was cooled slowly to room temperature to generate siRNAs.
3.2.3 Chemical and Structural Characterization of Oligonucleotides
3.2.3.1 Circular Dichroism Spectroscopy
Equimolar amounts of each RNA (2.4 nmol) were annealed to their compliment in 500
μL of a sodium phosphate buffer (90 mM NaCl, 10 mM Na2HPO4, 1 mM EDTA, pH 7)
at 90 ᵒC for 2 min and this solution was cooled slowly to rt. CD measurements of each
duplex were recorded in quadruplicate from 200 to 310 nm at 20 ᵒC in the sodium
phosphate buffer, with a scanning rate of 10 nm/min and a 0.2 nm data pitch. The average
of four accumulations was calculated using Jasco′s Spectra Manager version 2 software
and adjusted against the baseline measurement of the buffer.
3.2.3.2 Melting Temperature (Tm) Determination Through UV-Monitored Thermal
Denaturation
Melting temperatures (Tm) were measured in the sodium phosphate buffer at 260 nm with
a temperature range of 10 to 95 ᵒC. The temperature was increased at a rate of 0.5 ᵒC/min
while absorbance was measured at the end of each 0.5 ᵒC increment. Absorbance
readings were automatically adjusted against the baseline absorbance of the sodium
phosphate buffer. After averaging the range of absorbance values obtained from three
independent experiments for each siRNA, Tm′s were calculated using Meltwin version 3.5
software assuming the two-state model.17
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3.2.3.3 High-Resolution Mass Spectrometry
Compounds 1 through 8 were analyzed through positive electrospray ionization using a
mobile phase of acetonitrile/MeOH (95:5) with 0.1% formic acid. Being acid labile, the
mobile phase for compound 8 was pure MeOH.
3.2.3.4 Quantitative Time-of-Flight Mass Spectrometry
All single-stranded RNAs were gradient eluted through a Zorbax Extend C18 HPLC
column with a MeOH/H20 (5:95) solution containing 200 mM hexafluoroisopropyl
alcohol and 8.1 mM triethylamine, and finally with 70% MeOH. The eluted RNAs were
subjected to ESI-MS (ES-), producing raw spectra of multiply-charged anions and
through resolved isotope deconvolution, the molecular weights of the resultant neutral
oligonucleotides were confirmed for all the RNAs (Table A6, Appx. II).
3.2.4 Methods for Culturing Eukaryotic Cells
HeLa cells were cultured in Dulbecco′s modified eagle′s medium (DMEM) containing
10% fetal bovine serum (FBS) (Perbio) and 1% Penicillin-Streptomycin (Sigma) at 37 ᵒC
with 5% CO2. For passaging cells, a 1X solution of 0.25% Trypsin (SAFC Bioscience) as
used to disperse the cells.
3.2.5 Time-Dependent Nuclease Stability Assays
Duplex siRNAs wt, 17, 18 and 22 (12 μM) were incubated at 37 ᵒC in 10 μL of a 13.5%
solution of FBS for 0.5, 1, 1.5, 3 and 5 hours. In order to visualize duplex degradation as
a function of time, samples were immediately resolved using 20% native PAGE after
each incubation time. Gels were stained with a 3X solution of Gel Red nucleic acid stain
(Biotium) for 30 min and visualized on a Fluorchem SP (Figure A51, Appx. II). These
siRNAs were digested under similar identical conditions 5 and 12 hours, after which they
were incubated at 95 ᵒC to for 5 min to reduce or eliminate any residual nuclease activity
and gradually cooled to room temperature. HeLa cells were transfected with 80 pM of
each digested siRNA and efficiency was monitored using the protocol described below
(Figure A52, Appx. II).
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3.2.6 Gene-Silencing Capabilities of Triazole-Modified siRNAs
3.2.6.1 Firefly luciferase Dual-Reporter In Vitro Assay
Prior to transfection, HeLa cells were seeded on 12-well plates (Greiner Bio-One) at a
density of 100,000 cells per well and incubated at 37 ᵒC with 5% CO2 in DMEM
containing 10% FBS. After 24 hr, varying concentrations of anti-luciferase siRNAs 9 - 20
were co-transfected with both pGL3 (Promega) and pRLSV40 (York University)
luciferase-expressing plasmids using Lipofectamine 2000 (Invitrogen) in Gibco′s Opti-
Mem Reduced Serum Medium 1X (Invitrogen) according to the manufacturer′s protocol.
After an additional 24 hr, cells were incubated in 1X passive lysis buffer (Promega) for
20 min at room temperature, and cell lysate was loaded onto white and opaque, 96-well
plates (Costar). Using the Dual-luciferase Reporter Assay kit (Promega), observed
luminescence was proportional to both firefly and renilla luciferase expression, recorded
on a Synergy HT (Bio-Tek) plate luminometer. The ratio of firefly/renilla luminescence
expressed as a percentage relates the reduction in firefly expression to siRNA efficacy
when compared to untreated controls. Each value is the average of at least three
independent experiments with the indicated error (SDOM).
3.2.6.2 Quantitative Real-Time Expression of Glyceraldehyde-3-Phosphate
Dehydrogenase
On a 12-well plate, 65,000 HeLa cells were added to each well and incubated at 37 ᵒC
with 5% CO2 in DMEM with 10% FBS. After 24 hr, cells were treated with 10 nM and
20 nM concentrations of anti-GAPDH siRNAs using Lipofectamine 2000 in 1X Opti-
Mem according to the manufacturer′s protocol. Achieving a cellular concentration of
approximately 260,000 cells/well after a total incubation time of 48 hr, cells were
dispersed with trypsin and lysed for the reverse transcription (RT) of total RNA. RT was
performed using the Cells-to-cDNA II kit (Applied Biosystems) following the
manufacturer′s protocol. Amplification of GAPDH and 18S cDNA was accomplished on
a CFX96 Real-Time reactor (BIO-RAD), using SsoFast EvaGreen Supermix (BIO-RAD)
as the source of SYBR green and Taq Polymerase, along with 800 nM of GAPDH
forward/reverse primers and 60 nM of 18S forward/reverse primers, all contained within
20 μL reaction volumes. The GAPDH forward and reverse primers were 5′- AGG GCT
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GCT TTT AAC TCT GG -3′ and 5′- TTG ATT TTG GAG GGA TCT CG - 3′,
respectively, yielding a 200-bp amplicon.18 The 18S forward and reverse primers were 5′-
CGG CTA CCA CAT CCA AGG AAG -3′ and 5′- CGC TCC CAA GAT CCA ACT AC
-3′, respectively, yielding a 247-bp amplicon.18 Non-reverse transcriptase controls were
performed for each GAPDH and 18S sample, and a no-template control accompanied
each set of GAPDH and 18S samples. The reactor protocol consisted of the following
events: pre-heat to 95 ᵒC for 60 sec; 40 cycles of denaturing at 95 ᵒC for 5 sec and
annealing/elongating at 47 ᵒC for 20 sec. The protocol concluded with thermal
denaturation analysis of the PCR products by raising the temperature from 65 to 95 ᵒC at
0.5 ᵒC/min and measuring the absorbance at 260 nm. GAPDH gene expression was
normalized to 18S using the Comparative Ct method (2(∆Ct18S-∆CtGAPDH)), while error was
calculated as the overall coefficient of variance (CV = CV18S
2 + CVGAPDH
2 ).
3.2.7 Synthesis and Characterization of Organic Compounds
3.2.7.1 Synthesis of 2-Azido-N-(2-(tert-butyldimethylsilyloxy)ethyl)ethanamine –
Compound (1)
________________________________________________________________________
i. To a solution of NaN3 (23.8 g, 366 mmol) in 200 mL of water was added 2-
bromoethylamine hydrobromide (25 g, 122 mmol) and this solution was heated to 75 ᵒC.
The reaction mixture was stirred for 24 h and was then cooled in an ice-water bath. To
the cooled solution was added NaOH (28.5 g, 712.5 mmol) and the reaction mixture was
stirred until the NaOH was fully dissolved. To this aqueous solution was added Et2O
(x3). The ether fractions were collected, dried over Na2SO4 and evaporated in vacuo to
Scheme 3.4 Stepwise Synthesis of Compound 1.
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afford 2-azidoethanamine as a clear oil (6.7 g, 64%). The 1H proton and 13C NMR shifts
were confirmed in the report by Mayer and Maier (Scheme 3.4).19
ii. To a solution of tert-butyldimethylsilyl chloride (TBS-Cl) (11.6 g, 77 mmol) in
25 mL of DMF was added imidazole (6.2 g, 91 mmol) followed by the dropwise addition
of 2-bromoethanol (8.7 g, 70 mmol). The reaction mixture was stirred for 12 h at room
temperature, extracted with EtOAc and washed with H2O (x3). The combined organic
fractions were dried over Na2SO4 and concentrated in vacuo to afford (2-
bromoethoxy)(tert-butyl)dimethylsilane as a clear colourless oil (15.3 g, 92%) The 1H
proton and 13C NMR shifts were confirmed in the report by Vader et al (Scheme 3.4).20
iii. The (2-bromoethoxy)(tert-butyl)dimethylsilane from step ii (5.8 g, 24.4 mmol)
was added dropwise to a solution of 2-azidoethanamine from step i (2.1 g, 24.4 mmol)
and diisopropylethylamine (6.7 g, 51.8 mmol) in 100 mL of dry DMF under N2 while
stirring in an ice bath. This reaction mixture was then stirred for an additional 48 h at
room temperature. The solution was extracted with EtOAc and washed with H2O and
brine (x3). The EtOAc fractions were collected, dried over Na2SO4 and evaporated under
reduced pressure to yield a crude orange oil. The oil was loaded directly onto a silica
column by eluting with MeOH (2% to 10%) in CH2Cl2, to afford the title compound 1 as
a clear yellow oil (2.3 g, 39%) (Scheme 3.4); 1H NMR (400 MHz, CDCl3) δ 0.07 (s, 6H),
0.91 (s, 9H), 1.67 (br s, 1H), 2.74 (t, 2H, J = 5.1 Hz), 2.83 (t, 2H, J = 5.5 Hz), 3.43 (t, 2H,
J = 5.7 Hz), 3.72 (t, 2H, J = 5.3 Hz); 13C NMR (100 MHz, CDCl3) δ -5.4, 18.3, 25.9,
48.4, 51.4, 51.6, 62.3; ESI-HRMS (ES+) m/z calcd for [C10H24N4OSi + H]+: 245.1792,
found 245.1797 [M+H]+.
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i. To a solution of cytosine (10 g, 90 mmol) in 400 mL of dry DMF was added
NaH (2.2 g, 90 mmol) under N2 in an ice-water bath. This solution was then stirred for 2
h at room temperature, followed by the dropwise addition of methyl bromoacetate (15.1
g, 99 mmol). The reaction was stirred for an additional 48 h at room temperature, after
which the solvent was evaporated in vacuo. The crude remains were mixed with 200 mL
of cold H2O and stored at 4 ᵒC to maximize precipitate formation. The suspension was
filtered and washed with minimal amounts of cold H2O and EtO2 and recrystallized from
MeOH/H2O affording methyl cytosin-1-yl acetate as a light pink powder (9.9 g, 60%).
1H
proton and 13C NMR shifts were confirmed in the report by Schwergold et al (Scheme
3.5).21b
ii. To a solution of methyl cytosin-1-yl acetate from step i (5.0 g, 27.3 mmol) in
50 mL of pyridine was added benzoylchloride (4.6 g, 32.8 mmol) and the reaction was
stirred overnight at room temperature. The solvent was evaporated in vacuo and the crude
remains were dissolved and stirred in 1M NaOH for 3 h. Using concentrated HCl, the pH
of the solution was adjusted to 5.5 and any undesirable salts were removed through
vacuum filtration. Upon further acidification to pH 2, the solution was filtered and the
precipitate was washed with cold H2O affording the N
4-benzoylprotected cytosin-1-yl
Scheme 3.5 Stepwise Synthesis of Compound 2.
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acetic acid building block as a light pink powder (4.1 g, 55%). 1H proton and 13C NMR
shifts were confirmed in the report by Christensen et al (Scheme 3.5).21a
iii. To a round-bottom flask was added N4-(benzoyl)cytosin-1-yl acetic acid from
step ii (2.6 g, 9.5 mmol) in 100 mL of DMF and 5 mL of DMSO in order to further
solubilise the starting material. After being placed in an ice bath, to this stirring solution
was added compound 1 (2.3 g, 9.5 mmol) followed by activation of the acid for 30 min
with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC-Cl) (3.7 g,
19.3 mmol). The reaction was then stirred overnight at room temperature and extracted
with EtOAc and washed with H2O and brine (x3). The combined organic fractions were
dried over Na2SO4 and concentrated in vacuo yielding a crude oil. This oil was purified
by flash column chromatography with a gradient of MeOH (1% to 5%) in CH2Cl2 to
afford the title compound 2 as a white powder (2.5 g, 53%) (Scheme 3.5). Compound 2 is
a mixture of slowly-exchanging rotamers; 1H NMR (400 MHz, CDCl3) δ 0.06 (s, 2H),
0.11 (s, 4H), 0.90 (s, 3H), 0.92 (s, 6H), 3.50-3.55 (m, 4H), 3.66 (t, 1H, J = 5.1), 3.71-3.74
(m, 1H), 3.79 (t, 0.5H, J = 5.3 Hz), 3.84 (t, 1.5H, J = 5.1 Hz), 4.83 (s, 0.5H), 4.85 (s,
1.5H), 7.53 (t, 3H, J = 7.62 Hz), 7.61-7.64 (m, 1.5H), 7.72 (d, 0.5H, J = 6.25 Hz), 7.90
(d, 2H, J = 7.03 Hz), 8.64 (br s, 1H); 13C NMR (100 MHz, CDCl3) δ -5.5, 11.6, 18.2,
18.3, 25.9, 46.2, 46.7, 48.3, 49.0, 49.6, 49.7, 49.9, 51.0, 61.1, 61.3, 96.7, 127.5, 129.0,
133.1, 149.9, 150.1, 155.5, 162.5, 162.6, 166.7, 167.3; ESI-HRMS (ES+) m/z calcd for
[C23H33N7O4Si + H]
+: 500.2436, found 500.2441 [M+H]+.
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3.2.7.3 Synthesis of N-(1-(2-((2-Azidoethyl)(2-(bis(4-
methoxyphenyl)(phenyl)methoxy)ethyl)amino)-2-oxoethyl)-N4-
(benzoyl)cytosin-1-yl) – Compound (3)
________________________________________________________________________
i. To a solution of compound 2 (2.5 g, 5.0 mmol) in 100 mL of CH2Cl2 was added
an excess of 3HF/TEA (2.8 g, 17.5 mmol), and this reaction was stirred until TLC
analysis indicated the complete conversion of starting material to the alcohol (4 h). The
reaction was then quenched with MeOH, concentrated under reduced pressure and
immediately subjected to silica column purification eluting with a gradient of MeOH (2%
to 5%) in CH2Cl2. The combined fractions were concentrated and co-evaported with
hexanes in vacuo affording compound 3a as a white powder (1.7g, 91%) (Scheme 3.6).
Compound 3a is a mixture of slowly-exchanging rotamers; 1H NMR (400 MHz, CDCl3)
δ 3.54 (s, 3H), 3.61-3.64 (m, 1.5H), 3.68 (d, 0.5H, J = 4.3 Hz), 3.70 (d, 1H, J = 4.7 Hz),
3.79-3.82 (m, 0.5H), 3.83-3.85 (m, 1.5H), 4.50 (br s, 1H), 4.83 (s, 0.5H), 4.94 (s, 1.5H),
7.47 (t, 2.5H, J = 7.6 Hz), 7.58 (t, 1.5H, J = 7.4 Hz), 7.70 (d, 0.5H, J = 2.3 Hz), 7.72 (d,
0.5H, J = 2.3 Hz), 7.90-7.94 (m, 2H), 9.16 (br s, 1H); 13C NMR (100 MHz, CDCl3) δ
46.6, 48.3, 49.0, 49.7, 50.0, 50.5, 50.9, 51.3, 59.9, 60.3, 97.1, 127.7, 127.8, 128.9, 132.9,
133.1, 150.3, 150.4, 156.2, 163.0, 163.2, 167.5, 167.7; ESI-HRMS (ES+) m/z calcd for
[C17H19N7O4 + H]
+: 386.1571, found 386.1582 [M+H]+.
ii. To a solution of compound 3a (1.7 g, 4.4 mmol) in 50 mL of dry pyridine
under N2 was added dimethoxytrityl chloride (DMT-Cl) (3.0 g, 8.8 mmol), and the
reaction was stirred overnight at room temperature. The reaction was extracted with
Scheme 3.6 Stepwise Synthesis of Compound 3.
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EtOAc, washed with NaHCO3 (x3) and dried over Na2SO4. The combined organic
fractions were concentrated in vacuo and the crude remains were purified through flash
column chromatography with a gradient of hexanes/EtOAc (7:3) to 100% EtOAc to elute
the title compound 3 as a white solid (2.9 g, 99%) (Scheme 3.6). Compound 3 is a pair of
rotamers; wherever possible, the signals to the major (ma.) and minor (mi.) rotamers are
designated; 1H NMR (400 MHz, CDCl3) δ 3.35-3.41 (m, 2H), 3.46 (t, 3H, J = 5.3 Hz),
3.55 (t, 0.5H, J = 4.9 Hz), 3.67 (t, 2H, J = 4.5 Hz), 3.74 (t, 0.5H, J = 5.9 Hz), 3.82 (s,
1.5H, mi.), 3.83 (s, 4.5H, ma.), 4.83 (s, 0.5H, mi.), 4.92 (s, 1.5H, ma.), 6.85-6.90 (m, 4H),
7.24 (t, 0.5H, J = 7.0 Hz), 7.28-7.29 (m, 2.5H), 7.30 (s, 3.5H), 7.35 (t, 2H, J = 7.6 Hz),
7.39-7.42 (m, 2.5H), 7.54 (t, 2H, J = 7.6 Hz), 7.62-7.66 (m, 1H), 7.71 (d, 0.3H, J = 7.4
Hz, mi.), 7.93 (d, 1.7H, J = 7.4 Hz, ma.), 8.77 (br s, 1H); 13C NMR (100 MHz, CDCl3) δ
13.7, 19.1, 22.6, 30.6, 31.9, 46.2, 47.1, 47.7, 48.9, 49.0, 49.4, 49.6, 49.9, 55.2, 55.3, 61.1,
61.8, 64.3, 86.6, 87.3, 96.5, 113.2, 113.3, 126.8, 127.2, 127.5, 127.9, 128.0, 128.2, 129.0,
129.9, 130.1, 133.1, 135.2, 135.8, 144.2, 144.6, 149.8, 158.5, 158.7, 162.5, 166.6, 167.1;
ESI-HRMS (ES+) m/z calcd for [C38H37N7O6 + H]
+: 688.2878, found 688.2878 [M+H]+.
3.2.7.4 Synthesis of N-(2-(tert-Butyldimethylsilyloxy)ethyl)prop-2-yn-1-amine –
Compound (4)
________________________________________________________________________
i. To a solution of ethanolamine (9.6 mL, 159 mmol) in 100 mL of CH2Cl2 was
dissolved imidazole (10.8 g, 159 mmol) and this solution was cooled in an ice-water bath.
To this solution was added tert-butyldimethylsilyl chloride (24 g, 159 mmol) and the
reaction mixure was stirred overnight at rt. Sat. NaHCO3 was added and the resulting
mixture was partitioned. The organic fractions were dried over Na2SO4 and concentrated
in vacuo to afford 2-(tertbutyldimethylsilyloxy) ethanamine as a clear light yellow oil
(26.8 g, 96%) (Scheme 3.7).22
Scheme 3.7 Stepwise Synthesis of Compound 4.
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ii. To a solution of 2-(tert-butyldimethylsilyloxy)ethanamine from step i (10 g, 57
mmol) in 100 mL of CH2Cl2 was added diisopropylethylamine (DIPEA) (3.7 g, 28.5
mmol), and this solution was cooled in an ice-water bath. To this solution was added 3-
bromoprop-1-yne (3.4 g, 28.5 mmol) dropwise over 30 min. This reaction mixture was
stirred at rt. until TLC analysis indicated the complete consumption of starting material (3
h). Sat. NaHCO3 was added and the reaction mixture was partitioned. The organic
fraction was dried over Na2SO4 and concentrated in vacuo, to afford an oil which was
purified by silica gel chromatography eluting with a gradient of hexanes/EtOAc (7:3 to
3:7) to afford the title compound 4 as a clear yellow oil (2.9 g, 71%) (Scheme 3.7); 1H
NMR (500 MHz, CDCl3) δ 0.07 (s, 6H), 0.90 (s, 9H), 1.67 (br s, 1H), 2.21 (s, 1H), 2.80
(t, 2H, J = 5.5 Hz), 3.46 (s, 2H), 3.75 (t, 2H, J = 5.1 Hz); 13C NMR (125 MHz, CDCl3) δ
-5.4, -5.2, 18.3, 25.8, 26.0, 38.2, 50.5, 62.3, 71.2, 71.2, 82.2; ESI-HRMS (ES+) m/z calcd
for [C11H23NOSi + H]
+: 214.1622, found 214.1626 [M + H]+.
3.2.7.5 Synthesis of N-(2-(tert-Butyldimethylsilyloxy)ethyl)-uracil-1-yl-N-(prop-2-
ynyl)acetamide – Compound (5)
To a solution of uracil-1-yl acetic acid23 (4.0 g, 23.5 mmol) in 100 mL of dry DMF was
added compound 4 (4.5 g, 21.1 mmol), and this solution was cooled in an ice-water bath.
Following the addition of EDC-Cl (9.0 g, 46.9 mmol) to the solution, the acid was
activated for 30 min while stirring. The reaction mixture was then stirred for 12 h at room
temperature, extracted with EtOAc and washed with H2O and brine (x3). The combined
organic fractions were dried over Na2SO4 and concentrated in vacuo to afford the crude
product. This crude product was purified by flash column chromatography with a
gradient of hexanes/EtOAc (7:3) to 100% EtOAc to elute the title compound 5 as a white
solid (5.0 g, 65%). Compound 5 is a pair of rotamers; wherever possible, the signals to
the major (ma.) and minor (mi.) rotamers are designated; 1H NMR (500 MHz, CDCl3) δ
0.04 (s, 2H, mi.), 0.08 (s, 4H, ma.), 0.88 (s, 3H, mi.), 0.89 (s, 6H, ma.), 2.25 (br s, 0.66H,
ma.), 2.41 (br s, 0.33H, mi.), 3.58 (t, 0.6H, J = 5.3 Hz, mi.), 3.65 (t, 1.4H, J = 5.2 Hz,
ma.), 3.76 (t, 0.6H, J = 5.3 Hz, mi.), 3.85 (t, 1.4H, J = 5.0 Hz, ma.), 4.27 (2s, 2H), 4.68
(m, 2H), 5.71-5.74 (m, 1H), 7.13 (d, 0.66H, J = 7.9 Hz, ma.), 7.17 (d, 0.33H, J = 7.9 Hz,
mi.), 9.43 (br s, 0.66H, ma.), 9.48 (br s, 0.33H, mi.); 13C NMR (125 MHz, CDCl3) δ -5.6,
-5.4, -3.7, -3.5, 17.9, 18.1, 18.3, 25.5, 25.7, 25.8, 25.9, 26.0, 35.2, 38.7, 48.0, 48.1, 48.8,
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49.6, 60.6, 61.7, 72.7, 73.6, 77.9, 78.1, 102.1, 102.2, 145.0, 145.1, 150.9, 163.6, 166.3,
166.7; ESI-HRMS (ES+) m/z calcd for [C17H27N3O4Si + H]
+: 366.1844, found 366.1845
[M + H]+.




To a solution of compound 3 (1.2 g, 1.7 mmol) and compound 5 (570 mg, 1.6 mmol)
dissolved in 70 mL of THF/H2O (3:2) was added sodium ascorbate (519 mg, 2.6 mmol)
until fully dissolved. To this mixture was added CuSO4 (220 mg, 880 pmol), and the
reaction was stirred for 4 h at room temperature. The reaction was extracted with EtOAc,
washed with H2O (x3) and the combined organic fractions were dried over Na2SO4. The
organic layer was concentrated under reduced pressure and the resultant crude product
was purified by flash column chromatography eluting with a gradient of MeOH (2% to
5%) in CH2Cl2 to afford the title compound 6 as a white solid (1.6 g, 98%). Compound 6
is a mixture of slowly-exchanging rotamers; 1H NMR (400 MHz, CDCl3) δ 0.06 (s, 2H),
0.10 (s, 4H), 0.90 (s, 3H), 0.92 (s, 6H), 3.03 (m, 1.5H), 3.12 (m, 0.5H), 3.24-3.28 (m,
2.5H), 3.51-3.54 (m, 1H), 3.55-3.57 (m, 1.5H), 3.63-3.69 (m, 2H), 3.74-3.78 (m, 2H),
3.81 (s, 1.5H), 3.83 (s, 4.5H), 4.49-4.52 (m, 1.5H), 4.56-4.57 (m, 0.5H), 4.72 (br s, 1.5H),
4.74-4.78 (dd, 3.5H, J = 7.0 Hz), 4.84 (d, 0.5H, J = 5.1 Hz), 4.88 (s, 0.5H), 5.59-5.70 (m,
1H), 6.81-6.84 (m, 1H), 6.87 (d, 3H, J = 9.0 Hz), 7.23 (d, 3H, J = 2.3 Hz), 7.25 (s, 2H),
7.27-7.29 (m, 2H), 7.31 (s, 1.5H), 7.34 (d, 2.5H, J = 4.7 Hz), 7.38-7.42 (m, 0.5H), 7.52 (t,
2.5H, J = 7.6 Hz), 7.60-7.63 (m, 1H), 7.70-7.73 (m, 0.25H), 7.75 (s, 0.5H), 7.93-8.02 (m,
2H), 8.07 (d, 0.25H, J = 7.4 Hz), 9.66 (br s, 0.5H), 9.85 (br s, 0.5H); 13C NMR (100
MHz, CDCl3) δ -5.5, 18.1, 18.3, 25.8, 25.9, 41.8, 44.0, 47.6, 47.7, 47.9, 48.0, 48.4, 48.6,
48.7, 49.0, 49.1, 49.2, 50.9, 55.2, 60.7, 60.8, 87.3, 96.8, 101.6, 101.7, 113.1, 113.2, 124.7,
124.9, 127.2, 127.9, 128.0, 128.1, 128.7, 128.8, 129.9, 130.1, 132.9, 133.0, 135.1, 135.8,
143.4, 144.1, 144.2, 145.7, 146.0, 149.9, 151.1, 155.7, 158.4, 158.7, 163.3, 164.0, 164.1,
166.6, 167.4, 167.5, 167.7; ESI-HRMS (ES+) m/z calcd for [C55H64N10O10Si + H]
+:




3.2.7.7 Synthesis of N-(1-(2-((2-(bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)(2-(4-
((2-(uracil-1-yl)-N-(2-hydroxyethyl)acetamido)methyl)-1H-1,2,3-triazol-1-
yl)ethyl)amino)-2-oxoethyl)-N4-(benzoyl)cytosin-1-yl) – Compound (7)
To a solution of compound 6 (1.3 g, 1.2 mmol) in 25 mL of THF was added TBAF (500
mg, 1.9 mmol), and this solution was stirred until TLC analysis displayed the complete
conversion of starting material to the alcohol (2.5 h). After concentrating the reaction
mixture in vacuo, the crude product was purified by flash column chromatography with a
gradient of MeOH (2% to 15%) in CH2Cl2 eluting the title compound 7 as a white
powder (1.1 g, 99%). Compound 7 is a mixture of slowly-exchanging rotamers; 1H NMR
(400 MHz, CDCl3) δ 3.09 (br s, 1.5H), 3.15 (br s, 0.5H), 3.25-3.30 (m, 2H), 3.62 (d, 4H,
J = 3.1 Hz), 3.73 (br s, 2H), 3.81 (s, 1.5H), 3.83 (s, 4.5H), 4.51 (d, 1.5H, J = 4.7 Hz),
4.59-4.61 (m, 0.5H), 4.67-4.71 (m, 3.5H), 4.82 (br s, 1.5H), 4.87-4.89 (m, 2H), 5.61 (t,
1H, J = 7.0 Hz), 6.88 (d, 4H, 9.0 Hz), 7.24 (s, 3H), 7.26 (s, 2H), 7.28-7.32 (m, 3H), 7.35
(d, 3.5H, J = 4.7 Hz), 7.38, (br s, 0.5H), 7.50 (t, 2H, J = 7.6 Hz), 7.58-7.61 (m, 1.5H),
7.76 (s, 0.5H), 8.00 (d, 1.5H, J = 7.8 Hz), 8.04 (d, 0.5H, J = 10.9 Hz), 9.72-9.85 (m, 2H);
13C NMR (100 MHz, CDCl3) δ 20.1, 43.0, 43,8, 47.4, 48.0, 48.9, 49.2, 48.0, 51.2, 51.3,
55.3, 59.6, 60.7, 60.8, 87.3, 87.4, 97.3, 101.6, 113.2, 113.3, 124.9, 125.6, 127.2, 128.0,
128.1, 128.2, 128.8, 129.9, 130.1, 132.9, 133.1, 135.1, 135.7, 143.3, 144.1, 144.2, 144.5,
146.0, 146.2, 150.0, 151.1, 151.2, 156.2, 158.2, 158.5, 158.7, 163.6, 164.1, 164.2, 167.0,
167.6, 167.8; ESI-HRMS (ES+) m/z calcd for [C49H50N10O10 + H]
+: 939.3784, found
939.3776 [M+H]+; for [C49H50N10O10 + Na]
+: 961.3604, found 961.3591 [M+Na]+.
3.2.7.8 Synthesis of 2-(N-((1-(2-(2-(N4-(benzoyl)cytosin-1-yl)-N-(2-(bis(4-
methoxyphenyl)(phenyl)methoxy)ethyl)acetamido)ethyl)-1H-1,2,3-triazol-4-
yl)methyl)-2-(uracil-1-yl)acetamido)ethyl (2-cyanoethyl)
diisopropylphosphoramidite – Compound (8)
To a solution of compound 7 (300 mg, 320 μmol) in 10 mL of dry CH2Cl2 under N2, was
added DIPEA (227 mg, 1.8 mmol) and 4-dimethylaminopyridine (20 mg, 160 μmol)
while stirring. To this mixture was added 2-cyanoethyl
diisopropylphosphoramidochloridite (227 mg, 960 μmol), and the consumption of
starting material was monitored by TLC (3 h). After concentrating this reaction in vacuo,
the crude product was loaded directly on to a silica column for purification with a
gradient of 2% triethylamine in acetone/hexanes (1:1 to 3:1) to afford the title compound
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8 as a white powder (266 mg, 73%). Compound 8 is a mixture of slowly-exchanging
rotamers. The two phosphorus signals in the 31P NMR spectrum are due to the
diasteromeric nature of the 31P atom for the respective phosphoramidite 8; 1H NMR (400
MHz, CDCl3) δ 1.15-1.20 (m, 13H), 1.26 (s, 3H), 2.63-2.68 (m, 3H), 3.02 (br s, 1H),
3.13-3.18 (m, 1H), 3.21 (t, 1H, J = 4.3 Hz), 3.24-3.28 (m, 1H), 3.55-3.67 (m, 6H), 3.75-
3.79 (m, 2.5H), 3.80 (s, 1.5H), 3.81 (s, 4.5H), 3.82-3.90 (m, 1.5H), 4.51 (t, 1.5H, J = 4.5
Hz), 4.55 (t, 0.5H, J = 4.7 Hz), 4.70 (s, 2H), 4.75 (d, 2.5H, J = 4.3 Hz), 4.79 (d, 0.5H, J =
3.1 Hz), 4.88 (s, 1H), 5.66-5.69 (m, 1H), 6.85 (d, 4H, J = 9.0 Hz), 7.21 (d, 2H, J = 2.3
Hz), 7.23 (m, 2H), 7.28-7.29 (m, 0.5H), 7.32 (d, 3.5H, J = 3.9 Hz), 7.37-7.40 (m, 1H),
7.52 (t, 2.5H, J = 7.6 Hz), 7.60-7.63 (m, 1H), 7.79 (s, 0.5H), 7.95-8.01 (m, 2H); 13C
NMR (100 MHz, CDCl3) δ 20.3, 20.4, 24.5, 24.6, 24.7, 26.6, 29.2, 29.6, 31.7, 31.8, 41.7,
42.9, 43.0, 43.1, 43.5, 46.0, 47.1, 47.5, 47.8, 48.0, 48.5, 48.8, 49.0, 51.0, 53.8, 55.2, 58.1,
58.2, 58.4, 60.6, 60.8, 60.9, 69.4, 87.2, 87.3, 96.8, 101.6, 106.5, 113.1, 113.2, 117.9,
118.1, 123.6, 124.7, 124.9, 127.2, 127.8, 127.9, 128.0, 128.1, 128.6, 128.8, 129.9, 130.1,
132.9, 133.0, 135.1, 143.3, 144.1, 144.2, 146.1, 149.9, 151.1, 155.7, 158.4, 158.7, 163.3,
164.0, 164.2, 166.8, 167.5, 167.6; 31P NMR (167 MHz, CDCl3) δ 149.02 and 149.56;
ESI-HRMS (ES+) m/z calcd for [C58H67N12O11P + Na]
+: 1161.4682, found 1161.4672
[M+Na]+.
3.3 Results
3.3.1 Synthesis of DMT-Protected Cytosine Azide Monomer
In this paper, we expanded the scope of siRNA sequences and modified them with a
cytosine-triazole-uracil (CtU) dimer in addition to the uracil-triazole-uracil (UtU) dimer
previously synthesized. Synthesis of the CtU dimer phosphoramidite commenced through
the generation of 2-azidoethanamine from bromoethylamine combined with sodium
azide. This compound was alkylated with 2-bromoethoxy-tert-butyldimethylsilane20 in
39% yield to afford azide linker 1. Utilizing EDC as a coupling reagent, this compound
was amide-bond coupled to N4-benzoylcytosin-1-yl acetic acid21 to generate monomer 2
in 62% yield. TBS-deprotection of 2 with 3HF-TEA afforded a monoalcohol, which was




3.3.2 Synthesis of Uracil Alkyne Monomer
In order to generate an appropriate alkyne monomer, alkyne linker 4 was synthesized in
71% yield by treating TBS-protected ethanolamine with limiting equivalents of propargyl
bromide. This linker was amide-bond coupled to uracil-1-yl acetic acid24 using EDC as
the coupling reagent to produce monomer 5 in 52% yield (Scheme 3.9).
Scheme 3.8 Synthesis of azide intermediate.
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3.3.3 Synthesis of Triazole-Linked CtU Phosphoramidite
With both azide (3) and alkyne (5) monomers available, 1,4-triazole formation catalyzed
with CuSO4 and sodium ascorbate in a THF/H2O solution afforded compound 6 in 98%
yield. TBAF deprotection of the silyl protective group on compound 6 afforded
compound 7 in 99% yield. Finally, compound 7 was treated with a phosphitylating
reagent to afford the phosphoramidite 8 in 73% yield (Scheme 3.10). Both the CtU and
UtU phosphoramidites were used to synthesize a variety of triazole-modified siRNAs.
Scheme 3.9 Synthesis of alkyne intermediate.
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3.3.4 Helical Conformation and Tm′s of Triazole-Modified siRNAs
Various siRNAs were synthesized, bearing one to three triazole backbone modifications
through the use of an ABI DNA/RNA synthesizer. These siRNAs were designed to target
firefly luciferase mRNA expressed within HeLa cells, in order to gauge their functionality
within cells-based systems (Table 3.2).
To first examine the effects of our RNAs, we investigated the effect of circularly
polarized light on our siRNA duplexes to determine whether our chemically modified
duplexes were still able to retain A-type helical structure. Figure A50 (Appx. II)
illustrates that the siRNAs retain the characteristic A-form helix; however, a loss of
helicity for double-stranded RNAs that contain the internal triazole backbone
modification is observed.
Scheme 3.10 Synthesis of CtU phosphoramidite.
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In general, as the
modification approaches
the 5′-end of the sense
strand, its contribution is
less destabilizing. For
example, RNAs 9, 10





towards the center of the




duplex. For instance, siRNAs 13–16 exhibit changes in Tm of ca. -7.5 to -13 ᵒC. The
effect of a UtU modification on a 3′-overhang increases the Tm of siRNAs 15, 17, 18, 20
and 22, relative to the corresponding siRNA with dTdT overhangs, thus suggesting an
Table 3.2 Sequences of anti-luciferase siRNAs and Tm′s
RNA siRNA duplex


























5′- CUUACGCtUGAGUACUUCGAtt - 3′
3′ - ttGAAUGCGACUCAUGAAGCU - 5′
5′- CUUACGCUGAGUACtUUCGAtt - 3′
3′ - ttGAAUGCGACUCAUGAAGCU - 5′
5′- CUUACGCUGAGUACtUUCGAtt - 3′
3′ - UtUGAAUGCGACUCAUGAAGCU - 5′
5′- CUUACGCUGAGUACUtUCGAtt - 3′
3′ - ttGAAUGCGACUCAUGAAGCU - 5′
5′- CUUACGCUGAGUACUUCGAUtU -3′
3′ - ttGAAUGCGACUCAUGAAGCU - 5′
5′- CUUACGCUGAGUACUUCGAUtU- 3′
3′ - UtUGAAUGCGACUCAUGAAGCU - 5′
5′- CUUACGCUGAGUACUtUCGAUtU -3′
3′ - ttGAAUGCGACUCAUGAAGCU - 5′
5′- CUUACGCUGAGUACUtUCGAUtU -3′
3′- UtUGAAUGCGACUCAUGAAGCU - 5′
5′- CUtUACGCUGAGUACUtUCGAUtU -3′
3′ - ttGAAUGCGACUCAUGAAGCU - 5′
































aTms were measured in triplicate in a sodium phosphate
buffer (90 mM NaCl, 10 mM Na2HPO4, 1 mM EDTA, pH
7) at 260 nm, from 10 to 95 ⁰C. UtU corresponds to the
uracil-triazole-uracil modification; CtU corresponds to the
cytosine-triazole-uracil modification.
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element of stability. This stabilizing effect has been observed with other oligonucleotides
that bear 3′-overhangs.8,25 However, this trend is only observed when the modification is
not in combination with any other triazole modifications within the same oligonucleotide
strand (siRNAs 19 and 21 do not exhibit any increase in Tm). Finally, siRNA 21 contains
three UtU modifications within the sense strand. This siRNA bears a drop in Tm of -14.1ᵒC. SiRNA 11 contains two CtU modifications, and exhibits a Tm drop of -20.3 ᵒC
relative to wild-type. Overall, our Tm data is consistent with other similar studies
involving PNA–DNA chimeras26 and triazole-linked RNAs.14b
3.3.5 Silencing Activity of Triazole-Modified siRNAs Targeting firefly luciferase
To examine the effects of our backbone-modified siRNAs on the RNA interference
pathway, we performed cell-based assays within HeLa cells. The cells were co-
transfected with the siRNA duplexes identified in Table 3.2 at varying concentrations,
along with plasmids expressing the target firefly luciferase and a non-target Renilla
luciferase for use as an internal control. Following transfection with the desired siRNA
construct, cells were lysed after 24 h, at which point luciferase activity was monitored
(Fig. 3.9). The wild-type native siRNA inhibited luciferase expression in a dose-
dependent manner, while the modified siRNAs triggered varying levels of silencing
activity.
For siRNAs 9–12, a reduction in potency relative to wild-type is generally observed,
especially when using lower concentrations of siRNA (Fig. 3.9). These RNAs are
chemically modified in the area of the 5′-sense region and in general, display a decrease
in Tm relative to wild-type siRNA (Table 3.2). In accordance with other reports which
have identified that siRNAs exhibit thermodynamic asymmetry,27 our observations
support that destabilizing this area may lead to decreased potency. SiRNAs 13 and 14
contain a single CtU modification within an internal site of the sense strand, causing a
large decrease in duplex thermal stability compared to wild-type (Table 3.2). There is
also a noticeable decrease in potency observed with these two siRNAs relative to wild-
type (Fig. 3.9).
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RNAs 10, 15, 18, 20 and 22 contain UtU modifications at the 3′-overhang of the antisense
strand. When the activity of these siRNAs is compared to their analogous RNAs lacking
a 3′-UtU modification in general, a reduction in activity is observed at lower
concentrations. The effect of observing reduced activity of a large bulky 3′-modified
overhang on the antisense has been previously observed.28
________________________________________________________________________
SiRNAs 16, 17 and 19 contain UtU modification at various positions near the 3′-end of
the sense strand. Several of these siRNAs exhibit comparable or enhanced silencing when
compared to wild-type siRNA. With respect to thermal stability, siRNAs 16 and 19
exhibit a drop in Tm. Destabilizing this area of the duplex along with the 3′-UtU
modification (siRNA 19) may offer a favorable response by not only promoting favorable
incorporation of the guide strand to form the active RISC-guide complex,27a but by
increasing its resistance to nucleases.
Figure 3.9 Reduction in firefly luciferase expression related to the potency of
backbone-modified triazole-linked siRNAs using the Dual-luciferase reporter assay.
The siRNAs were tested at 8, 80, and 800 pM, with firefly luciferase expression






3.3.6 Nuclease Stability of 3′-UtU Modified siRNAs
To determine whether a 3′-UtU modified overhang provides enhanced stability to
nucleases, we performed time-dependent stability assays in serum. The analysis involving
siRNAs 17, 18 and 22 illustrated that these 3′-UtU modified duplex siRNAs have reduced
susceptibility to degradation by nucleases relative to wild-type native siRNA (Fig. A51,
Appx. II).
3.3.7 Silencing Activity of siRNAs Containing Multiple Triazole-Based Linkages
Finally, siRNAs 11 and 21, which contain multiple triazole modifications within their
sense strands, exhibit low thermal stability and these siRNAs manage to effectively
silence the target gene. This suggests that multiple triazoles within a duplex siRNA are
compatible within the RNAi pathway, albeit at reduced silencing efficiency compared to
wild-type.
3.3.8 RNAi Activity of Triazole-Modified siRNAs Targeting GAPDH
To determine whether this novel chemical modification would be amenable to
endogenous targets, we synthesized and investigated the effect that our triazole
backbone-modified siRNA would have on reducing the expression of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). We synthesized three siRNAs bearing a UtU
triazole modification (siRNAs 24–26). The siRNAs each contained a single UtU
modification placed either at positions 17–18, 18–19, or at the 3′-UtU overhang of the
sense strand (Table 3.3). The data from Figure 3.10 illustrates that our triazole-linked
siRNAs show a dose-dependent downregulation of GAPDH at 10 and 20 nM comparable
to wild-type (siRNA 23). This result is significant because it highlights that our novel
chemically modified siRNAs are capable of silencing relevant endogenous targets.
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Table 3.3 Sequences of anti-GAPDH siRNAs





5′ – GGUCAUCCAUGACAACUUUtt – 3′
3′ – ttCCAGUAGGUACUGUUGAAA – 5′
5′ – GGUCAUCCAUGACAACUtUUtt – 3′
3′ – ttCCAGUAGGUACUGUUGAAA – 5′
5′ – GGUCAUCCAUGACAACUUtUtt – 3′
3′ – ttCCAGUAGGUACUGUUGAAA – 5′
5′ – GGUCAUCCAUGACAACUUUUtU – 3′
3′ – ttCCAGUAGGUACUGUUGAAA – 5′
Figure 3.10 Analysis of GAPDH mRNA knockdown analyzed by real-time PCR
following the treatment of HeLa cells with GAPDH siRNAs 23–26. Levels of
GAPDH expression were normalized to the internal reference gene 18S.
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3.4 Discussion and Conclusion
In conclusion, we are reporting the practical synthesis of siRNAs bearing triazoles
interspersed throughout the backbone via DMT-phosphoramidite chemistry. Monomers 3
and 5 were readily synthesized through standard amide-bond coupling conditions. Via
click chemistry, the final triazole-linked CtU dimer phosphoramidite 8 was synthesized
with an overall yield of 33% from monomers 3 and 5. All RNA duplexes are substrates
for the RNAi pathway. Therefore, a triazole in place of a phosphodiester backbone shows
compatibility within siRNA duplexes and suggests that other novel backbone
modifications may also act as proper substrates. To the best of our knowledge, there are
no other reports of non-ionic hydrophobic backbone mimics that silence gene expression
when positioned within the internal Watson–Crick double-stranded region of siRNAs.
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Connecting Statement II
After confirming the results obtained from other studies by illustrating that siRNA
activity can be modulated through enhancing the thermodynamic asymmetry of the
duplex, we were inspired to further explore the promiscuity of RNAi machinery for other
unnatural and destabilized duplex ligands. Our previous study illustrated a trend between
thermodynamic asymmetry and siRNA activity as the position of the slightly-
destabilizing triazole backbone linkage on the passenger strand approached the 5′ end of
the preferred guide strand. These positive results inspired us to explore how the use of
other unnatural and destabilizing modifications could alter the thermodynamic profiles,
and ultimately the activity of siRNAs when positioned throughout the complex. We also
wished to confirm suspicions made by other research groups who speculated on the
existence of an alternative RNAi mechanism which does not require actual Ago2-
mediated cleavage of the passenger strand in order to load the active guide strand into
RISC. To explore these phenomena, the following study involved the chemical
introduction of abasic positions along the passenger strands of siRNAs, using alkyl chain
linkages of varying length and slightly different constitution. Several spacer-modified
siRNAs were all designed to target the firefly luciferase reporter gene whithin HeLa cells,
and their thermostabilities were characterized using UV-monitored thermal denaturation.
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The most widely accepted mechanism of RNAi-silencing involves the RNA-induced
silencing complex (RISC) liberating the active antisense strand from the sense strand of
an siRNA duplex to form an active RISC-antisense complex. This involves cleaving the
sense strand between positions 9 and 10 from the 5′ end of the strand prior to
dissociation. Destabilizing modifications near the center of the duplex in some cases can
enhance the efficacy of the resultant construct and may trigger an alternative mechanism
through which the sense strand is removed. By introducing alkyl spacers of varying
lengths near or within the sense strand′s cleavage site, this study illustrates that siRNAs,
in most cases, retained potent RNAi silencing activity. Our results highlight that by
substituting the scissile phosphodiester linkage on the sense strand with non-cleavable




RNA interference (RNAi) is an endogenous gene silencing pathway.1 The process
involves the cleavage of double-stranded RNA into short-interfering RNAs (siRNAs).2
The siRNAs are comprised of two strands, a sense and an antisense (AS) strand. The
antisense strand recognizes the target messenger RNA through Watson-Crick base-pair
specificity following sense strand removal. For activation, siRNAs serve as substrates for
the RNA-induced silencing complex (RISC) and this complex directs the antisense RNA
strand to the template mRNA strand.3,4
There has been considerable interest in utilizing siRNAs as biomolecular scaffolds to
target genes of interest that may be associated with disease.5 However, their impact has
been delayed due to problems associated with permeability, stability and off-target
effects.6,7 In order to overcome these limitations, there is attention directed at utilizing
chemical modifications to overcome some of the inherent problems associated with the
native structure of RNA.8–11
Over the last number of years, there have been numerous studies aimed at evaluating the
mechanism of the RNAi pathway, and elucidating the method through which RISC
removes the sense strand.12–15 This process is important because ultimately the antisense
strand must target the desired mRNA. Several studies have confirmed that the catalytic
portion of Argonaute 2 (Ago2) cleaves the sense strand between positions 9 and 10,
starting from the 5′-end of the strand.14–16 This cleavage is thought to promote the
dissociation of the sense strand from the antisense strand to help initiate an active RISC-
antisense RNA complex.
However, there have been a number of studies that suggest that RISC-mediated cleavage
of the sense strand is not an essential feature that governs activity.13,14,17 For example,
Zamore and coworkers demonstrated that the substitution of the scissile phosphodiester
on the sense strand with a phosphorothioate linkage significantly reduced cleavage by
Ago2, yet RNAi activity was retained.13 This study suggested that an alternative
mechanism for sense strand dissociation was possible for RNAi activity. Other studies
have illustrated that a pre-cleaved (nicked siRNA) at the sense strand′s Ago2 cleavage
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site resulted in efficient RNAi activity, which indicates that an actual cleavage event per
se is not an essential requirement to illicit a potent RNAi response.14,18,19 Furthermore,
Manoharan and coworkers demonstrated that a 2′-O-methyl or phosphorothioate
modification at the Ago2 cleavage site of the sense strand with destabilizing chemical
modifications were well tolerated within functional siRNAs.17 Among those already
mentioned, there are many other examples of chemical modifications performed on, or
near the sense strand′s cleavage site that are well tolerated by RISC.20–24
One of the features that is believed to help promote a bypass mechanism involves
destabilization of the central region of a siRNA. Many of the methods to achieve
destabilization include the incorporation of chemically modified bases, mismatches
and/or abasic sites.14,24–26 Many of the reported modifications require multiple steps to
synthesize and expertise in nucleoside phosphoramidite chemistry. The goal of this study
is to retain siRNA efficacy through duplex destabilization using various alkyl linkers as
simple alternatives to mismatches or other chemically modified derivatives. Alkyl linker
phosphoramidites such as those used in this study are commercially available and thus
their preparation does not rely on in-house multi-step phosphoramidite syntheses.
Based on the aforementioned reports and the well-established principle of
thermodynamic asymmetry exhibited within siRNAs,27–29 a variety of different length
alkyl spacer chains was chosen for this study to replace typical destabilizing
modifications.
4.2 Materials and Methods
4.2.1 General Methods
Unless otherwise noted, all starting materials were obtained from commercial sources and
were used without any additional purification. ESI Q-TOF spectra were recorded on an
Agilent QTOF. UV-monitored thermal denaturation was performed on a Jasco J-815
Spectropolarimeter equipped with temperature control.
96
4.2.2 Chemical Synthesis of Oligonucleotides
All standard β-cyanoethyl 2′-O-TBS protected RNA phosphoramidites along with spacer
phosphoramidites, reagents, and solid supports were purchased from Chemgenes
Corporation and Glen Research. Sequences such as the wild-type sense and 5′-
phosphorylated antisense strands, those with segmented strands, and those containing
hexaethyloxy-glycol (E17) modifications were purchased and purified from Integrated
DNA Technologies (IDT). All spacer-modified oligonucleotides were synthesized on an
Applied Biosystems 394 DNA/RNA synthesizer using 1.0 μM cycles with 16 min
coupling times for all spacer and standard phosphoramidites. All phosphoramidites were
dissolved in anhydrous acetonitrile to a concentration of 0.1 M. Spacer-modified
sequences were synthesized on 1.0 μM dT solid supports (Glen Research). Cleavage of
oligonucleotides from their solid supports was performed through on-column exposure to
1.5 mL of EMAM (methylamine 40% wt. in H2O and methylamine 33% wt. in ethanol,
1:1 (Sigma-Aldrich)) for 30 min at room temperature, followed by incubation in EMAM
overnight to deprotect the bases. After drying down the EMAM, the samples were
resuspended in a solution of DMSO:3HF/TEA (100μL:125μL) and incubated at 65 ᵒC for
2.5 hr in order to remove the 2′-O-TBS groups. Oligonucleotide purity was visualized on
a denaturing 20% polyacrylamide gel electrophoresis (PAGE) stained with ethidium
bromide. Crude oligonucleotides were precipitated in EtOH and desalted through
Millipore Amicon Ultra 3000 MW cellulose centrifugal filters. Oligonucleotides were
excised from the 20% denatured gel and were gel purified, followed by desalting through
centrifugal filters. Equimolar amounts of complimentary RNAs were annealed at 90 ᵒC
for 2 min in a binding buffer (75 mM KCl, 50 mM Tris-HCl, 3 mM MgCl2, pH 8.3) and
this solution was cooled slowly to room temperature to generate siRNAs.
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4.2.3 Chemical and Structural Characterization of Oligonucleotides
4.2.3.1 Melting Temperature (Tm) Determination Through UV-Monitored Thermal
Denaturation
Equimolar amounts of each RNA strand (2.4 nmol) were annealed to their compliment in
400 μL of a sodium phosphate buffer (90 mM NaCl, 10 mM Na2HPO4, 1 mM EDTA, pH
7) at 90 ᵒC for 2 min and this solution was cooled slowly to room temperature. Melting
temperatures (Tm) were measured in the sodium phosphate buffer at 260 nm with a
temperature range of 10 to 95 ᵒC. The temperature was increased at a rate of 0.5 ᵒC/min
while absorbance was measured at the end of each 0.5 ᵒC increment. Absorbance
readings were automatically adjusted against the baseline absorbance of the sodium
phosphate buffer. After averaging the range of absorbance values obtained from three
independent experiments for each siRNA, Tm′s were calculated using Meltwin version 3.5
software assuming the two-state model.30
4.2.3.2 Electrospray Ionization Quantitative Time-of-Flight Mass Spectrometry
All single-stranded RNAs were gradient eluted through a Zorbax Extend C18 HPLC
column with a MeOH/H20 (5:95) solution containing 200 mM hexafluoroisopropyl
alcohol and 8.1 mM triethylamine, and finally with 70% MeOH. The eluted RNAs were
subjected to ESI-MS (ES-), producing raw spectra of multiply-charged anions and
through resolved isotope deconvolution, the molecular weights of the resultant neutral
oligonucleotides were confirmed for all the RNAs.
4.2.4 Methods for Culturing Eukaryotic Cells
HeLa cells were cultured in Dulbecco′s modified eagle′s medium (DMEM) containing
10% fetal bovine serum (FBS) (Perbio) and 1% Penicillin-Streptomycin (Sigma) at 37 ᵒC
with 5% CO2. For passaging cells, a 1X solution of 0.25% Trypsin (SAFC Bioscience)
was used to disperse the cells.
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4.2.5 Firefly luciferase Dual-Reporter In Vitro Assay
Prior to transfection, HeLa cells were seeded on 12-well plates (Greiner Bio-One) at a
density of 100,000 cells per well and incubated at 37 ᵒC with 5% CO2 in DMEM
containing 10% FBS. After 24 hr, varying concentrations (20 pM, 80 pM, 160 pM, 400
pM) of all anti-luciferase siRNAs were co-transfected with both pGL3 (Promega) and
pRLSV40 (York University) luciferase-expressing plasmids using Lipofectamine 2000
(Invitrogen) in Gibco′s Opti-Mem Reduced Serum Medium 1X (Invitrogen) according to
the manufacturer′s protocol. After an additional 24 hr, cells were incubated in 1X passive
lysis buffer (Promega) for 20 min at room temperature, and cell lysate was loaded onto
white and opaque, 96-well plates (Costar). Using the Dual-luciferase Reporter Assay kit
(Promega), observed luminescence was proportional to both firefly and renilla luciferase
expression, recorded on a Synergy HT (Bio-Tek) plate luminometer. The ratio of
firefly/renilla luminescence expressed as a percentage relates the reduction in firefly
expression to siRNA efficacy when compared to untreated controls. Each value is the
average of at least three independent experiments with the indicated error (SDOM).
4.3 Results
4.3.1 Variable-Length Abasic Alkyl Chain Linkages
The C3 spacer places three carbons between the oxygens of the phosphodiester linkages,
which is exactly the same number of carbons between native RNA. The C4 and C5
spacer naturally have one or two additional carbons, respectively. These were chosen as it
had been shown previously that alkyl bulges with increased carbon length can be used for
siRNA constructs.31 Each introduction of these alkyl spacer modifications was designed
to replace the distance of a single nucleoside.
The E8 and C9 spacers contain eight or nine atoms between phosphodiester
functionalities, respectively. The intention of these spacer derivatives is to span across
two nucleotides with each introduction in RNA. Native RNA contains nine atoms
between alternating phosphodiesters. Finally, the E17 spacer contains 17 atoms and is a
mimic designed to span across three bases. Figure 4.11 illustrates the structural
differences amongst the different alkyl spacer linkers used.
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4.3.2 Spacer-Modified firefly luciferase-Targeting siRNAs
Various siRNAs were synthesized or purchased commercially that contained a
combination of the linkers identified in Figure 4.11. The siRNAs generated target firefly
luciferase mRNA transcribed from the plasmid pGL3 and expressed within mammalian
cells (Table 4.4). The siRNAs were tested in a dose-dependent manner and their silencing
data is illustrated in Figure 4.12.
Figure 4.11 Structure of various alkyl spacer linkers used within
siRNAs.
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Table 4.4 Sequences of anti-luciferase siRNAs and Tm′s32



















































































































































4.3.3 Silencing Activity and Tm′s of siRNAs with Spacer Linkages in Distal
Regions
Table 4.4 also highlights the melting temperature (Tm) for the various siRNAs. Not
surprisingly, all linkers display a degree of destabilization. With respect to destabilization
close to the 5′-end of the sense strand (siRNA 1), a loss of activity relative to wild-type is
observed. Activity is comparable to the parent siRNA as the duplex is destabilized closer
to its center (siRNA 2). In contrast, single modifications close to the 3′-end of the sense
strand exhibit potency comparable to wild-type siRNA (siRNAs 4 and 5). This
observation is consistent with trends observed with the asymmetry rule of siRNAs.28
However, if two alkyl chain linkages are placed at both position 4 and 7 (siRNA 3) or at
13 and 16 (siRNAs 6–8) of the sense strand, this results in siRNAs exhibiting reduced
gene silencing properties, likely due to the large destabilization occurring at those
positions (Fig. 4.12A).
4.3.4 Effects of Spacer Linkages Within the Passenger Strand Ago2 Cleavage Site
We next turned our attention to multiple spacer modifications within the internal region
of the siRNA, while continuing to focus on the Ago2 cleavage site (Fig. 4.12B). With
respect to spanning two spacers across the 9–10 region of the sense strand of the siRNA,
the C3-double spacer (siRNA 15) was quite effective at all concentrations tested. In
addition, as the number of atoms increased, a slight reduction in potency was observed,
especially with a two atom increase in linker length (siRNA 17) and at lower
concentrations. Nevertheless, the gene-silencing capabilities of siRNAs bearing two
spacers at these positions were relatively unhindered at higher concentrations. We
investigated the effect of a double spacer linkage spanning positions 10–11 of the sense
strand (siRNA 20), and we observed that it was also quite effective at silencing, albeit at
reduced efficacy to wild-type siRNA. With the addition of yet another spacer siRNA
containing two C4 linkages across positions 9 and 11 of the sense strand (siRNA 19), the
collective data suggests that siRNAs containing multiple and destabilizing spacer units
within the central region act as suitable substrates for the RNAi machinery.
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4.3.5 Double and Triple-Abasic Spacers Spanning the Passenger Strand Ago2
Cleavage Site
Following these results, we focused our attention on non-cleavable linkers spanning
across two (E8 and C9) to three (E17) nucleosides within the sense strand (Fig. 4.12C).
We were surprised to find that even though these large linkers were presumably
bypassing the sense strand cleavage mechanism, siRNA efficacy was not severely
compromised as expected. It is noteworthy to observe that the duplex containing the E8
spacer across positions 9 and 10 (siRNA 22) was capable of silencing luciferase with
efficiency comparable to wild-type siRNA, despite containing the non-cleavable linkage.
The siRNA with the C9 spacer spanning positions 9 and 10 (siRNA 25) also
demonstrated an active silencing profile, although not as potent as its E8 counterpart. It
was generally found that E8 linker-modified siRNAs (siRNAs 21–23) were slightly more
effective at silencing than C9-modified siRNAs (siRNAs 24–26). SiRNAs modified with
non-cleavable E17 linkages (siRNAs 27 and 28), spanning positions 8–10 or 9–11 did not
silence as efficiently as the other spacers. This indicates that function was severely
compromised by the extended linkage (covering the distance of three nucleobases).
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Figure 4.12 Reduction of luciferase activity as a function of siRNA activity using the
Dual-luciferase reporter assay. Alkyl chain-modified siRNAs were tested in HeLa cells at
20, 80, 160 and 400 pM, with firefly luciferase expression normalized to Renilla
luciferase. (A) siRNAs with alkyl spacers near the terminal ends of the sense strand. (B)
Centrally-modified siRNAs, each containing one or two single (C3, C4 or C5) spacers.
(C) Centrally-modified siRNAs, containing a double (E8 or C9) or a triple (E17) spacer.
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4.4 Discussion and Conclusion
We are presenting a novel method to destabilize the central region through the use of
simple alkyl linkers that are able to span within the central region of siRNAs. Many of
the linkers used within siRNAs are capable of gene silencing as efficiently as wild-type
siRNA. Our data suggests that non-cleavable long linkers, up to nine atoms in length that
span the equivalent of two nucleobases at and near the Ago2 cleavage site are effective
substrates for the RNAi machinery. As this linker is increased to seventeen atoms, thus
replacing three nucleobases, we observe a drop in efficacy. To confirm that the alkyl
linker is essential for activity, we tested some ′true space′ (TS) siRNAs containing
segmented sense strands annealed to unmodified antisense strands (Table A7, Appx. III).
The segments varied in length in order that they reveal spaces in the sense strand with
missing residues near and across the Ago2 cleavage site. These TS siRNAs were not
capable of effective gene silencing signifying the importance of an actual linkage
between residues that are separated by at least one space on the same strand. See Fig.
A53 and Table A7 for details (Appx. III).
In conclusion, this study presents a simple means to destabilize the central region of
siRNAs through the use of alkyl linkers. Alkyl linkers are attractive substituents due to
their commercial availability and their robust compatibility with standard DMT-
phosphoramidite chemistry and related protocols.31,33 In addition, the longer neutrally-
charged linkers such as E8, C9 and E17 assist in reducing the overall polyanionic charge
of the siRNA. The ability to use a non-cleavable alkyl linker within the central region of
an siRNA opens the future possibility of further chemically modifying it with desired
functionality that can assist with some of the problems associated with siRNAs such as
delivery, stability, and off-targeting. For example, designing a linker with positively-
charged nitrogens at physiological pH may assist with cell membrane permeability.
Future studies include delineating new structure–function relationships of novel
functionalized spacer moieties within siRNAs.
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Chapter V – General Discussion
The prospect of nucleic acid-based technology becoming a viable alternative to existing
therapies is becoming more realistic as scientists continue to unveil methods of reducing
their negative side effects and improve the delivery methods required to effectively
administer them to affected tissues. With the ability to manipulate both a highly variable
genetic sequence and the native structures of nucleic acids through chemical
modification, a variety of nucleic acid derivatives have demonstrated great utility as
protein ligands,1 and as transcript-targeting agents,2, 3 in addition to several other
applications.
Many diseases are the result of the uncontrolled expression of certain genes such as
growth-promoting factors and proto-oncogenes in cancer cells,4 and exogenous genes
from invasive virulents.5, 6 In light of this knowledge, the rate at which the scientific
community discovers endogenous genes which could lead to problematic protein
products is steadily increasing. Therefore, the use of oligonucleotides to target and to
effectively silence the expression of these genes at the translational level with extremely
high accuracy and potency is a palatable prospect when comparing with the long and
difficult processes of small-molecule drug discovery or re-purposing. As with any new
therapy, the goal while implementing nucleic acid-based drugs is to increase their
efficacy while minimizing toxicity to the recipient host. To strike this delicate balance,
chemical modification of nucleic acids is required with a particular focus on the
polyanionic and nuclease-cleavable phosphodiester backbone.
Very little studies have performed extensive backbone modifications which replace the
existing native structures with unnatural moieties, rather than modifying the original
structures. Even fewer studies have focused on these replacement modifications for the
purpose of developing effective siRNA molecules. One such study replaced the ribose
sugar with a morpholino moiety,7 while another study replaced the 3′-overhangs with a
PNA analog dimer.8 Confirming the results found in these studies, siRNAs modified
with the novel triazole-based internucleotide linkage proposed and synthesized with the
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likeness of a PNA scaffold, showed greater resilience to degradation by nucleases while
maintaining their potency. Greater nuclease stability was achieved with siRNAs
containing the UtU triazole-linked dimer as their 3′-overhangs and potency was
maintained when modification to the sense strand destabilized the region nearest the 5′
end of the guide strand. In addition, results from this study matched most findings which
notice a considerable reduction in siRNA potency upon direct modification of the
antisense strand. Taken together, these findings illustrate the possibility of drastically
improving siRNA technology by mitigating some of its side effects through heavy
chemical modification and replacement of the native sugar-phosphate backbone.
Besides studies focusing on the development of clinically approved siRNA-based
therapies, there is widespread use of the technology as a tool for molecular biologists to
characterize specific gene targets by down-regulating their expression and recording the
response.9, 10 Companies such as Ambion – Life TechnologiesTM, Dharmacon – Thermo
Scientific and Sigma-Aldrich can not only design specific siRNA sequences for any
desired target, but have also produced several pre-designed siRNA constructs which
guarantee potent knockdown efficiency of popular gene transcripts. However, as
previously outlined, native siRNAs are susceptible to hydrolytic cleavage which could
ultimately limit their activity to short intervals, requiring frequent applications for
sustained activity. Therefore, unique modifications to the native RNA backbone can not
only benefit the design of potential siRNA-based pharmacophores, but can produce
desirable constructs for their use in functional genomics due to their added nuclease-
resistance as evidenced by the unique triazole linkage described.
Although there are a number of triazole-modified nucleic acid derivatives with several
different uses ranging from materials and microarray development to molecular probes
and antifungal agents, there are few examples of active siRNAs modified at the backbone
with these heterocycles.11 In addition to their other favorable properties, these neutrally-
charged backbone modifications could add the potential for siRNAs to penetrate cellular
membranes unassisted or with minimal assistance from transfection reagents. Increased
membrane permeability and unassisted cellular delivery are favorable attributes for
siRNAs, given that there are undesirable side-effects and inefficiencies associated with
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current transfection methods9 and since safe and efficient siRNA delivery remains the
most prominent issue faced by the technology. This unique triazole linkage can also offer
a conjugation site for small molecules which could add tissue-directing capabilities to
modified oligonucleotides. By functionalizing various monomers with alkynes which
have been protected with tissue-targeting small molecules, the “click” cycloaddition has
been shown to produce 1,4,5-trisubstituted variants of the 1,2,3-triazole moiety.12 The
added steric bulk afforded by the additional small molecule tethered to the alkyne could
help direct the molecule′s conjugation site on the final heterocycle. For instance, if the
steric bulk of the monomer substituent attached to one end of the alkyne functionality is
less than that of the small molecule attached on the opposing end, the result from the
“click” cycladdition could favor the expected 1,4-triazole linkage between the azide-
alkyne monomers, with the small molecule tethered to the triazole′s C5 position. The
reverse could occur if the steric bulk of the small molecule would exceed the monomer
portion of the alkyne. Future studies can focus on utilizing this form of control over the
“click” cycladdition, by assessing the function of siRNA constructs containing small-
molecule conjugates ranging from fluorescent substituents to tissue-directing ligands.
Attaching compounds with fluorescent properties to the triazole heterocycle could
provide insight into the intracellular fate of these siRNAs, along with their cell-
trafficking capabilities visualized through live-cell imaging. There is also the added
benefit of internalizing small molecules along the synthesized oligonucleotide backbone
wherever the triazole-linked nucleoside dimer analogs have been positioned. In addition,
the prospect of functionalizing the 5′-terminus is possible once the alcohol portion of the
alkyne monomer is phosphitylated and the monomer is coupled to the growing oligomer,
thus terminating the sequence with an alkyne functionality in preparation for the post-
synthetic “click” attachment of various azide-tethered molecules.
The siRNAs which were modified with the novel triazole backbone linkage proposed in
this study were not only successful at silencing the expression of a transiently-expressed
reporter gene, but displayed potent activity when targeting an endogenous target
transcript as well. Based on these findings, another continuation of this study could focus
on targeting relevant genes which are implicated in perpetuating certain diseases.
Currently, there are studies using phosphorothioate antisense oligonucleotides to target
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relevant genes such as the anti-apoptosis gene Bcl-213 or the transcription factor c-myc,14
both of which are overexpressed within cancer cells. Additional work can use the
triazole-modified siRNAs produced in this study, to target similar genes within cancer
cells. With enough time and effort, these studies could ultimately lead to the in vivo
implementation of these unique derivatives, in addition to other modified siRNAs with
therapeutic potential.
When triazole-linked analog dimers were placed near the center of siRNAs, duplex
thermostability was significantly reduced along with silencing potency. Contrary to these
findings and those obtained in similar studies involving centrally-modified siRNAs, a
report by Maier and colleagues from Alnylam Pharmaceuticals observed an increase in
efficacy resulting from centrally-destabilized duplex siRNAs containing mismatches or
abasic sites.15 In this study, they also re-confirmed the theoretical mechanism involving
sense strand removal without the natural phosphodiester linkage at the putative Ago2
cleavage site. After replacing the two residues of the scissile site on the sense strand with
2′-O-Me protected nucleoside analogs or binding them through a phosphorothioate
linkage, Maier and colleagues did not notice any reduction in potency from the parent
siRNA. Although this study mirrored an earlier report which tested the same
modifications on a nearly identical siRNA sequence,16 its findings opposed those
obtained by the earlier report and from others with similar discoveries.17 The following
study involving the use of abasic variable-length alkyl chain spacers succeeded in
producing similar results to those obtained by Maier and colleagues.
With single spacer modifications either approaching the central portion or the 3′ end of
the sense strand, modified siRNAs were destabilized while silencing activity was
maintained. These results are in accordance with the enhancement of duplex
thermodynamic asymmetry18, 19 provided that the spacer is similar in length to a wild-type
nucleoside and that the sense strand contains a single spacer. In addition, siRNAs
containing abasic spacers in the G9 position and across the Ago2 cleavage site showed
silencing activity comparable to wild type, provided that their lengths were either similar
or shorter than native lengths. These results not only corroborate the findings by Maier
and colleagues,15 but give further credence to an alternative mechanism of sense strand
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removal. Additionally, future studies can explore the use of abasic modifications
containing alternate functionalities which could assist with siRNA delivery, stability and
overall silencing capability.
Given that all spacer-modified siRNAs retained their function when targeting the firefly
luciferase reporter gene, the prospect of functionalizing these spacers with tissue-
directing or fluorescent molecules forms the basis of a desirable study. Commercially
available alkyl chain phosphoramidites of varying length and with alternative functional
groups within the chain, can offer points of conjugation for small molecules of interest.
Using the automated process of DMT-phosphoramidite chemistry, these newly-
functionalized spacers can be placed anywhere internally throughout designer siRNAs,
and may add favorable properties in addition to duplex compatibility considering that
internally-modified siRNAs were amenable to these destabilizing linkages.
An extension of this study involving these simple spacer linkages could be to prove
definitively that these linkages which lack a phosphate moiety to be targeted for cleavage
by Ago2, are indeed considered as non-cleavable linkages. The range of melting
temperatures obtained for siRNAs modified at the Ago2 cleavage site within the sense
strand (48.8 ᵒC to 55.3 ᵒC) suggest that although profoundly destabilized, these siRNAs
retained their duplex format under physiological temperatures. Therefore, it is assumed
with great confidence that any silencing activity observed by these particular siRNAs is
the result of an alternative form of sense-strand removal, devoid of an actual cleavage
event. To prove with definite certainty that the sense strand does indeed remain intact, at
least from Ago2-mediated degradation, a future study can employ the use of fluorescence
resonance energy transfer (FRET) imaging in situ.20 FRET visualization involves the use
of two communicating dyes placed on opposing ends of a long molecule; in this case the
sense strand of an siRNA. When tethered to one another through an non-cleaved sense
strand, these dyes can freely communicate with each other through a chain reaction
involving the excitation of one dye, which then emits a wavelength spectrum which
excites the distant second dye, thus producing a signal which can be visualized through
fluorescence microscopy. This interaction between the two dyes on opposing ends of the
sense strand would be disrupted once sense strand cleavage occurs. Since FRET
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technology has previously gauged the integrity of siRNAs within cell-based systems,21 it
could find utility towards furthering our understanding of this alternative sense strand
removal mechanism, in addition to assessing the fates of other modified siRNAs prepared
in this study.
Ultimately, the RNA backbone modifications performed within this study provide several
avenues, some of which are relatively simple using commercial sources through which to
beneficially alter the thermodynamic profiles of siRNAs. Both triazole and spacer-
modified siRNAs have proven their utility within cell-based assays and they further
illustrate the extensive promiscuity of RNAi machinery for a variety of synthetic ligands.
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New chemically modified oligonucleotides at the site of the backbone are needed to improve the
properties of oligonucleotides. A practical synthesis for a triazole-linked nucleoside dimer based on a
PNA-like structure has been developed. This involves synthesizing two uracil-based monomers that con-
tain either an azide or an alkyne functionality, followed by copper-catalyzed 1,3-dipolar cycloaddition.
This dimer was incorporated within an oligonucleotide via phosphoramidite chemistry and UV-moni-
tored thermal denaturation data illustrates slight destabilization relative to its target complementary
sequence. This chemically modified dimer will allow for a future investigation of its properties within
DNA and RNA-based applications.
J. Heterocyclic Chem., 48, 533 (2011).
INTRODUCTION
Oligonucleotides have found tremendous use as bio-
logical tools and as agents with therapeutic promise.
One promising example involves RNA interference
(RNAi), and exploiting this pathway has become a
major tool in elucidating gene function [1]. Furthermore,
utilization of the RNAi pathway by administering short
interfering RNAs (siRNAs) to cells [2] has offered ther-
apeutic hope in combating diseased cells with aberrant
gene expression profiles [3]. Despite awareness of this
potential, improvements in enzymatic stability, biodistri-
bution, cell-membrane permeability, and reducing off-
target effects are still needed [4,5]. One way to poten-
tially overcome these limitations involves altering the
stability and specificity profile of the siRNA through
chemical modification.
Within the areas of siRNA, the most common type of
chemical modification involves alterations within the
ribose moiety. Extensive studies involving 20-O-Me, flu-
orinated sugars and locked nucleic acids (LNA) have
shown favorable siRNA knockdown results depending
on its position and sequence context [6–9]. Studies
involving chemical modification of the backbone within
the field of siRNA are less prevalent than sugar modifi-
cations. Some key examples include the negatively
charged backbone modification involving a phosphoro-
thioate [10] and boranophosphates [11]. Backbone-alter-
ing modifications such as a morpholino analogue [12]
and neutral amide bonds at 30 overhangs of siRNA
duplexes, have shown favorable results when utilized
for gene-knockdown studies [13,14]. Therefore, it is
possible that the RNAi pathway will adopt less conven-
tional backbone modifications at specific positions of the
oligonucleotide. Given that siRNA duplexes exhibit
thermodynamic asymmetry, being able to potentially
destabilize the 50 end of the guide strand with novel
backbone modifications may offer favorable properties.
Outside of the RNAi field, modified backbone constructs
could have many other potential applications such as in
antisense technology, artificial aptamer design or tem-
plate driven enzymatic reactions. To explore this pro-
spective, we are interested in pursuing alternative back-




Within the field of backbone modified oligonucleo-
tides, one of the most successful examples involves pep-
tide nucleic acid (PNA) [15] and this has shown remark-
able stability and specificity to its complementary tar-
gets [16,17]. PNA synthesis occurs by the successful
amide-bond formation between an acid and an amine
with high-yields. Therefore, we envisioned that a scaf-
fold based on a triazole functional group would serve as
a potentially good candidate (Fig. 1). To date, a number
of different triazole-based backbone modifications have
been reported [18–20] from the one presented herein.
RESULTS AND DISCUSSION
The repetitive backbone unit in most analogues,
including PNA, contains six atoms. Although the six-
atom spacer unit dominates by choice for a large num-
ber of chemically modified nucleic acids, analogues
with shorter (five atom linker) [21–23] and longer back-
bones (seven atom linker) [24,25] have shown varying
degrees of specificity to its target, depending on its
sequence context and type of backbone. This suggests
that site-specific incorporation of unnatural nucleoside
backbones of different atom lengths can produce func-
tioning oligonucleotides, capable of binding to their
complement strand with varying specificity and stability.
As such, chemically modifying oligonucleotides could
offer an alternative way to fine-tune their functional
effects.
We hypothesized that a copper (I)-catalyzed Huisgen
[3 þ 2] cycloaddition [26] based on a PNA-type struc-
ture would generate an alternative scaffold for bridging
adjacent nucleotides together. We report the synthesis of
a modified 1,4-triazole-linked uracil dimer through a
distance of seven atoms and report its compatibility with
hybridization to a complement sequence when appended
at the 50 or 30 end of a DNA oligonucleotide.
Our strategy involves the synthesis of a uracil-based
monomer possessing an alkyne functional group and a
uracil-based monomer with an azide. For the synthesis
of the uracil-based alkyne monomer, the first step
involved tert-butyldimethylsilyl (TBS) protection of eth-
anolamine and this was conducted using TBSCl under
standard basic conditions to afford 1 in 96% yield.
Alkylation of 1 with propargyl bromide generated the
alkyne 2 as a liquid in 71% yield. Utilizing peptide
bond coupling conditions involving HBTU, the alkyne 2
was amide-bond coupled to uracil-1-yl acetic acid [27]
to afford compound 3 as a white solid in 44% yield
(Scheme 1).
For the synthesis of the azide-based uracil monomer
6, 2-azidoethylamine 4 was prepared by the addition of
2-bromoethylamine to an aqueous solution of sodium
azide. Alkylation of 4 with a limiting amount of ethyl
2-bromoacetate afforded compound 5 as an off-colored
liquid in 83% yield. This liquid 5 was amide-bond
coupled with uracil-1-yl acetic acid using DCC/HOBt to
afford the azide-based uracil monomer, compound 6 in
62% yield (Scheme 2).
Figure 1. Chemical differences between peptide nucleic acid (left) and
triazole-linked nucleic acid (right).
Scheme 1. Reagents and conditions: (i) 1 equiv imidazole, 1 equiv
TBS-Cl, DCM, room temperature 96% yield of 1; (ii) 0.5 equiv
DIPEA, 0.5 equiv propargyl bromide, DCM, room temperature, 3 h,
71% yield of 2; (iii) 1.5 equiv uracil-1-yl acetic acid, 1.5 equiv
DIPEA, 1.5 equiv HBTU, DMF, 24 h, 44% yield of 3.
Scheme 2. Reagents and conditions: (i) 3 equiv NaN3, H2O, 75
C, 24
h; (ii) 5.8 equiv NaOH, 0C, Et2O, 64% yield of 4; (iii) 1 equiv NEt3,
0.6 equiv ethyl 2-bromoacetate, DMF, 4 h, 83% yield of 5; (iv) 1.1
equiv uracil-1-yl acetic acid, 1.1 equiv DCC, 1.1 equiv HOBt, DMF,
24 h, 62% yield of 6.
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With respect to the synthesis of the phosphoramidite,
the first task was to cyclize both monomers together.
Under copper (I) conditions, 1,4-triazole formation
occurred with copper sulfate and sodium ascorbate to
afford a white solid 7 in 98% yield. This newly formed
dimer 7 was selectively reduced with 2.5 equivalents of
LiBH4 in a methanol/THF mixture to afford the alcohol
8 in 76% yield. Alcohol 8 was treated with 4,40-dime-
thoxytrityl-chloride (DMT-Cl) to afford the compound 9
in 79% yield. The subsequent removal of the TBS group
using TBAF provided the alcohol 10 in 85% yield. This
was then followed by synthesis of phosphoramidite 11
by reacting alcohol 10 with 2-cyanoethyl N,N-diisopro-
pylchlorophosphoramidite to afford a clear oil in 63%
yield (Scheme 3). With this phosphoramidite 11, its
incorporation within a DNA oligonucleotide was accom-
plished by employing solid-phase oligonucleotide syn-
thesis on a 394 ABI synthesizer.
UV-melting denaturation studies indicate that moder-
ate destabilization occurs with the UU-dimer on both
the 50 and 30 position relative to the native strand (Table
1). A reduction in Tm of 4.5
C and 2.8C is observed
when native TT is replaced with the UU-dimer modifi-
cation at the 50 end and the 30 end, respectively. How-
ever, this suggests a certain degree of compatibility as
the Tm values for both modified oligonucleotides are
higher when compared to corresponding 12-mer sequen-
ces lacking the heterocyclic pyrimidine dimer (UU)
(Table 1). In comparison to other studies [28] and that
of Kraicsovits and coworkers, a similar Tm drop was
Table 1
UV-melting denaturation studies.
Entry Sequence Tm (
C) DTm (C)
a
I 50 TTTTTCTCTCTCTT 30 40.9 0
II 50 TTTTTCTCTCTCUU 30 38.1 2.8
III 50 TTTTTCTCTCTC 30 37.1 3.8
IV 50 UUTTTCTCTCTCTT 30 36.4 4.5
V 50 TTTCTCTCTCTT 30 35.3 5.6
UV melting temperatures for duplexes to complement strand DNA (50-
AAG AGA GAG AAA AA-30). The total strand concentration ranged
from 2.4 to 3.0 lM in 90 mM NaCl, 10 mM sodium phosphate, and
1 mM EDTA at pH 7.0.
aFor the DTm values, the Tm of Entry I is the reference (Tm ¼
40.9 C).
Scheme 3. Reagents and conditions: (i) 2 equiv sodium ascorbate, 0.5 equiv Cu(II)SO4, THF/t-BuOH/H2O (1:1:1), 24 h, 98% yield of 7; (ii) 2.5
equiv LiBH4, THF/MeOH (12:1), reflux 1.5 h, 76% yield of 8; (iii) 3 equiv DMT-Cl, pyridine, 24 h, 79% yield of 9; (iv) 3 eq TBAF, THF, 12 h,
85% yield of 10; (v) 2 equiv 2-cyanoethyl N,N-diisopropylchlorophosphoramidite, 5.5 equiv DIPEA, 0.5 equiv DMAP, DCM, 8 h, 63% yield of
11.
May 2011 535Synthesis and Properties of Oligonucleotides that Contain a
Triazole-Linked Nucleic Acid Dimer
Journal of Heterocyclic Chemistry DOI 10.1002/jhet
observed when compared to a PNA-DNA chimera that
contained a PNA element at the terminal end [29].
CONCLUSIONS
In conclusion, a facile and practical synthesis of a
new uracil-uracil dimer linked together through a tria-
zole functionality has been developed and is readily syn-
thesized from inexpensive starting material precursors.
Our alkyne-uracil monomer 3 was synthesized in 44%
yield and the azide-uracil monomer 6 was generated in
62% yield. Following heterocyclic cyclization, the phos-
phoramidite 11 was generated in four steps in 32%
yield. Incorporation of the heterocyclic dimer at both
the 50 and 30 ends of DNA oligonucleotides suggests a
certain degree of compatibility when analyzed by UV-
monitored thermal denaturation. The effects of this mod-
ification within different positions of other various oli-
gonucleotides will be investigated. Notwithstanding,
these oligonucleotides may have potential use when tar-
geted at messenger RNA in diseased cells, or for other
downstream applications.
EXPERIMENTAL
Unless otherwise noted, all starting materials were obtained
from commercial sources and were used without any additional
purification. Anhydrous CH2Cl2, THF, and DMF were pur-
chased from Sigma-Aldrich and degassed by stirring under a
dry N2 atmosphere. Purification by flash chromatography was
carried out with Silicycle Siliaflash 60 (230–400 mesh) accord-
ing to the procedure of Still et al. [30] 1H NMR spectra were
recorded in DMSO-d6 or CDCl3 at 400 or 500 MHz and
13C
NMR spectra were recorded at 100 or 125 MHz. High-Resolu-
tion MS (HRMS) was recorded on a Micromass AutoSpec
Ultima Magnetic sector mass spectrometer.
2-(tert-Butyldimethylsilyloxy)ethanamine (1). To a solu-
tion of ethanolamine (9.6 mL, 159 mmol) in 100 mL of CH2Cl2
was dissolved imidazole (10.8 g, 159 mmol) and this solution
was cooled in an ice-water bath. To this solution was added
tert-butyldimethylsilyl chloride (24 g, 159 mmol) and the reac-
tion mixture was stirred overnight at room temperature. Sat.
NaHCO3 was added and the resulting mixture was partitioned.
The organic fractions were concentrated in vacuo to afford the
title compound as a clear light yellow oil (26.8 g, 96%) [31].
N-(2-(tert-Butyldimethylsilyloxy)ethyl)prop-2-yn-1-amine (2). To
a solution of 1 (10 g, 57 mmol) in 100 mL of CH2Cl2 was
added diisopropylethylamine (3.7 g, 28.5 mmol), and this solu-
tion was cooled in an ice-water bath. To this solution was
added 3-bromoprop-1-yne (3.4 g, 28.5 mmol) dropwise over
30 min. This reaction mixture was stirred at room temperature
until TLC analysis indicated the complete consumption of
starting material (3 h). Sat. NaHCO3 was added and the reac-
tion mixture was partitioned. The organic fraction was concen-
trated in vacuo, to afford an oil which was purified by silica
gel chromatography eluting with a gradient of hexanes/EtOAc
(7:3 to 3:7) to afford the title compound as a clear yellow oil
(2.9 g, 71%); 1H NMR (500 MHz, CDCl3) d 0.07 (s, 6H),
0.90 (s, 9H), 1.67 (br s, 1H), 2.21 (s, 1H), 2.80 (t, 2H, J ¼ 5.5
Hz), 3.46 (s, 2H), 3.75 (t, 2H, J ¼ 5.1 Hz); 13C NMR (100
MHz, CDCl3) d 5.36, 25.89, 29.66, 38.18, 50.52, 62.32,
71.21, 82.15; ESI-HRMS (ESþ) m/z calcd for C11H23NOSi:
213.1549, found 214.1626 [M þ H]þ. Anal. Calcd. for
C11H23NOSi: C, 61.91; H, 10.86. Found: C, 61.56; H, 10.49.
N-(2-(tert-Butyldimethylsilyloxy)ethyl)-uracil-1-yl-N-(prop-
2-yn-1-yl)acetamide (3). To a solution of uracil-1-yl acetic
acid (2.4 g, 14 mmol) in 240 mL of DMF was added diisopro-
pylethylamine (1.8 g, 14 mmol) and this solution was cooled
in an ice-water bath. The acid was activated with the addition
of O-benzotriazole-N,N,N0,N0-tetramethyl-uronium-hexafluoro-
phosphate (5.3 g, 14 mmol) to the stirring solution over the
course of 5 min, followed by the dropwise addition of 2 (2 g, 9.4
mmol) over 15 min. The reaction mixture was stirred for 24 h at
ambient temperature and then extracted with EtOAc and the or-
ganic layer was washed with H2O and brine (x3). The organic
layer was collected and concentrated in vacuo to afford the crude
product. This crude product was purified by flash chromatography
with a gradient of hexanes/EtOAc (7:3) to 100% EtOAc to elute
the title compound as a white solid (1.5 g, 44%). Compound 3 is
a pair of rotamers; the signals to the major (ma.) and minor (mi.)
rotamers are designated; 1H NMR (500 MHz, CDCl3) d 0.04 (s,
2H, mi.), 0.08 (s, 4H, ma.), 0.88 (s, 3H, mi.), 0.89 (s, 6H, ma.),
2.25 (br s, 0.66H, ma.), 2.41 (br s, 0.33H, mi.), 3.58 (t, 0.6H, J
¼ 5.3 Hz, mi.), 3.65 (t, 1.4H, J ¼ 5.2 Hz, ma.), 3.76 (t, 0.6H, J
¼ 5.3 Hz, mi.), 3.85 (t, 1.4H, J ¼ 5.0 Hz, ma.), 4.27 (2s, 2H),
4.68 (m, 2H), 5.71–5.74 (m, 1H), 7.13 (d, 0.66H, J ¼ 7.9 Hz,
ma.), 7.17 (d, 0.33H, J ¼ 7.9 Hz, mi.), 9.43 (br s, 0.66H, ma.),
9.48 (br s, 0.33H, mi.); 13C NMR (125 MHz, CDCl3) d 5.61,
5.55, 5.41, 5.36, 3.72, 3.53, 17.94, 18.11, 18.28, 25.54,
25.69, 25.75, 25.81, 25.89, 25.96, 35.16, 38.67, 48.03, 48.06,
48.78, 49.55, 60.58, 61.67, 72.72, 73.59, 77.93, 78.13, 102.13,
102.24, 145.02, 145.09, 150.90, 150.93, 163.58, 166.30, 166.66;
ESI-HRMS (ESþ) m/z calcd for C17H27N3O4Si: 365.1771, found
366.1845 [M þ H]þ. Anal. Calcd. for C17H27N3O4Si: C, 55.86;
H, 7.45; N, 11.50. Found: C, 55.67; H, 7.80; N, 11.89.
2-Azidoethanamine (4). To a solution of NaN3 (23.8 g, 366
mmol) in 200 mL of water was added 2-bromoethylamine
hydrobromide (25 g, 122 mmol) and this solution was heated
to 75C. The reaction mixture was stirred for 24 h and was
then cooled in an ice-water bath. To the cooled solution was
added NaOH (28.5 g, 712.5 mmol) and the reaction mixture
was stirred until the NaOH was fully dissolved. To this aque-
ous solution was added Et2O (x3). The ether fractions were
collected, dried over Na2SO4, and evaporated in vacuo to
afford the title compound as a clear oil (6.7 g, 64%). The 1H
proton and 13C NMR shifts were confirmed with the report by
Mayer and Maier [32].
Ethyl 2-(2-azidoethylamino)acetate (5). To a solution of 4
(5 g, 58.1 mmol) in 100 mL of DMF was added triethylamine
(5.9 g, 58.1 mmol). Ethyl 2-bromoacetate (5.8 g, 34.9 mmol)
was then added dropwise over 15 min to the stirring solution
and the reaction was stirred for 4 h at room temperature. The
solution was then extracted with EtOAc, washed with H2O
(three times) and the EtOAc fractions were collected and dried
over Na2SO4. This solution was evaporated under reduced
pressure to yield a crude orange oil. The oil was loaded
directly onto a silica column for purification by gradient elut-
ing with hexanes/EtOAc (5:5) to 100% EtOAc to afford the
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title compound as a clear light yellow oil (5.0 g, 83%); 1H
NMR (400 MHz, CDCl3) d 1.25 (t, 3H, J ¼ 7.1 Hz), 1.98 (br
s, 1H), 2.80 (t, 2H, J ¼ 5.7 Hz), 3.39 (t, 2H, J ¼ 5.9 Hz),
3.40 (s, 2H), 4.17 (q, 2H, J ¼ 7.4 Hz); 13C NMR (100 MHz,
CDCl3) d 14.09, 48.01, 50.50, 51.33, 60.74, 172.07; ESI-
HRMS (ESþ) m/z calcd for C6H12N4O2: 172.0960, found
173.1034 [M þ H]þ. Anal. Calcd. for C6H12N4O2: C, 41.85;
H, 7.02; N, 32.54. Found: C, 41.65; H, 6.82; N, 32.12.
Ethyl 2-(N-(2-azidoethyl)-uracil-1-yl-acetamido)acetate (6). To
a solution of uracil-1-yl acetic acid (1.1 g, 6.4 mmol) in 100 mL
of anhydrous DMF under N2 was added dicyclohexylcarbodii-
mide (1.3 g, 6.4 mmol) and 1N-hydroxybenzotriazole (1.0, 6.4
mmol). This solution was stirred for 15 min on an ice-water
bath, followed by 1 h of stirring at ambient temperature. To
this solution was added compound 5 (1 g, 5.8 mmol) dropwise
over 10 min, and the reaction mixture was stirred for 24 h af-
ter which the DCU precipitate was collected by filtration. The
filtrate was dried down in vacuo, dissolved in EtOAc, and
washed with water and brine (x3). The EtOAc solutions were
concentrated in vacuo. The resulting crude product was dis-
solved in a minimal amount of CH2Cl2 and purified by flash
chromatography with a gradient of hexanes/EtOAc (5:5) to
100% EtOAc to elute the title compound as a white solid (1.2
g, 62%). Compound 6 is comprised of a pair of rotamers, each
displaying signals of equal intensity; 1H NMR (500 MHz,
CDCl3) d 1.28 (t, 1.5H, J ¼ 7.1 Hz), 1.33 (t, 1.5H, J ¼ 7.1
Hz), 3.55 (s, 2H), 3.59 (t, 1H, J ¼ 5.6 Hz), 3.66 (t, 1H, J ¼
5.4 Hz), 4.12 (s, 1H), 4.21 (q, 1H, J ¼ 7.1 Hz), 4.26 (s, 1H),
4.28 (q, 1H, J ¼ 7.1 Hz), 4.49 (s, 1H), 4.72 (s, 1H), 5.74 (d,
0.5H, J ¼ 6.0 Hz), 5.75 (d, 0.5H, J ¼ 5.6 Hz), 7.20 (d, 0.5H,
J ¼ 2.0 Hz), 7.21 (d, 0.5H, J ¼ 2.0 Hz), 9.08 (br s, 1H); 13C
NMR (125 MHz, CDCl3) d 47.75, 47.82, 48.05, 48.31, 48.86,
49.84, 49.92, 50.95, 61.67, 62.31, 102.30, 102.38, 145.02,
145.14, 150.90, 150.92, 163.44, 167.16, 167.46, 168.64,
169.03; ESI-HRMS (ESþ) m/z calcd for C12H16N6O5:
324.1182, found 325.1262 [M þ H]þ. Anal. Calcd. for




cil-1-yl-acetamido)acetate (7). To a solution of compounds 3
(677 mg, 1.9 mmol) and 6 (600 mg, 1.9 mmol) dissolved in
18 mL of THF/t-BuOH/H2O (1:1:1) was added sodium ascor-
bate (733 mg, 3.7 mmol) and Cu(II)SO4 (231 mg, 925 lmol).
This reaction mixture was stirred for 24 h at room temperature
and then extracted with CH2Cl2. The organic layer was washed
with H2O (three times) to wash off the excess copper. The pre-
cipitate in the organic layer was collected by filtration and
washed with cold H2O to afford the crude product. This crude
product was redissolved in minimal CH2Cl2/MeOH for 1 h
and purified by flash column chromatography eluting with 5%
(10% NH4OH in MeOH) in CH2Cl2 to afford the title com-
pound as a white solid (1.3 g, 98%). Compound 7 is a mixture
of rotamers with varying signal intensities. 1H NMR (400
MHz, DMSO-d6) d 0.03 (s, 2H), 0.05 (m, 4H), 0.85, 0.86 (2s,
9H), 1.18 (t, 1.5H, J ¼ 7.2 Hz), 1.23 (t, 1.5H, J ¼ 7.0 Hz),
3.48–3.50 (m, 1H), 3.63–3.91 (m, 4H), 4.01–4.03 (m, 1H),
4.08 (q, 1.2H, J ¼ 7.3 Hz), 4.16 (q, 0.8H, J ¼ 7.3 Hz), 4.24,
4.29 (2s, 1H), 4.44–4.77 (m, 9H), 5.56 (d, 2H, J ¼ 7.8 Hz),
7.31–7.47 (m, 2H), 7.89, 8.05, 8.13, 8.24 (4s, 1H), 11.29 (br
m, 2H); 13C NMR (100 MHz, DMSO-d6) d 5.45, 5.39,
13.99, 14.04, 17.89, 18.04, 25.82, 25.90, 41.05, 47.31, 47.58,
47.91, 48.00, 60.18, 60.65, 60.83, 61.25, 100.57, 100.79,
123.70, 124.04, 124.12, 124.61, 143.18, 143.34, 143.41,
143.56, 146.12, 146.19, 146.29, 146.50, 146.54, 150.92,
150.98, 151.04, 151.07, 151.11, 163.76, 163.80, 163.81,
163.85, 163.88, 166.74, 166.82, 166.88, 166.90, 167.43,
167.97, 168.03, 168.85, 169.15; ESI-HRMS (ESþ) m/z calcd
for C29H43N9O9Si: 689.2953, found 690.3030 [M þ H]þ.




azol-4-yl)methyl)acetamide (8). To a solution of compound 7
(300 mg, 435 lmol) suspended in 12 mL of dry THF, drops of
MeOH were added until the compound was dissolved. To this
solution was then added LiBH4 (544 lL, 1.09 mmol) and the
reaction mixture was refluxed until TLC analysis indicated the
complete consumption of starting material (1.5 h). This reaction
mixture was quenched with MeOH and dried down in vacuo to
afford the crude product. The crude product was then redis-
solved in minimal CH2Cl2/MeOH and purified by flash column
chromatography eluting with a gradient of 10% NH4OH in
MeOH (5 to 15%) in CH2Cl2 to afford the title compound as a
white crystalline solid (213 mg, 76%). Compound 8 is a mixture
of rotamers with varying signal intensities; 1H NMR (500 MHz,
DMSO-d6) d 0.03 (s, 2H), 0.05 (s, 4H), 0.85, 0.87 (2s, 9H),
3.16–3.27 (m, 2H), 3.43–3.54 (m, 4H), 3.63–3.74 (m, 3H),
3.80–3.87 (m, 2H), 4.36–4.38 (m, 1H), 4.46 (t, 1.2H, J ¼ 6.3
Hz), 4.51 (t, 0.8H, J ¼ 6.3 Hz), 4.56–4.81 (m, 6H), 4.94–5.00
(m, 1H), 5.54–5.58 (m, 2H), 7.35–7.47 (m, 2H), 7.87, 8.04,
8.13, 8.23 (4s, 1H), 11.30 (br s, 2H); 13C NMR (125 MHz,
DMSO-d6) d 5.44, 5.37, 17.91, 18.05, 25.83, 25.92, 30.74,
41.04, 46.24, 46.55, 46.71, 46.92, 48.29, 48.32, 48.51, 49.07,
49.26, 58.49, 58.81, 58.85, 60.21, 60.85, 100.57, 100.63,
123.76, 124.11, 124.55, 143.23, 143.39, 143.43, 143.58, 146.48,
146.52, 146.58, 151.04, 151.08, 151.11, 163.84, 163.87, 166.69,
166.74, 166.81, 167.43, 167.54; ESI-HRMS (ESþ) m/z calcd for
C27H41N9O8Si: 647.2847, found 648.2918 [M þ H]þ. Anal.
Calcd. for C27H41N9O8Si: C, 50.06; H, 6.38; N, 19.46. Found:




cetamide (9). To a solution of compound 8 (1.06 g, 1.64
mmol) dissolved in 10 mL of dry pyridine under N2, was
added an excess of 4,40-dimethoxytrityl chloride (1.66 g, 4.91
mmol) until TLC analysis revealed the consumption of starting
material. This reaction mixture was stirred overnight at room
temperature. while under N2, after which the entire mixture
was extracted with CH2Cl2 and washed with H2O (two times).
The organic fractions were collected, dried over Na2SO4 and
subsequently condensed in vacuo to afford the crude product.
The crude was dissolved in minimal CH2Cl2/MeOH and puri-
fied by flash column chromatography eluting with a gradient
of MeOH (5 to 15%) in CH2Cl2 to afford the title compound
as a white solid (1.22 g, 79%). Compound 9 is a mixture of
rotamers with varying signal intensities; 1H NMR (400 MHz,
CDCl3) d 0.03 (s, 2H), 0.06 (s, 4H), 0.86, 0.88 (2s, 9H), 2.87–
2.94 (m, 1.5H), 3.03–3.08 (m, 0.5H), 3.20 (t, 1.5H, J ¼ 4.7
Hz), 3.26 (t, 0.5H, J ¼ 4.5 Hz), 3.29–3.31 (m, 0.2H), 3.36–
3.43 (m, 0.3H), 3.46–3.55 (m, 2.5H), 3.60–3.67 (m, 2H), 3.72–
3.75 (m, 0.75H), 3.76, 3.77 (2s, 7H), 3.80 (t, 1.25H, J ¼ 4.9
Hz), 4.51 (t, 1.5H, J ¼ 5.3 Hz), 4.55 (t, 0.5H, J ¼ 5.3 Hz),
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4.59 (s, 1H), 4.63–4.64 (m, 1H), 4.67 (s, 3H), 4.73 (d, 1H, J ¼
7.4 Hz), 5.51–5.55 (m, 1H), 5.62 (d, 0.1H, J ¼ 1.6 Hz), 5.64
(d, 0.1H, J ¼ 1.6 Hz), 5.64–5.68 (m, 0.8H), 6.57 (d, 0.1H, J ¼
7.8 Hz), 6.66 (d, 0.7H, J ¼ 7.8 Hz), 6.80–6.84 (m, 4.3H),
7.06–7.09 (m, 0.8H), 7.17–7.36 (m, 7.2H), 7.71, 7.81, 7.88,
7.94 (4s, 1H), 10.11 (br s, 2H); 13C NMR (100 MHz, CDCl3)
d 5.44, 5.16, 18.13, 18.29, 25.61, 25.83, 25.90, 41.33,
44.08, 47.64, 47.74, 48.27, 48.50, 48.62, 48.87, 48.93, 49.09,
55.23, 60.41, 60.66, 60.79, 60.98, 87.24, 87.39, 102.02,
102.21, 102.25, 113.15, 113.25, 124.37, 125.24, 127.18,
127.24, 127.86, 127.98, 128.15, 129.91, 130.08, 135.03,
135.09, 135.70, 143.49, 143.76, 144.01, 144.05, 144.65,
145.00, 145.10, 145.15, 145.21, 145.54, 151.26, 151.32,
151.38, 151.46, 158.42, 158.67, 158.71, 163.91, 164.00,
164.08, 166.48, 167.25, 167.67. ESI-HRMS (ESþ) m/z calcd
for C48H59N9O10Si 949.4154, found 972.4035 [M þ Na]þ.
Anal. Calcd. for C49H59N9O10Si: C, 60.68; H, 6.26; N, 13.27.
Found: C, 60.50; H, 6.28; N, 12.90.
N-(2-(Bis(4-methoxyphenyl)(phenyl)methoxy)ethyl)-2-(uracil-
1-yl)-N-((1-(2-(2-(uracil-1-yl)-N-(2-hydroxyethyl)acetamido)ethyl)-
1H-1,2,3-triazol-4-yl)methyl)acetamide (10). To a solution of
compound 9 (1.12 g, 1.18 mmol) dissolved in 26 mL of dry
THF was added TBAF (926 mg, 3.54 mmol). This reaction
mixture was stirred for 12 h at room temperature and then
extracted with CH2Cl2. The organic layer was washed with
H2O and brine (2), at which point the combined organic
fractions were dried over Na2SO4, and evaporated under
reduced pressure. The crude was dissolved in minimal
CH2Cl2/MeOH and purified by flash column chromatography,
first eluting with 100% CH2Cl2 followed by a gradient of
MeOH (5 to 15%) in CH2Cl2 to afford the title compound as a
yellow solid (840 mg, 85%). Compound 10 is a mixture of
rotamers with varying signal intensities; 1H NMR (400 MHz,
CDCl3) d 2.49 (br s, 1H), 2.98 (br s, 1H), 3.16–3.20 (br m,
2H), 3.27–3.31 (m, 3H), 3.45–3.57 (m, 4H), 3.68–3.81 (m,
8H), 4.45–4.80 (m, 8H), 5.50–5.53 (m, 0.8H), 5.56–5.60 (m,
1.2H), 6.63 (d, 0.15H, J ¼ 8.2 Hz), 6.66 (d, 0.35H, J ¼ 7.8
Hz), 6.78–6.83 (m, 4H), 7.17–7.31 (m, 8.5H), 7.69, 7.88, 7.90,
8.09 (4s, 1H), 10.20–10.42 (br m, 2H); 13C NMR (100 MHz,
CDCl3) d 22.13, 27.75, 29.14, 29.64, 42.18, 47.37, 48.29,
49.13, 50.35, 55.24, 59.15, 60.78, 68.46, 87.23, 87.32, 101.65,
101.91, 107.85, 113.16, 113.26, 124.97, 127.16, 127.99,
128.17, 129.92, 130.09, 135.15, 135.73, 143.56, 144.11,
144.28, 145.47, 146.36, 151.41, 151.47, 158.40, 158.64,
164.30, 164.39, 164.56, 167.63, 167.68; ESI-HRMS (ESþ) m/z
calcd for C42H45N9O10: 835.3289, found 858.3217 [M þ
Na]þ. Anal. Calcd. for C42H45N9O10: C, 60.35; H, 5.43.




phoramidite (11). To a solution of compound 10 (230 mg,
275 lmol) dissolved in 6 mL of dry CH2Cl2 under N2, was
added diisopropylethylamine (196 mg, 1.51 mmol) along with
4-dimethylaminopyridine (16.8 mg, 138 lmol). To this solu-
tion was added 2-cyanoethyl N,N-diisopropylchlorophosphora-
midite (195 mg, 825 lmol), until TLC analysis revealed the
maximum consumption of starting material. This mixture was
then stirred for 6 h at room temperature under N2 and dried in
vacuo to afford the crude product. The crude was dissolved in
minimal 2% triethylamine in hexanes/acetone and purified by
flash column chromatography eluting with a gradient of 2%
triethylamine in acetone/hexanes (1:1 to 4:1) to afford the title
compound as a white solid (180 mg, 63%). Compound 11 is a
mixture of rotamers with varying signal intensities; 1H NMR
(400 MHz, CDCl3) d 1.14–1.19 (m, 12H), 2.62–2.66 (m,
3.25H), 2.92 (t, 1H, J ¼ 3.9 Hz), 3.07 (t, 0.75H, J ¼ 4.3 Hz),
3.21 (t, 1.25H, J ¼ 4.7 Hz), 3.26 (t, 0.5H, J ¼ 4.3 Hz), 3.29–
3.37 (m, 0.25H), 3.54–3.61 (m, 5.5H), 3.70–3.77 (m, 2H), 3.78
(s, 6.25H), 3.81–3.90 (m, 2.25H), 4.52 (t, 1H, J ¼ 5.3 Hz),
4.55 (t, 0.5H, J ¼ 5.5 Hz), 4.61–4.65 (m, 2H), 4.70 (s, 2.5H),
4.74–4.77 (m, 1H), 5.52–5.55 (m, 1H), 5.66–5.70 (m, 1H),
6.56 (d, 0.33H, J ¼ 7.8 Hz), 6.63 (d, 0.66H, J ¼ 7.8 Hz),
6.81–6.84 (m, 4H), 7.17–7.31 (m, 12H), 7.70, 7.76, 7.89, 7.95
(4s, 1H); 13C NMR (100 MHz, CDCl3) d 14.10, 14.84, 20.45,
20.52, 22.66, 23.34, 24.58, 24.62, 24.65, 24.69, 24.77, 29.24,
29.34, 29.66, 31.72, 31.89, 33.80, 34.43, 41.51, 43.02, 43.14,
45.82, 47.67, 47.80, 48.29, 48.60, 48.71, 48.93, 53.76, 55.26,
58.08, 58.30, 60.53, 60.70, 60.80, 69.48, 87.29, 87.42, 102.08,
102.20, 102.25, 113.27, 117.90, 118.12, 125.13, 127.24,
128.01, 128.20, 130.12, 135.05, 135.09, 143.39, 143.82,
144.05, 145.07, 145.46, 151.24, 151.34, 151.45, 158.71,
158.75, 163.63, 163.87, 163.91, 166.67, 167.41, 167.74; ESI-
HRMS (ESþ) m/z calcd for C51H62N11O11P: 1035.4368, found
1058.4298 [M þ Na]þ.
Oligonucleotide synthesis. All standard b-cyanoethyl DNA
phosphoramidites, solid supports and reagents were purchased
from Glen Research. All oligonucleotides were synthesized on
an Applied Biosystems 394 DNA/RNA synthesizer using a 0.2
lM cycle with a 25 s coupling time for unmodified phosphora-
midites. All phosphoramidites were dissolved in anhydrous
acetonitrile to a 0.1M concentration immediately prior to syn-
thesis. Synthesis on solid phase was accomplished using 0.2
lM solid supports. Cleavage of the unmodified oligonucleo-
tides from their solid supports was performed through expo-
sure to 1.5 mL of 30% NH4OH for 2 h at room temperature,
followed by incubation in 30% NH4OH at 55
C overnight. All
oligonucleotides were purified on a 20% denaturing polyacryl-
amide gel by utilizing the ‘‘crush and soak’’ method, followed
by ethanol precipitation and desalting through Millipore 3000
MW cellulose centrifugal filters. The oligonucleotides were
characterized by MALDI-TOF mass spectrometry (Waters Tof-
spec-2E) (Table 2).
Table 2












50 TTTTTCTCTCTCUU 30 4123 4122 [M – H]
50 TTTTTCTCTCTC 30 3529 3530 [M þ H]
50 UUTTTCTCTCTCTT 30 4123 4164 [M – H þ K]
50 TTTCTCTCTCTT 30 3529 3530 [M þ H]
Observed masses obtained from MALDI-TOF Mass Spectrometry.
Polyacrylamide gel-purified samples were desalted using Millipore
Zip-Tip C18-column micropipette tips to a final concentration of 5
lM. 5 lL of matrix solution (3-hydroxypicolinic acid at 25 mg/mL,
dissolved in 50/50 acetonitrile/water with 5 mg/mL ammonium citrate)
was added to each sample vial.
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Synthesis of 50 TTTTTCTCTCTCUU 30 and 50
UUTTTCTCTCTCTT 30. Phosphoramidite 11 was attached
to the 50 end of the growing oligonucleotide being synthesized
on the ABI 394 DNA/RNA synthesizer, with an increased cou-
pling time of 600 s. To perform the 30 modification, compound
11 was attached to a Universal III solid support (Glen
Research) via the ABI 394 synthesizer with a 600 s coupling
time. Cleavage from the Universal III solid support was per-
formed through exposure to 1.5 mL of 2M NH3 in MeOH for
30 min at room temperature, followed by incubation in 30%
NH4OH at 55
C for 8 h.
Synthesized sequences. Oligonucleotides synthesized using
standard dT/dA supports: (i) 50-AAG AGA GAG AAA AA–30;
(ii) 50–TTT TTC TCT CTC TT–30; and (iii) 50–UUT TTC
TCT CTC TT–30. The UU–30 modified sequence synthesized
on the Universal III solid support: 50–TTT TTC TCT CTC
UU–30. The sequence 50-AAG AGA GAG AAA AA-30 was
purchased and purified from Integrated DNA Technologies.
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5.1 Tables







5′ TTTTTCTCTCTCUU 3′ 4123 4122 [M – H]
5′ TTTTTCTCTCTC 3′ 3529 3530 [M + H]
5′ UUTTTCTCTCTCTT 3′ 4123 4164 [M – H + K]
5′ TTTCTCTCTCTT 3′ 3529 3530 [M + H]
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5.2 NMR Spectra
5.2.1 Proton NMR Spectrum of Compound 2
Figure A13. 1H – NMR Spectrum of Compound 2 observed in CDCl3 at 500 MHz.
126
5.2.2 Carbon NMR Spectrum of Compound 2
Figure A14. 13C – NMR Spectrum of Compound 2 observed in CDCl3 at 100 MHz.
127
5.2.3 Proton NMR Spectrum of Compound 3
Figure A15. 1H – NMR Spectrum of Compound 3 observed in CDCl3 at 500 MHz.
128
5.2.4 Carbon NMR Spectrum of Compound 3
Figure A16. 13C – NMR Spectrum of Compound 3 observed in CDCl3 at 125 MHz.
129
5.2.5 Proton NMR Spectrum of Compound 5
Figure A17. 1H – NMR Spectrum of Compound 5 observed in CDCl3 at 400 MHz.
130
5.2.6 Carbon NMR Spectrum of Compound 5
Figure A18. 13C – NMR Spectrum of Compound 5 observed in CDCl3 at 100 MHz.
131
5.2.7 Proton NMR Spectrum of Compound 6
Figure A19. 1H – NMR Spectrum of Compound 6 observed in CDCl3 at 500 MHz.
132
5.2.8 Carbon NMR Spectrum of Compound 6
Figure A20. 13C – NMR Spectrum of Compound 6 observed in CDCl3 at 125 MHz.
133
5.2.9 Proton NMR Spectrum of Compound 7
Figure A21. 1H – NMR Spectrum of Compound 7 observed in DMSO-d6 at 400 MHz.
134
5.2.10 Carbon NMR Spectrum of Compound 7
Figure A22. 13C – NMR Spectrum of Compound 7 observed in DMSO-d6 at 100 MHz.
135
5.2.11 Proton NMR Spectrum of Compound 8
Figure A23. 1H – NMR Spectrum of Compound 8 observed in DMSO-d6 at 500 MHz.
136
5.2.12 Carbon NMR Spectrum of Compound 8
Figure A24. 13C – NMR Spectrum of Compound 8 observed in DMSO-d6 at 125 MHz.
137
5.2.13 Proton NMR Spectrum of Compound 9
Figure A25. 1H – NMR Spectrum of Compound 9 observed in CDCl3 at 400 MHz.
138
5.2.14 Carbon NMR Spectrum of Compound 9
Figure A26. 13C – NMR Spectrum of Compound 9 observed in CDCl3 at 100 MHz.
139
5.2.15 Proton NMR Spectrum of Compound 10
Figure A27. 1H – NMR Spectrum of Compound 10 observed in CDCl3 at 400 MHz.
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5.2.16 Carbon NMR Spectrum of Compound 10
Figure A28. 13C – NMR Spectrum of Compound 10 observed in CDCl3 at 100 MHz.
141
5.2.17 Proton NMR Spectrum of Compound 11
Figure A29. 1H – NMR Spectrum of Compound 11 observed in CDCl3 at 400 MHz.
142
5.2.18 Carbon NMR Spectrum of Compound 11
Figure A30. 13C – NMR Spectrum of Compound 11 observed in CDCl3 at 100 MHz.
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An efficient synthesis of siRNAs modified at the backbone with a triazole functionality is reported.
Through the use of 4,40-dimethoxytrityl (DMT) phosphoramidite chemistry, triazole backbone dimers
were site-specifically incorporated throughout various siRNAs targeting both firefly luciferase and glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) gene transcripts as representatives of an exogenous
and endogenous gene, respectively. Following the successful silencing of the firefly luciferase reporter
gene, triazole-modified siRNAs were also found to be capable of silencing GAPDH in a dose-dependent
manner. Backbone modifications approaching the 30-end on the sense strand were tolerated without
compromising siRNA potency. This study highlights the compatibility of triazole-modified siRNAs within
the RNAi pathway, and the modification’s potential to impart favorable properties to siRNAs designed to
target other endogenous genes.
 2011 Elsevier Ltd. All rights reserved.In 1998, Fire and Mello reported that short interfering RNAs
(siRNAs) could be introduced into cells in Caenorhabditis elegans
and block gene expression.1 This process involves the incorpora-
tion of siRNAs into an RNA-induced silencing complex (RISC),
which serves to select and deliver the guide strand to its target
messenger RNA (mRNA) for selective gene silencing.2 Since this
discovery, there has been considerable interest in utilizing siRNAs
as potential therapeutic agents in combating disease.3 However,
natural siRNAs are prone to degradation by nucleases and exhibit
poor cell membrane permeability due to their polyanionic charge.
There is wide interest in chemically modifying siRNAs in order to
alleviate the aforementioned problems.
A vast number of studies have thoroughly explored the proper-
ties of chemically modified oligonucleotides that contain the
unnatural architecture at the sugars4 and bases.5 However, rela-
tively very little has been done with respect to modifying the inter-
nucleotide linkage of siRNAs with nonionic moieties. With respect
to negatively charged backbone mimics, phosphorothioates (PS)
have been shown to be accommodated within the RNAi pathway;
however, ranges in potency are often observed and cytotoxicity is a
concern.6 Alternatively, functional data of siRNAs bearing borano-
phosphate linkages show RNAi compatibility and offer enhanced
potency comparable to PS with reduced cytotoxicity.7
With respect to nonionic backbone modifications, two studies
have shown that these can be accommodated within the 30-over-
hangs of siRNAs. Iwase and co-workers have shown that an amideAll rights reserved.
1; fax: +1 905 721 3304.
. Desaulniers).linkage enhances thermodynamic stability and resistance to
nucleases.8 Potenza and co-workers have also illustrated that an
amide-bond at the 30-end of siRNAs acts as a substrate for the RNAi
pathway.9
The crystal structure of the RISC complex by Patel et al., com-
plexed with a duplex oligonucleotide reveals that a number of
key phosphodiester contacts are necessary for its interaction with
the protein complex; however, many of these ionic contacts are not
present on the sense strand of the oligonucleotide.10 Therefore, we
envisioned that by modifying the sense strand, we could synthe-
size novel siRNAs with uncharged backbones within the duplex
that could thus serve as appropriate substrates for the RNAi path-
way without compromising their potency.
Utilizing the well-known Cu(I)-assisted Huisgen 1,3-dipolar
cycloaddition,11 the triazole moiety can be introduced as an un-
charged oligonucleotide backbone modification with relative ease.
Although a variety of triazole-modified oligonucleotide mimics
have been reported, most constructs are DNA-based.12 Reports of
click-ligated RNAs include one from El-Sagheer and Brown,13
who were successful in synthesizing functional hairpin ribozymes
containing both cross- and intra-strand triazole linkages. Other re-
ports of triazoles within RNAs include work from Das and co-work-
ers,14a and most recently from Rozners and co-workers14b who
demonstrated site-specific incorporation of a triazole-linked nucle-
oside dimer within RNAs.
In previous work, we have synthesized a triazole-linked nucleo-
side dimer phosphoramidite based on a PNA-like structure, and this
modification displayed compatibility when hybridized to its com-









Figure 1. Triazole-linked nucleic acid.
T. C. Efthymiou et al. / Bioorg. Med. Chem. Lett. 22 (2012) 1722–1726 1723backbone derivatives linked together through a triazole moiety,
none of the derivatives have been reported as substrates within
the RNAi pathway. Herein, we report the incorporation of tria-
zole-linked nucleic acids based on a PNA-type scaffold (Fig. 1) with-
in duplex siRNAs. The RNAs display effective gene silencing and
thus exhibit a high degree of compatibility as RNAi substrates.
In this paper, we expanded the scope of siRNA sequences and
modified them with a cytosine-triazole-uracil (CtU) dimer in addi-
tion to the uracil-triazole-uracil (UtU) dimer previously synthe-
sized. Synthesis of the CtU dimer phosphoramidite commenced
through the generation of 2-azidoethanamine from bromoethyl-
amine combined with sodium azide. This compound was alkylated
with 2-bromoethoxy-tert-butyldimethylsilane16 in 39% yield to af-
ford azide linker 1. Utilizing EDC as a coupling reagent, this com-
pound was amide-bond coupled to N4-benzoylcytosin-1-yl acetic
acid17 to generate monomer 2 in 62% yield. TBS-deprotection of 2
with 3HF-TEA afforded a monoalcohol, which was then protected
with a 4,40-dimethoxytrityl group (DMT) to produce compound 3

































Scheme 2. Synthesis of aIn order to generate an appropriate alkyne monomer, alkyne
linker 4 was synthesized in 71% yield by treating TBS-protected
ethanolamine with limiting equivalents of propargyl bromide. This
linker was amide-bond coupled to uracil-1-yl acetic acid18 using
EDC as the coupling reagent to produce monomer 5 in 52% yield
(Scheme 2).
With both azide (3) and alkyne (5) monomers available, 1,4-tri-
azole formation catalyzed with CuSO4 and sodium ascorbate in a
THF/H2O solution afforded compound 6 in 98% yield. TBAF depro-
tection of the silyl protective group on compound 6 afforded com-
pound 7 in 99% yield. Finally, compound 7 was treated with a
phosphitylating reagent to afford the phosphoramidite 8 in 73%
yield (Scheme 3). Both the CtU and UtU phosphoramidites were
used to synthesize a variety of triazole-modified siRNAs.
Various siRNAs were synthesized, bearing one to three triazole
backbone modifications through the use of an ABI DNA/RNA syn-
thesizer. These siRNAs were designed to target firefly luciferase
mRNA expressed within HeLa cells, in order to gauge their func-
tionality within cells-based systems (Table 1).
To first examine the effects of our RNAs, we investigated the ef-
fect of circularly polarized light on our siRNA duplexes to deter-
mine whether our chemically modified duplexes were still able
to retain A-type helical structure. Figure S1 (Supplementary data)
illustrates that the siRNAs retain the characteristic A-form helix;
however, a loss of helicity for double-stranded RNAs that contain
the internal triazole backbone modification is observed.
In addition to the listing of luciferase-targeting siRNAs, Table 1
highlights melting temperature (Tm) data indicating that the mod-
ification can have either a destabilizing or stabilizing contribution
on the dsRNA depending on its location.
In general, as the modification approaches the 50-end of the
sense strand, its contribution is less destabilizing. For example,




































Figure 2. Reduction in firefly luciferase expression related to the potency of backbone-modified triazole-linked siRNAs using the Dual-luciferase reporter assay. The siRNAs














































































Scheme 3. Synthesis of CtU phosphoramidite.
1724 T. C. Efthymiou et al. / Bioorg. Med. Chem. Lett. 22 (2012) 1722–1726wild-type. However, the closer the modifications lie towards the
center of the duplex, the greater the destabilizing contribution of
that modification to the duplex. For instance, siRNAs 13–16 exhibit
changes in Tm of ca.7.5 to 13 C. The effect of a UtU modification
on a 30-overhang increases the Tm of siRNAs 15, 17, 18, 20 and 22,
relative to the corresponding siRNA with dTdT overhangs, thus
suggesting an element of stability. This stabilizing effect has been
observed with other oligonucleotides that bear 30-overhangs.8,19
However, this trend is only observed when the modification is
not in combination with any other triazole modifications within
the same oligonucleotide strand (siRNAs 19 and 21 do not exhibit
any increase in Tm). Finally, siRNA 21 contains three UtU modifica-
tions within the sense strand. This siRNA bears a drop in Tm of
14.1 C. SiRNA 11 contains two CtU modifications, and exhibitsa Tm drop of 20.3 C relative to wild-type. Overall, our Tm data
is consistent with other similar studies involving PNA–DNA chime-
ras20 and triazole-linked RNAs.14b
To examine the effects of our backbone-modified siRNAs on the
RNA interference pathway, we performed cell-based assays within
HeLa cells. The cells were co-transfected with the siRNA duplexes
identified in Table 1 at varying concentrations, along with plasmids
expressing the target firefly luciferase and a non-target Renilla
luciferase for use as an internal control. Following transfection
with the desired siRNA construct, cells were lysed after 24 h, at
which point luciferase activity was monitored (Fig. 2). The wild-
type native siRNA inhibited luciferase expression in a dose-depen-
dent manner, while the modified siRNAs triggered varying levels of
silencing activity.
Table 2
Sequences of anti-GAPDH siRNAs
Figure 3. Analysis of GAPDH mRNA knockdown analyzed by real-time PCR
following the treatment of HeLa cells with GAPDH siRNAs 23–26. Levels of GAPDH
expression were normalized to the internal reference gene 18S.
Table 1
Sequences of anti-luciferase siRNAs and Tm Data
a Tms were measured in triplicate in a sodium phosphate buffer (90 mM NaCl,10 mM
Na2HPO4, 1 mM EDTA, pH 7) at 260 nm, from 10 to 95 C. corresponds to the
uracil-triazole-uracil modification; corresponds to the cytosine-triazole-uracil
modification.
T. C. Efthymiou et al. / Bioorg. Med. Chem. Lett. 22 (2012) 1722–1726 1725For siRNAs 9–12, a reduction in potency relative to wild-type is
generally observed, especially when using lower concentrations of
siRNA (Fig. 2). These RNAs are chemically modified in the area of
the 50-sense region and in general, display a decrease in Tm relative
to wild-type siRNA (Table 1). In accordance with other reports
which have identified that siRNAs exhibit thermodynamic asym-
metry,21 our observations support that destabilizing this area
may lead to decreased potency. SiRNAs 13 and 14 contain a single
CtU modification within an internal site of the sense strand, caus-
ing a large decrease in duplex thermal stability compared to
wild-type (Table 1). There is also a noticeable decrease in potency
observed with these two siRNAs relative to wild-type (Fig. 2).
RNAs 10, 15, 18, 20 and 22 contain UtU modifications at the
30-overhang of the antisense strand. When the activity of thesesiRNAs is compared to their analogous RNAs lacking a 30-UtU
modification in general, a reduction in activity is observed at lower
concentrations. The effect of observing reduced activity of a large
bulky 30-modified overhang on the antisense has been previously
observed.22
SiRNAs 16, 17 and 19 contain UtU modification at various posi-
tions near the 3’-end of the sense strand. Several of these siRNAs
exhibit comparable or enhanced silencing when compared to
wild-type siRNA. With respect to thermal stability, siRNAs 16
and 19 exhibit a drop in Tm. Destabilizing this area of the duplex
along with the 30-UtU modification (siRNA 19) may offer a favor-
able response by not only promoting favorable incorporation of
the guide strand to form the active RISC-guide complex,21a but
by increasing its resistance to nucleases. To determine whether a
30-UtU modified overhang provides enhanced stability to nucleas-
es, we performed time-dependent stability assays in serum. The
analysis involving siRNAs 17, 18 and 22 illustrated that these 30-
UtU modified duplex siRNAs have reduced susceptibility to degra-
dation by nucleases relative to wild-type native siRNA (Fig. S2,
Supplementary data).
Finally, siRNAs 11 and 21, which contain multiple triazole mod-
ifications within their sense strands, exhibit low thermal stability
and these siRNAs manage to effectively silence the target gene.
This suggests that multiple triazoles within a duplex siRNA are
1726 T. C. Efthymiou et al. / Bioorg. Med. Chem. Lett. 22 (2012) 1722–1726compatible within the RNAi pathway, albeit at reduced silencing
efficiency compared to wild-type.
To determine whether this novel chemical modification would be
amenable to endogenous targets, we synthesized and investigated
the effect that our triazole backbone-modified siRNA would have
on reducing the expression of glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH). We synthesized three siRNAs bearing a UtU tri-
azole modification (siRNAs 24–26). The siRNAs each contained a
single UtU modification placed either at positions 17–18, 18–19, or
at the 3’-UtU overhang of the sense strand (Table 2). The data from
Figure 3 illustrates that our triazole-linked siRNAs show a dose-
dependent downregulation of GAPDH at 10 and 20 nM comparable
to wild-type (siRNA 23). This result is significant because it high-
lights that our novel chemically modified siRNAs are capable of
silencing relevant endogenous targets.
In conclusion, we are reporting the practical synthesis of siRNAs
bearing triazoles interspersed throughout the backbone via DMT-
phosphoramidite chemistry. Monomers 3 and 5 were readily syn-
thesized through standard amide-bond coupling conditions. Via
click chemistry, the final triazole-linked CtU dimer phosphorami-
dite 8 was synthesized with an overall yield of 33% from monomers
3 and 5. All RNA duplexes are substrates for the RNAi pathway.
Therefore, a triazole in place of a phosphodiester backbone shows
compatibility within siRNA duplexes and suggests that other novel
backbone modifications may also act as proper substrates. To the
best of our knowledge, there are no other reports of nonionic
hydrophobic backbone mimics that silence gene expression when
positioned within the internal Watson–Crick double-stranded re-
gion of siRNAs.
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6.1 NMR Spectra of Organic Compounds
6.1.1 Proton NMR Spectrum of Compound 1
Figure A31. 1H – NMR Spectrum of Compound 1 observed in CDCl3 at 400 MHz.
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6.1.2 Carbon NMR Spectrum of Compound 1
Figure A32. 13C – NMR Spectrum of Compound 1 observed in CDCl3 at 100 MHz.
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6.1.3 Proton NMR Spectrum of Compound 2
Figure A33. 1H – NMR Spectrum of Compound 2 observed in CDCl3 at 400 MHz.
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6.1.4 Carbon NMR Spectrum of Compound 2
Figure A34. 13C – NMR Spectrum of Compound 2 observed in CDCl3 at 100 MHz.
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6.1.5 Proton NMR Spectrum of Compound 3a
Figure A35. 1H – NMR Spectrum of Compound 3a observed in CDCl3 at 400 MHz.
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6.1.6 Carbon NMR Spectrum of Compound 3a
Figure A36. 13C – NMR Spectrum of Compound 3a observed in CDCl3 at 100 MHz.
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6.1.7 Proton NMR Spectrum of Compound 3
Figure A37. 1H – NMR Spectrum of Compound 3 observed in CDCl3 at 400 MHz.
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6.1.8 Carbon NMR Spectrum of Compound 3
Figure A38. 13C – NMR Spectrum of Compound 3 observed in CDCl3 at 100 MHz.
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6.1.9 Proton NMR Spectrum of Compound 4
Figure A39. 1H – NMR Spectrum of Compound 4 observed in CDCl3 at 500 MHz.
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6.1.10 Carbon NMR Spectrum of Compound 4
Figure A40. 13C – NMR Spectrum of Compound 4 observed in CDCl3 at 125 MHz.
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6.1.11 Proton NMR Spectrum of Compound 5
Figure A41. 1H – NMR Spectrum of Compound 5 observed in CDCl3 at 500 MHz.
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6.1.12 Carbon NMR Spectrum of Compound 5
Figure A42. 13C – NMR Spectrum of Compound 5 observed in CDCl3 at 125 MHz.
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6.1.13 Proton NMR Spectrum of Compound 6
Figure A43. 1H – NMR Spectrum of Compound 6 observed in CDCl3 at 400 MHz.
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6.1.14 Carbon NMR Spectrum of Compound 6
Figure A44. 13C – NMR Spectrum of Compound 6 observed in CDCl3 at 100 MHz.
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6.1.15 Proton NMR Spectrum of Compound 7
Figure A45. 1H – NMR Spectrum of Compoud 7 observed in CDCl3 at 400 MHz.
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6.1.16 Carbon NMR Spectrum of Compound 7
Figure A46. 13C – NMR Spectrum of Compound 7 observed in CDCl3 at 100 MHz.
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6.1.17 Proton NMR Spectrum of Compound 8
Figure A47. 1H – NMR Spectrum of Compound 8 observed in CDCl3 at 400 MHz.
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6.1.18 Carbon NMR Spectrum of Compound 8
Figure A48. 13C – NMR Spectrum of Compound 8 observed in CDCl3 at 100 MHz.
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6.1.19 Phosphorus NMR Spectrum of Compound 8
Figure A49. 31P – NMR Spectrum of Compound 8 observed in CDCl3 at 167 MHz.
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6.2 Masses of Triazole-Modified RNA Molecules Recorded Using Quantitative
Time-Of-Flight Spectrometry
Table A6. Predicted and recorded masses for UtU and CtU-modified sense and
antisense RNAs







lucRNA 9 5′ - CtUUACGCUGAGUACUUCGAtt - 3′ 6587.0 6587.0
lucRNA 10 5′ - CtUUACGCUGAGUACtUUCGAtt - 3′ 6570.1 6570.1
lucRNA 11 5′ - CUtUACGCUGAGUACUUCGAtt - 3′ 6587.0 6587.0
lucRNA 12 5′ - CUUACGCtUGAGUACUUCGAtt - 3′ 6587.0 6587.0
lucRNA 13 5′ - CUUACGCUGAGUACtUUCGAtt - 3′ 6587.0 6587.0
lucRNA 14 5′ - CUUACGCUGAGUACUtUCGAtt - 3′ 6587.0 6587.0
lucRNA 15 5′ - CUUACGCUGAGUACUUCGAUtU - 3′ 6591.0 6591.0
lucRNA 16 5′ - CUUACGCUGAGUACUtUCGAUtU - 3′ 6574.1 6574.1
lucRNA 17 5′ - CUtUACGCUGAGUACUtUCGAUtU - 3′ 6557.2 6557.2
lucRNA 18 5′-ph- UCGAAGUACUCAGCGUAAGUtU -3′ 6756.0 6757.0
gapdhRNA 19 5′ - GGUCAUCCAUGACAACUtUUtt - 3′ 6570.9 6571.0
gapdhRNA 20 5′ - GGUCAUCCAUGACAACUUtUtt - 3′ 6570.9 6571.1
gapdhRNA 21 5′ - GGUCAUCCAUGACAACUUUUtU - 3′ 6574.9 6575.0
ESI Q-TOF recorded in negative electrospray mode after HPLC elution using two
mobile phases; MeOH/H2O (5:95) with 200 mM hexafluoroisopropyl alcohol and 8.1
mM triethylamine; and 70% MeOH.
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6.3 Conformational Characteristics of Triazole-Modified siRNAs Observed
Using Circular Dichroism Spectroscopy
Figure A50. RNA duplex conformation of all anti-luciferase siRNAs displayed through
circular dichroism spectroscopy. Wild-type and modified anti-luciferase siRNAs 9-22
(~2.4 nmol/duplex, except for siRNAs 11 & 15 at ~1.4 nmol/duplex) were suspended in
500 μL of a sodium phosphate buffer (90 mM NaCl, 10 mM Na2HPO4, 1 mM EDTA,
pH 7) and the solution was scanned from 200–310 nm at 20 ⁰C. All scans were




6.4.1 Nuclease Stability of 3′ - UtU Modified siRNAs
Figure A51. Native PAGE gel displaying degradation patterns of 3′-modified siRNAs
in a time-dependent nuclease stability assay. (A) Degradation pattern of wt anti-
luciferase siRNA. (B) Degradation pattern of siRNA 17. (C) Degradation pattern of
siRNA 22. (D) Degradation pattern of siRNA 18. Samples were incubated at 37 ⁰C in
13.5% FBS before they were resolved in 20% PAGE at low voltage (80-90V) overnight
at rt. Bands were stained with Gel Red (3X).
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6.4.2 Silencing Activity of siRNAs Cleaved by Nucleases
Figure A52. Firefly luciferase expression with siRNAs wt, 17, 18 and 22 after
incubation with 13.5% FBS using the Dual-luciferase reporter assay. Prior to
transfection, the siRNAs were incubated with 13.5% FBS at 37 ⁰C for 5 hours (red) or
12 hours (blue). The siRNAs were tested at 80 pM and their potency was measured
using the Dual-luciferase reporter assay with firefly luciferase expression normalized to
Renilla luciferase. Each value is the average of at least three independent experiments
with the indicated error (SDOM). SiRNAs wt and 17 do not silence firefly luciferase to
any significant degree at both 5 and 12 hours. Both siRNAs wt and 17 do not have an
observable native 21-mer duplex band in the gel presented in Fig. S2 at the 5 hour point.
The silencing data of siRNAs 18 and 22 suggests minimal silencing, likely due to the
increased lifetime of these duplex siRNAs relative to siRNAs wt and 17 (see Fig. S2 for
band pattern). As the incubation time increases to 12 hours, reduced silencing is
observed. The data from this graph suggests that the cleaved siRNAs illustrated in Fig.
S2 do not contribute to RNAi-knockdown.
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(RISC) liberating the active antisense strand from the sense strand of an siRNA duplex to form an active
RISC-antisense complex. This involves cleaving the sense strand between positions 9 and 10 from the 50
end of the strand prior to dissociation. Destabilizing modifications near the center of the duplex in some
cases can enhance the efficacy of the resultant construct and may trigger an alternative mechanism
through which the sense strand is removed. By introducing alkyl spacers of varying lengths near or within
the sense strand’s cleavage site, this study illustrates that siRNAs, in most cases, retained potent RNAi-
silencing activity. Our results highlight that by substituting the scissile phosphodiester linkage on the
sense strand with non-cleavable alkyl chains provides a novel and alternative method to destabilize
the central region of siRNAs.
Crown Copyright  2012 Published by Elsevier Ltd. All rights reserved.RNA interference (RNAi) is an endogenous gene silencing path- However, there have been a number of studies that suggest that
way.1 The process involves the cleavage of double-stranded RNA
into short-interfering RNAs (siRNAs).2 The siRNAs are comprised
of two strands, a sense and an antisense (AS) strand. The antisense
strand recognizes the target messenger RNA through Watson-Crick
base-pair specificity following sense strand removal. For activation,
siRNAs serve as substrates for the RNA-induced silencing complex
(RISC) and this complex directs the antisense RNA strand to the
template mRNA strand.3,4
There has been considerable interest in utilizing siRNAs as bio-
molecular scaffolds to target genes of interest that may be associ-
ated with disease.5 However, their impact has been delayed due to
problems associated with permeability, stability and off-target
effects.6,7 In order to overcome these limitations, there is attention
directed at utilizing chemical modifications to overcome some of
the inherent problems associated with the native structure of
RNA.8–11
Over the last number of years, there have been numerous stud-
ies aimed at evaluating the mechanism of the RNAi pathway, and
elucidating the method through which RISC removes the sense
strand.12–15 This process is important because ultimately the anti-
sense strand must target the desired mRNA. Several studies have
confirmed that the catalytic portion of Argonaute 2 (Ago2) cleaves
the sense strand between positions 9 and 10, starting from the 50-
end of the strand.14–16 This cleavage is thought to promote the
dissociation of the sense strand from the antisense strand to help
initiate an active RISC-antisense RNA complex.012 Published by Elsevier Ltd. All
21; fax: +1 905 721 3304.
. Desaulniers).RISC-mediated cleavage of the sense strand is not an essential
feature that governs activity.13,14,17 For example, Zamore and
coworkers demonstrated that the substitution of the scissile phos-
phodiester on the sense strand with a phosphorothioate linkage
significantly reduced cleavage by Ago2, yet RNAi activity was re-
tained.13 This study suggested that an alternative mechanism for
sense strand dissociation was possible for RNAi activity. Other
studies have illustrated that a pre-cleaved (nicked siRNA) at the
sense strand’s Ago2 cleavage site resulted in efficient RNAi activity,
which indicates that an actual cleavage event per se is not an
essential requirement to illicit a potent RNAi response.14,18,19 Fur-
thermore, Manoharan and coworkers demonstrated that a 20-O-
methyl or phosphorothioate modification at the Ago2 cleavage site
of the sense strand with destabilizing chemical modifications were
well tolerated within functional siRNAs.17 Among those already
mentioned, there are many other examples of chemical modifica-
tions performed on, or near the sense strand’s cleavage site that
are well tolerated by RISC.20–24
One of the features that is believed to help promote a bypass
mechanism involves destabilization of the central region of a siR-
NA. Many of the methods to achieve destabilization include the
incorporation of chemically modified bases, mismatches and/or
abasic sites.14,24–26 Many of the reported modifications require
multiple steps to synthesize and expertise in nucleoside phospho-
ramidite chemistry. The goal of this study is to retain siRNA effi-
cacy through duplex destabilization using various alkyl linkers as
simple alternatives to mismatches or other chemically modified
derivatives. Alkyl linker phosphoramidites such as those used in
this study are commercially available and thus their preparation
does not rely on in-house multi-step phosphoramidite syntheses.rights reserved.
Table 1
Sequences of anti-luciferase siRNAs and Tm data31
T. C. Efthymiou et al. / Bioorg. Med. Chem. Lett. 22 (2012) 5590–5594 5591Based on the aforementioned reports and the well-established
principle of thermodynamic asymmetry exhibited within siR-
NAs,27–29 a variety of different length alkyl spacer chains was cho-
sen for this study to replace typical destabilizing modifications.
The C3 spacer places three carbons between the oxygens of the
phosphodiester linkages, which is exactly the same number of car-
bons between native RNA. The C4 and C5 spacer naturally have one
or two additional carbons, respectively. These were chosen as it
had been shown previously that alkyl bulges with increased carbon
length can be used for siRNA constructs.30 Each introduction of
these alkyl spacer modifications was designed to replace the dis-
tance of a single nucleoside.
The E8 and C9 spacers contain eight or nine atoms between
phosphodiester functionalities, respectively. The intention of these
spacer derivatives is to span across two nucleotides with each
introduction in RNA. Native RNA contains nine atoms between
alternating phosphodiesters. Finally, the E17 spacer contains 17
atoms and is a mimic designed to span across three bases. Figure
1 illustrates the structural differences amongst the different alkyl
spacer linkers used.
Various siRNAs were synthesized or purchased commercially
that contained a combination of the linkers identified in Figure 1.
The siRNAs generated target firefly luciferase mRNA transcribed
from the plasmid pGL3 and expressed within mammalian cells
(Table 1). The siRNAs were tested in a dose-dependent manner
and their silencing data is illustrated in Figure 2.Figure 1. Structure of various alkyl spacer linkers used within siRNAs.
Figure 2. Reduction of luciferase activity as a function of siRNA activity using the Dual-luciferase reporter assay. Alkyl chain-modified siRNAs were tested in HeLa cells at 20,
80, 160 and 400 pM, with firefly luciferase expression normalized to Renilla luciferase. (A) SiRNAs with alkyl spacers near the terminal ends of the sense strand. (B) Centrally-
modified siRNAs, each containing one or two single (C3, C4 or C5) spacers. (C) Centrally-modified siRNAs, each containing a double (E8 or C9) or a triple (E17) spacer.
5592 T. C. Efthymiou et al. / Bioorg. Med. Chem. Lett. 22 (2012) 5590–5594
T. C. Efthymiou et al. / Bioorg. Med. Chem. Lett. 22 (2012) 5590–5594 5593Table 1 also highlights the melting temperature (Tm) for the var-
ious siRNAs. Not surprisingly, all linkers display a degree of desta-
bilization. With respect to destabilization close to the 50-end of the
sense strand (siRNA 1), a loss of activity relative to wild-type is ob-
served. Activity is comparable to the parent siRNA as the duplex is
destabilized closer to its center (siRNA 2). In contrast, single mod-
ifications close to the 30-end of the sense strand exhibit potency
comparable to wild-type siRNA (siRNAs 4 and 5). This observation
is consistent with trends observed with the asymmetry rule of siR-
NAs.28 However, if two alkyl chain linkages are placed at both po-
sition 4 and 7 (siRNA 3) or at 13 and 16 (siRNAs 6–8) of the sense
strand, this results in siRNAs exhibiting reduced gene silencing
properties, likely due to the large destabilization occurring at those
positions (Fig. 2A).
We next examined the effect of placing C3, C4 and C5 spacer
linkers within the central region of the siRNA, with a focus on posi-
tions 9, 10 and 11 which constitute and/or surround the Ago2
cleavage site (Fig. 2B). Placing a C3 spacer in place of a nucleobase
at position 9 (siRNA 9), displays silencing efficiency very compara-
ble to wild-type. Although the Tm of siRNA 9 is almost 20 degrees
below the Tm of the wild-type siRNA, no change in potency is ob-
served. As we increase the number of atoms from C3 to C4 and
C5 (siRNAs 10 and 11) a small drop in potency is observed. For po-
sition 10, all single spacer siRNAs (siRNAs 12–14) exhibit potent
gene silencing ability, particularly at concentrations greater than
20 pM. A single C4 spacer was introduced at position 11 (siRNA
18) producing a siRNA which also displayed efficient gene silenc-
ing. Even though substantial drops in Tm were observed with all
single spacer siRNAs, the data suggests that they are compatible
within the RNAi machinery.
We next turned our attention to multiple spacer modifications
within the internal region of the siRNA, while continuing to focus
on the Ago2 cleavage site (Fig. 2B). With respect to spanning two
spacers across the 9–10 region of the sense strand of the siRNA,
the C3-double spacer (siRNA 15) was quite effective at all concen-
trations tested. In addition, as the number of atoms increased, a
slight reduction in potency was observed, especially with a two-
atom increase in linker length (siRNA 17) and at lower concentra-
tions. Nevertheless, the gene-silencing capabilities of siRNAs bear-
ing two spacers at these positions were relatively unhindered at
higher concentrations. We investigated the effect of a double
spacer linkage spanning positions 10–11 of the sense strand (siRNA
20), and we observed that it was also quite effective at silencing,
albeit at reduced efficacy to wild-type siRNA. With the addition
of yet another spacer siRNA containing two C4 linkages across
positions 9 and 11 of the sense strand (siRNA 19), the collective
data suggests that siRNAs containing multiple and destabilizing
spacer units within the central region act as suitable substrates
for the RNAi machinery.
Following these results, we focused our attention on non-cleav-
able linkers spanning across two (E8 and C9) to three (E17) nucleo-
sides within the sense strand (Fig. 2C). We were surprised to find
that even though these large linkers were presumably bypassing
the sense strand cleavage mechanism, siRNA efficacy was not se-
verely compromised as expected. It is noteworthy to observe that
the duplex containing the E8 spacer across positions 9 and 10 (siR-
NA 22) was capable of silencing luciferase with efficiency compa-
rable to wild-type siRNA, despite containing the non-cleavable
linkage. The siRNA with the C9 spacer spanning positions 9 and
10 (siRNA 25) also demonstrated an active silencing profile,
although not as potent as its E8 counterpart. It was generally found
that E8 linker-modified siRNAs (siRNAs 21–23) were slightly more
effective at silencing than C9-modified siRNAs (siRNAs 24–26). SiR-
NAs modified with non-cleavable E17 linkages (siRNAs 27 and 28),
spanning positions 8–10 or 9–11 did not silence as efficiently as
the other spacers. This indicates that function was severelycompromised by the extended linkage (covering the distance of
three nucleobases).
We are presenting a novel method to destabilize the central re-
gion through the use of simple alkyl linkers that are able to span
within the central region of siRNAs. Many of the linkers used with-
in siRNAs are capable of gene silencing as efficiently as wild-type
siRNA. Our data suggests that non-cleavable long linkers, up to
nine atoms in length that span the equivalent of two nucleobases
at and near the Ago2 cleavage site are effective substrates for the
RNAi machinery. As this linker is increased to seventeen atoms,
thus replacing three nucleobases, we observe a drop in efficacy.
To confirm that the alkyl linker is essential for activity, we tested
some ‘true space’ (TS) siRNAs containing segmented sense strands
annealed to unmodified antisense strands (Table S1). The segments
varied in length in order that they reveal spaces in the sense strand
with missing residues near and across the Ago2 cleavage site.
These TS siRNAs were not capable of effective gene silencing signi-
fying the importance of an actual linkage between residues that are
separated by at least one space on the same strand. See Fig S1 and
Table S1 for details (Supporting data).
In conclusion, this study presents a simple means to destabilize
the central region of siRNAs through the use of alkyl linkers. Alkyl
linkers are attractive substituents due to their commercial avail-
ability and their robust compatibility with standard DMT-phos-
phoramidite chemistry and related protocols.32,31 In addition, the
longer neutrally-charged linkers such as E8, C9 and E17 assist in
reducing the overall polyanionic charge of the siRNA. The ability
to use a non-cleavable alkyl linker within the central region of an
siRNA opens the future possibility of further chemically modifying
it with desired functionality that can assist with some of the prob-
lems associated with siRNAs such as delivery, stability, and off-tar-
geting. For example, designing a linker with positively-charged
nitrogens at physiological pH may assist with cell membrane per-
meability. Future studies include delineating new structure–func-
tion relationships of novel functionalized spacer moieties within
siRNAs.
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7.1 Tables
Table A7. Sequences of Mismatched (MM) and True-Space (TS) anti-luciferase
siRNAs.
Sample No. Sense and Antisense RNAs Tm (⁰C) a∆Tm (⁰C)
MM1
5′- CUUACGCUCAGUACUUCGAtt -3′
3′- ttGAAUGCGACUCAUGAAGCU -5′ 61.8 -9.6
MM2
5′ - CUUACGCUCUGUACUUCGAtt - 3′
3′- ttGAAUGCGACUCAUGAAGCU -5′ 60.5 -10.9
MM3
5′- CUUACGCUCUCUACUUCGAtt -3′
3′- ttGAAUGCGACUCAUGAAGCU -5′ 52.9 -18.5
TS1
5′- CUUACGCU AGUACUUCGAtt -3′
3′- ttGAAUGCGACUCAUGAAGCU -5′ 47.5 -23.9
TS2
5′- CUUACGCU      GUACUUCGAtt -3′
3′- ttGAAUGCGACUCAUGAAGCU -5′ 46.4 -25.0
TS3
5′- CUUACGCU        UACUUCGAtt -3′
3′- ttGAAUGCGACUCAUGAAGCU -5′ 39.9 -31.5
a Tm′s are compared to that obtained for the wild-type duplex (71.4 ⁰C).
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7.2 Figures
Figure A53. Reduction of firefly luciferase expression using four concentrations (20,
80, 160 and 400 pM) of siRNAs containing destabilizing mismatches (MM) or
missing residues (TS) in the central region of the duplex (Table A7). Firefly
luciferase expression is normalized to Renilla luciferase.
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8.0 Experimental Protocols
8.1 Mammalian Cell Culturing & Assays
8.1.1 Thawing HeLa Cells
A 50 mL fulcan tube containing 10 mL of growth medium (Dulbecco′s modified eagle′s
medium (DMEM) (Sigma) with 10% Fetal bovine serum (FBS) (Perbio) and 1%
Penicillin-Streptomycin (Sigma)) is warmed at 37 ᵒC in preparation for the frozen cells.
A cryovial stored in the vapor phase of liquid N2 containing 950k frozen cells, is placed
into a portable cooler at -80 ᵒC for transport. After removing the vial from the cooler, 500
µL of warm growth medium is immediately added to the tube and gently mixed with the
cells as they thaw. The 500 µL mixture of medium and thawed cells is removed from the
vial and added into the fulcan tube containing the growth medium. Another 500 µL of
medium is added to the frozen cell vial, mixed, removed. This process is repeated until
the all cells have thawed and are contained within the fulcan tube. The cells are then
centrifuged at 1200 rpm for 5 min, after which the medium is discarded. The pellet is
resuspended in 1 mL of new 37 ᵒC growth medium and the entire amount is then added
to a small culture flask containing 10 mL of growth medium. The cells are incubated for
24 hr at 37 ᵒC with 5% CO2, after which they are passaged (section 8.2) and all cells are
added to a large culture flask containing 25 mL of growth medium. These cells are then
incubated at 37 ᵒC with 5% CO2 until they reach 70 – 80% confluency (3 – 4 days), at
which point they are sub-cultured (section 8.2) once again.
8.1.2 Sub-Culturing HeLa Cells
Either 24 hr post-cell thawing or at 70 – 80% confluency, the growth medium is removed
from the culture flask and the cells are washed twice with 10 mL of cool phosphate buffer
saline solution (0.01 M phosphate buffered saline (NaCl 138 mM; KCl 2.7 mM; pH 7.4)
(Sigma). Being surface-adhering cells, the HeLa cells are dispersed by adding 1 – 2 mL
of 37 ᵒC 0.25% trypsin (SAFC Bioscience) to a small or large culture flask, respectively.
The cells are then incubated with the trypsin for approximately 2 min at 37 ᵒC with 5%
CO2, after which they are re-suspended in 10 mL of 37 ᵒC growth medium and placed in
a 50 mL fulcan tube. The cells are centrifuged at 1200 rpm for 5 min and the supernatant
182
is discarded. The pellet is re-suspended in 5 mL of 37 ᵒC growth medium and the cell
concentration is determined using a hemacytometer (mix 50 µL of cells with 150 µL of
Trypan blue (Sigma)). After determining the concentration of cells in the growth
medium, they are diluted to a concentration of 1x106/mL with 37 ᵒC growth medium. To
a culture flask containing 24 mL of 37 ᵒC growth medium, 1 mL of cells is added and
they are incubated at 37 ᵒC with 5% CO2 until they reach 70 – 80% confluency.
8.1.3 Protocol for Freezing HeLa Cells
After sub-culturing the cells and diluting them to a concentration of 1x106 cells/mL with
37 ᵒC growth medium (section 8.2), 50 µL of dimethylsulfoxide (DMSO) (Fisher) is
added to a sterile cryovial. We then add 950 µL of suspended cells (950k cells) to the
DMSO, and mix this solution only once. The cells are stored at -80 ᵒC for 24 hr and then
transferred the vapor phase of liquid N2 for long-term storage.
8.1.4 Dual-Luciferase Reporter Assay
8.1.4.1 Transfection of HeLa Cells with siRNAs
After passaging and achieving a 1x106 cell concentration (Section 8.2) using growth
medium without antibiotics (DMEM containing 10% FBS), HeLa cells were seeded on
12-well plates (Greiner Bio-One) by adding 100 µL of cells (100k cells) to each well,
with each well containing 1 mL of identical growth medium devoid of antibiotics. The
plates were incubated at 37 ᵒC with 5% CO2. After 24 hr and in preparation for the
transfection of HeLa cells, 100 ng of each luciferase-expressing plasmid (pGL3
(Promega) and pRLSV40 (York University) was added to a microfuge tube on ice. To the
same tube, amounts ranging from 0.01 – 1 pmol of a particular siRNA was added in order
to achieve a final siRNA concentration of 8 pM to 800 pM. To this tube was then added
100 µL of Gibco′s Opti-Mem Reduced Serum Medium 1X (Invitrogen). In a separate
microfuge tube kept at room temperature, 1 µg of Lipofectamine 2000 (Invitrogen)
followed by 100 µL of Opti-Mem was added, thoroughly mixed, and left at room
temperature. After 5 min, this solution was added to the plasmid/siRNA tube, thoroughly
mixed, and left to stand at room temperature for an additional 20 min. Several pairs of
tubes were setup at the same time for each assay utilizing this protocol, with each pair of
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tubes used for a separate siRNA, or siRNA concentration being tested. After 20 mins, the
siRNA/plasmid/Opti-Mem/lipofectamine mixtures were added to the seeded wells of the
12-well plate. Each siRNA or siRNA concentration being tested was added to its own
well. The plates were re-incubated at 37 ᵒC with 5% CO2 in order for the transfection to
take place.
8.1.4.2 Measuring siRNA Efficacy Using the Dual-Reporter Luciferase Assay
After 24 hr, the cell growth medium was discarded from each well, followed by washing
each well twice with 1x PBS buffer. To each well was then added 250 µL of 1X passive
lysis buffer (5X stock) supplied from the Dual-luciferase Reporter Assay System
(Promega) and warmed to room temperature. The plates were gently agitated for 20 min
at room temperature in order to ensure that all cells are lysed. 10 µL of each cell lysate
was loaded in triplicate onto a white and opaque 96-well plate (Costar). Using a
multichannel pipette, 50 µL of luciferase assay substrate was quickly added and mixed
with each set of triplicates. Substrate was added to a maximum of four sets of triplicates
for each luminescence reading, due to the time-sensitive nature of the substrate-enzyme
reaction. Using the KC4 program on a Synergy HT (Bio-Tek) plate luminometer,
luminescence was recorded for each well containing substrate. After this reading, 50 µL
of Stop & Go Renilla luciferase substrate was added and mixed to the exact same
triplicate wells in order to fully inhibit the firefly luciferase reaction and start the Renilla
luciferase reaction. Luminescence was once again for the same wells. This process was
repeated for each new set of triplicates until all samples were analyzed. The ratio of
firefly/renilla luminescence expressed as a percentage relates the reduction in firefly
expression to siRNA efficacy when compared to untreated controls. Each value is the
average of at least three independent experiments with the indicated error (SDOM).
8.1.5 Quantitative Real-Time PCR
8.1.5.1 HeLa Cell Post-Transfection Preparation
After the addition of siRNAs to 12-well plates seeded with HeLa cells for final siRNA
concentrations of 10 – 20 nM per well, and the 24 hr transfection period (section 8.1.4.1),
the growth medium was discarded and each well was washed twice with 4 ᵒC 1X PBS
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buffer. Cells were dispersed after adding 100 µL of 0.25% trypsin to each well and
incubating the plate at 37 ᵒC with 5% CO2 for 2 min. The detached cells from each well
were then added to separate microfuge tubes containing 1 mL of 37 ᵒC growth medium
without antibiotics. The cells were centrifuged at 1200 rpm for 5 min at 37 ᵒC, after
which the supernatant was discarded and the cells were re-suspended in 500 µL of the
same growth medium without antibiotics. After counting the cells and ensuring equal cell
concentrations for each sample for a maximum of 250k cells/sample, the cells were re-
pelleted at 1200 rpm for 5 min at 4 ᵒC, the supernatant was discarded, and the pellets
were placed on ice. After re-suspending the pellets in 500 µL of ice-cold 1X PBS buffer
(Ambion), the cells were re-pelleted at 1200 rpm for 5 min at 4 ᵒC, followed by
discarding the supernatant and placing the pellets back on ice.
8.1.5.2 Cell Lysis & Reverse Transcription (RT)
The following protocols involve the use of reagents found in the Cells-to-cDNA kit by
Ambion. To the pellets was added ice-cold 100 uL of cell lysis buffer II and these
solutions were then vortexed. Until lysis buffer was added to each sample, all other
samples remained on ice. After all samples contained lysis buffer and were vortexed, the
samples were immediately incubated at 75 ᵒC for 10 min. After placing the samples back
on ice, to each tube was added 2 uL of DNase 1 and these mixtures were gently vortexed,
and briefly centrifuged to concentrate the solutions. These mixtures were then incubated
at 37 ᵒC for 15 min in order to activate the DNase enzyme. The samples were then heated
to 75 ᵒC for 5 min to deactivate DNase 1.
To new and sterile microfuge tubes on ice, 5 µL of cell lysate (template RNA) from each
sample is added, along with 4 µL of dNTP mix, 2 µL of random decamers, and 9 µL of
nuclease-free H2O. In order to denature both the template RNA and the primers, the
samples are heated at 70 ᵒC for 3 min, placed on ice for 1 min, briefly centrifuged and
then replaced on ice. To these tubes is added 2 µL of 10X RT buffer, 1 µL of M-MLV
RT (reverse transcriptase) or 1 µL of H2O for No-RT (NRT) control, and 1 µL of RNase
Inhibitor. The solutions are then incubated at 42 ᵒC for 45 min for the reverse
transcription of RNA, which yields template cDNA for PCR. To inactivate the RT,
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samples were incubated at 95 ᵒC for 10 min. At this stage, the samples could be stored at
-20 ᵒC until needed, or they could be immediately used for amplification.
8.1.5.3 Quantitative Real-Time PCR
To each reaction tube within the 96-well PCR plate (BIO-RAD) was added the following:
2 µL of template cDNA (or 2 µL of H2O for No-template control (NTC)), 10 µL of
SsoFast EvaGreen Supermix (BIO-RAD) as the source of SYBR green dye and Taq
Polymerase, 800 nM of forward/reverse GAPDH and 20 nM of forward/reverse 18S
primers (as concentrated in nuclease-free H2O as possible so as not to exceed reaction
volume), each topped up to a 20 µL reaction volume with nuclease-free H2O. Master
Mixes for each set of primers were made up in order to simplify the addition of reagents
to each reaction tube, therefore only requiring the addition of 2 µL of template cDNA or
H2O (NTC) to each reaction tube before adding 18 µL of Master Mix. NRT controls were
performed for each new siRNA and/or siRNA concentration for each set of primers (# of
siRNAs and/or # of [siRNA] x 2 primer sets = # of NRTs), in addition to NTC controls
performed for each set of primers (2 primer sets = 2 NTCs).
The GAPDH forward and reverse primers were 5′- AGG GCT GCT TTT AAC TCT GG
-3′ and 5′- TTG ATT TTG GAG GGA TCT CG - 3′, respectively, yielding a 200-bp
amplicon. The 18S forward and reverse primers were 5′- CGG CTA CCA CAT CCA
AGG AAG -3′ and 5′- CGC TCC CAA GAT CCA ACT AC -3′, respectively, yielding a
247-bp amplicon. Utilizing a CFX96 Real-Time reactor (BIO-RAD), the protocol to
amplify both GAPDH and 18S transcripts consisted of the following events: pre-heat to
95 ᵒC for 60 sec; 40 cycles of denaturing at 95 ᵒC for 5 sec and annealing/elongating at
47 ᵒC for 20 sec. The protocol concluded with thermal denaturation analysis of the PCR
products by raising the temperature from 65 to 95 ᵒC at 0.5 ᵒC /min and measuring the
absorbance at 260 nm. GAPDH gene expression was normalized to 18S using the
Comparative Ct method (2(∆Ct18S-∆CtGAPDH)), while error was calculated as the overall




8.2 Oligonucleotide Quantification, Purification and Characterization
8.2.1 Oligonucleotide Quantification
Following the full deprotection of synthesized single-strands of DNA and RNA
oligonucleotides, each sample was dried down using a SC210A Speed-Vac (Thermo) and
re-dissolved in 200 µL of nuclease-free H2O. Using 1 mL UV-compatible disposable
plastic cuvettes, 1 µL of the re-dissolved sample was added to 999 µL of nuclease-free
H2O, and this solution was thoroughly mixed. After measuring the absorbance of this
solution at 260 nm using a Genesys 10S Vis Spectrophotometer (Thermo), the value
obtained was then multiplied by the total volume of the stock oligonucleotide sample
(200 µL). This optical density (OD) value A is then plugged into the Beer-Lambert
equation: A=εbc; where ε is the extinction coefficient particular to the oligonucleotide
sequence; b is the sample′s path length of 10 mm; and c is the oligonucleotide′s molar
concentration in 1 mL of solution. The ε value is determined for each individual DNA or
RNA oligonucleotide using the following link to a web tool provided by Integrated DNA
Technologies (IDT): http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/. After
determining the concentration c in mol/L per mL, we then calculate the new
oligonucleotide concentration in 200 µL (stock volume). This new concentration is
considered the crude oligonucleotide concentration, since the molecules hasn′t undergone
purification at this point. This method of determining the concentrations of
oligonucleotide samples is used to form the relationship between ODs of oligonucleotides
and their molar concentrations.
8.2.2 PAGE Gel Electrophoresis
To visualize the purity of our fully deprotected single-stranded DNA and RNA
oligonucleotides with adequate resolution not offered by agarose-based gels, we required
the use of concentrated polyacrylamide gel electrophoresis (PAGE). The recipes required
to make the polyacrylamide solution are as follows: For the 10X stock Tris/Borate/EDTA
(TBE) buffer, we dissolved 108 g of Tris Base (Fisher), 55 g of Boric Acid (Fisher), and
40 mL of 0.5 M EDTA (pH 8.3) (Fisher) in nuclease-free H2O for a total volume of 1 L;
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for the 40% stock acrylamide solution, we dissolved 380 g of acrylamide (Sigma) and 20
g of bis-acrylamide (Sigma) in nuclease-free H2O for a total volume of 1 L; for the
bromophenol blue loading buffer, we dissolved 74 mg of *EDTA (Fisher), 4.8 g of *Urea
(Acros), 50 µL of 1M *Tris-base (pH 5.0) (Fisher) (1.21 g/10 mL of H2O for 1 M
solution; adjust to pH 7.5 with conc. HCl), 1.5 mL of glycerol (Fisher), and 25 mg of
bromophenol blue (Fisher) in nuclease-free H2O, for a total volume of 10 mL. *These
reagents were only added to the denaturing loading buffer.
The recipe for a 20% polyacrylamide gel is as follows: 30 mL of 40% acrylamide, 6 mL
of 10X TBE, 25.23g of Urea (7 M), 80 µL of 25% ammonium persulfate (APS) (Fisher)
(375 mg of APS for 1.5 mL of 25% solution; lasts 1 month at 4 ᵒC), and 80 uL
tetramethylethylenediamine (TEMED) topped up to 60 mL with nuclease-free H2O. After
mixing all of the ingredients together and making sure to add the last two ingredients
after everything else is dissolved, the gel solidifies in the PAGE apparatus where it is
kept moist by the 0.5X TBE running buffer (25 mL of 10X TBE in 475 mL of H2O),
which is also in contact with both the anode and cathode. For visualizing oligonucleotide
purity, 0.05 to 0.5 ODs of oligonucleotide can be combined with denaturing loading dye
for a total volume of 20 µL and added to each well. For purification, a maximum of 2
ODs of oligonucleotide can be added to each well, combined with denaturing loading dye
for a total volume of 20 µL. PAGE is then performed at 300V for 5 hr, or until the
bromophenol blue band has travelled 75% of the gel′s length. The gels can be visualized
by staining them for 30 min in a solution of dilute solution of ethidium bromide in 0.5X
TBE running buffer, or by UV-shadowing, where the gel is placed on a fluorescent silica
background and bands of interest will appear dark against this background due to the
sample′s absorbance of UV light.
8.2.3 Post-Synthetic Oligonucleotide Purification
8.2.3.1 Crush & Soak Oligonucleotide Purification
After fully deprotecting, quantifying, and visualizing synthesized oligonucleotides on a
gel, further purification was required if more than one band was present. This process
began with the Crush & Soak Method, where 2 ODs of quantified crude oligonucleotide
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was added to each well of a 20% PAGE gel which was run for 5 hr and visualized using
the UV-shadowing technique (section 8.2.2). At least 20 to 24 ODs of each
oligonucleotide was run on a single PAGE gel in order to maximize the final yield of
purified sample. After identifying the bands of interest, they were physically excised
from the gel and placed in microfuge tubes. After freezing the gel pieces in a dry
ice/EtOH bath for 5 min, the pieces were chopped up as much as possible using a skinny
scoopula. The chopped up pieces were re-frozen in the dry ice/EtOH bath and then
suspended in 500 µL of gel eluting buffer (1 mL (0.3 M) of 3 M NaOAc (pH 5.2)
(Fisher), 2.9 mg (1 mM) EDTA in 10 mL buffer solution), where they were quickly
chopped even further as they began to defrost in the buffer. This slurry was re-frozen in
the dry ice/EtOH bath for another 15 min and then left to thaw at room temperature for
15 min. After incubating the slurry overnight at 37 ᵒC, the slurry was filtered through a
0.4 micron syringe filter and the filtrate was collected in a sterile microfuge tube, and
dried down in the speed-vac.
8.2.3.2 EtOH Precipitation and Desalting of Gel-Purified Oligonucleotides
Following the crush & soak method, the oligonucleotides were then in cold ethanol. After
drying down the oligonucleotide samples on a speed-vac, the pellets were re-suspended
in 600 µL of EtOH, chilled in dry ice. To these mixtures, 25 µL of 3 M NaOAc (pH 5.2)
(2.46 g of NaOAc in 10 mL of H2O; adjust to pH 5.2) was added and the solutions were
vortexed and placed in dry ice for 1 hr. After centrifuging the samples at 12k rpm for 30
min at 4 ᵒC, as much supernatant as possible was discarded from each sample. The
pellets were re-suspended in 600 µL of cold EtOH and the process was repeated 2 to 3X
without adding any additional NaOAc. After the final removal of supernatant, the
samples were dried down using the speed-vac.
The dried samples were dissolved in 500 µL of nuclease-free H2O and desalted using
3000 MW cellulose centrifugal filters (Millipore). The samples were loaded into the
filters which were then spun at 12k rpm for approximately 10 min at 25 ᵒC, or until there
was roughly 50 µL of oligonucleotide solution left. Added to this remaining amount was
400 – 500 µL of H2O and the sample was re-spun. This process was repeated for a total
of 3 to 4X, after which the remaining 50 µL of sample was collected in a microfuge tube
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and dried down. The purified sample was then re-suspended in 100 µL of nuclease-free
H2O and quantified (section 8.2.1).
8.2.4 Circular Dichroism and UV-Monitored Thermal Denaturation
In a microfuge tube, equimolar amounts of each purified DNA or RNA oligonucleotide
(0.5 ODs) (section 8.2.1) were added to their compliment in 500 μL of a sodium
phosphate buffer (90 mM NaCl (Sigma), 10 mM Na2HPO4 (Fisher), 1 mM EDTA, pH 7).
The strands were denatured at 90 ᵒC for 2 min and then slowly cooled to rt, thus
annealing the complimentary strands. The 500 μL samples of newly-formed duplexes
were added to quartz cuvettes with 1 mm path lengths, sealed with Teflon caps in
preparation for CD and Tm measurements using a Jasco J-815 spectropolarimeter. The
CDs of each RNA duplex were recorded in quadruplicate, scanning from 200 to 310 nm
at 20 ᵒC in the sodium phosphate buffer, with a scanning rate of 10 nm/min and a 0.2 nm
data pitch. The average of four accumulations was calculated using Jasco′s Spectra
Manager version 2 software and adjusted against the baseline measurement of the buffer.
Melting temperatures (Tm) were measured at 260 nm following CD measurements for
each sample and using the same solution. Sample temperatures were slowly increased
from 10 to 95 ᵒC, at a rate of 0.5 ᵒC /min. The absorbance was measured at the end of
each 0.5 ᵒC increment, which was every minute. Absorbance readings were automatically
adjusted against the baseline absorbance of the sodium phosphate buffer. After averaging
the range of absorbance values obtained from three independent experiments for each
siRNA, Tm′s were calculated using Meltwin software version 3.5 assuming the Van′t Hoff
two-state model.
8.3 Transformation of E. Coli and Mini-Preparation of pGL3/SV40 Plasmids
Using competent DH5α cells, several copies of both pGL3 and SV40 plasmids could be
prepared. After thawing 50 µL of competent DH5α E. coli cells on ice, 100 ng of either
plasmid (pGL3 or SV40) were gently mixed with the cells. The cells were first incubated
on ice for 15 min, then heat-shocked at 42 ᵒC for exactly 1 min, and then replaced on ice
for 2 min. To the cells was then added 950 µL of room temperature LB broth, and this
mixture was incubated at 37 ᵒC for 1 hr at 250 rpm. The cells were then pelleted at 14k
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rpm for 30 sec, the supernatant was discarded, then the pellet was re-suspended in 100 µL
of LB broth. The cells were then plated onto ampicillin-containing agar plates and then
grown overnight to select for ampicillin resistance given to cells which were successfully
transformed. After identifying ampicillin-resistant bacterial colonies, culture tubes filled
with 5 mL of LB and 100 µg/mL of ampicillin were inoculated with single ampicillin-
resistant colonies, and these cultures were then incubated at 37 ᵒC for exactly 16 hr.
The process of harvesting the bacterial cells began by centrifuging the culture tubes at
8000 rpm for 3 min at room temperature. Each additional step of the plasmid preparation
involved the use of reagents from the QIAprep Spin Miniprep kit (Qiagen). After
discarding the supernatant, the pellet was re-suspended and thoroughly mixed with 250
µL of pre-lysis re-suspension buffer (buffer P1) containing 100 µg/mL RNase inhibitor
(RNase A), and transferred to a microfuge tube. To this suspension was added 250 µL of
lysis buffer (buffer P2), and the tube was gently inverted to mix the contents. At this
point, the solution turns blue as an indication of cell lysis. To neutralize the suspension,
350 µL of a neutralizing solution (buffer N3) was added and the contents of the tube wer
thoroughly mixed by inverting the tube 4 to 6 times. This solution was mixed until it was
no longer blue, but white and cloudy throughout. The tubes were then centrifuged for 10
min at 13k rpm and a white precipitate was formed. The supernatants were transferred to
individual QIAprep spin columns by decanting them. The columns were flash-
centrifuged for 60 sec in order to discard the flow-through. The columns were then
washed by adding 750 µL of wash buffer (buffer PE; contains EtOH) and flash-
centrifuging for another 60 sec. After discarding the flow-through from the collection
microfuge tube, the column was spun again for an additional 60 sec in order to remove
any remaining EtOH. The column was then removed from the collection tube and placed
into a clean and sterile microfuge tube. The DNA was collected from the column by
adding either 50 µL of column eluting buffer (buffer EB; 10 mM Tris-HCl, pH 8.5) or
nuclease-free H2O directly in the center of the column. After letting the buffer or H2O
stand for 5 min, the column was flash-centrifuged for one last minute in order to elute the
plasmid trapped inside. The purified plasmids were quantified (section 8.2.1) and their
ability to express the enzyme they code for and produce an appropriate level of
luminescence was tested using the dual-reporter luciferase assay (section 8.1.4.2).
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8.4 1H/13C – NMR of Small Molecules
For each small molecule synthesized, approximately 10 to 15 mg of compound was
dissolved in 1 mL of deuterated solvent (CDCl3 or d6-DMSO (Sigma)). All solubilized
compounds were filtered through Pasteur pipettes equipped with glass wool filters into
clean NMR tubes. NMRs were either performed on our own Varian 400 MHz or a Varian
500 MHz, located at Trent University. With lock values hovering around 40 to 50, 1H-
NMRs were performed for either 16 or 32 transients and 13C-NMRs were typically
performed overnight for 20k to 50k transients. All acquired spectra were processed and
integrated using ACD Labs software build 9.06. Peaks for experiments performed in
CDCl3 were referenced to 7.27 ppm, while peaks for experiments performed in d6-DMSO
were referenced to 2.50 ppm.
